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ABSTRACT

The current treatment methods in cancer are associated with toxicity in healthy
tissues, partial therapeutic response, drug resistance and finally recurrence of the disease.
The cancer drugs are challenged by non-specific binding, undesired toxicity in healthy
cells, low therapeutic index and finally poor therapeutic outcome. In this work, a
targeted nanoscale therapeutic system Antibody Drug Nanoparticle (ADN) was
engineered to selectively inhibit the breast cancer cell growth with reduced toxicity in
healthy cells. The ADNs were designed by synthesizing rod shaped nanoparticles using
pure chemotherapeutic drug and covalently conjugating a therapeutic monoclonal
antibody (mAb) on the surface of the drug nanorods. The rod shaped nanosized
formulation of ADNs significantly enhanced the aqueous phase stability and therapeutic
payload of the system while the conjugated mAb was utilized for specific targeting of
breast cancer cells. The designed ADN was effective for active targeting and synergistic
inhibition of breast cancer cells. The mechanisms of actions of ADN was investigated at
the cellular, molecular and genetic levels in cancer cells. The engineered ADN
synergistically inhibited the growth of >80% of the human epidermal growth factor
receptor 2 (HER2) - positive breast cancer cells in vitro. The cell cycle and protein
expression analysis showed that ADN arrested the cellular growth for a prolonged time
and induced a programmed cell death mechanism in HER2-positive breast cancer cells in
vitro. Finally, the gene regulatory analysis showed the genetic mechanisms of
programmed cell death regulation induced by ADN in breast cancer cell lines.
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1. INTRODUCTION

1.1. NANOTECHNOLOGY IN CANCER
In 2020, cancer is still the second leading cause of death in the United States. It
was estimated that in 2019, close to 1.8 million new cases of cancer were expected to be
diagnosed in the U.S. and over 0.6 million people would die from the disease1. The
conventional treatment methods in cancer are still associated with poor diagnostics,
toxicity to the normal cells and drug resistance. The limitations in conventional
therapeutic methods promoted the use of nanoparticles as cancer therapeutics for safer
and more efficacious treatment 2. The term “Nanotechnology” is defined as the
“intentional design, characterization, production, and applications of materials, structures,
devices, and systems by controlling their size and shape in the nanoscale range” 3,4 The
concept of nanotechnology in cancer has shifted the paradigm of developing cancer
drugs. The cancer nanomedicine field aims to utilize the multifunctional novel physical
characteristics of nanosized materials for the diagnostic and therapeutic application at the
molecular level 5. In cancer treatment, nanomaterials are being engineered to enhance the
transport property of therapeutic agents and diagnostic tools through the complex
biological barriers and to aid the interaction with biomolecules. The unique
characteristics of nanomaterials, for example, high surface area to volume ratio, surface
physical and chemical characteristics depending on variable sizes or shapes, tunable
optical, magnetic and electronic properties have made the use of nanomedicine more
appealing in cancer treatment than the contemporary atomic or macroscale materials 6,7
These characteristics of nanomaterials are potentially being applied in drug delivery,

2

diagnosis of early-stage cancer, imaging and tracking the progression of tumor
formation, development of anti-cancer nano-vaccine therapeutics. The current Food and
Drug Administration (FDA) approved and clinically used nanomaterials with size ranging
from 1-100 nm for cancer treatment shown in Figure 1.1 can be categorized into
inorganic and organic nanoparticle platforms 5’8,9.

Figure 1.1. Inorganic and organic nanomaterials used in cancer therapy 5

The inorganic nanoparticles comprises mostly carbon nanotubes, fullerenes,
quantum dots and multifunctional metal nanoparticles 5. A combination of materials
integrating a wide range of physical and chemical properties into a single system has
enabled the design of novel inorganic materials for cancer treatment. The organic
nanomaterials include polymers, lipids, micelles, dendrimers, small protein molecules
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and nucleic acid based nano assemblies 8. The hydrophilic surface and biocompatibility
of organic nanomaterials have made them highly potential therapeutics for cancer
treatment.

1.2. CURRENT TREATMENT METHODS IN CANCER
1.2.1.

Surgery. Surgery is conducted to diagnose, characterize and treat cancer. A

revolution in cancer surgery arose in 1957 marking the beginning of cancer surgery based
on laboratory research and clinical trial outcomes 10. The studies showed that the
bloodstream plays a major role in the dissemination of cancer and regional surgical
therapies are not enough for improving the survival of patients 11. A scientific basis of
cancer surgery was established and the studies justified less radical surgery and systemic
therapy after surgery 10. Currently, surgeries are conducted in cancer treatment in
combination with other treatment strategies e.g., radiation therapy, chemotherapy at
different stages of cancer treatment. Initially, surgical biopsies are performed by taking
out a tissue sample from the possibly affected organ and checking the sample under a
microscope or by performing necessary pathological tests on the sample. After an initial
positive diagnosis of cancer, staging surgery may be performed to investigate the extent
of cancer cell dissemination in the primary organ or to the distant secondary sites (known
as metastasis). Curative surgeries are operated in order to remove the tumor that has
spread in a confined area. If the cancer has spread covering a lot of areas and is very
close to sensitive organs then surgery is conducted to debulk a portion of the affected site
known as debulking surgery. The rest of the cancer cells are treated by radiation or
chemotherapy. In ovarian cancer and some lymphoma, debulking is a common surgical
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procedure. Palliative surgery helps the patients get rid of any form of side effects of
cancer treatment and to continue with the ongoing treatment.
1.2.2. Radiation Therapy. Radiation therapy involves high energy particles or
waves to damage or destroy the cancer cells. The therapy might involve delivery of
radioactive particles or substances, engineered nanomaterials accumulating in the tumor
site and consequent ablation of substances by radiation to exert therapeutic effect 10,12-15.
In the U.S. about 60% of the cancer patients receive radiation treatment at some point of
the systemic cancer treatment 16. Radiation damages the DNA of the cancer cells and
inhibit the growth 16-18. The therapy also affects the normal cells but most of the slow
growing normal cells are able to fix the damage and go back to their normal functioning.
As the cancer cells are rapidly dividing cells and replicate their DNA more often than the
normal cells, the toxic effect is more dominant on the cancer cells upon DNA damage.
The radiation therapy is conducted in a confined tumor area. The objective of the
radiation therapy in cancer treatment is to eradicate maximally possible cancer cells while
minimal killing of normal cells 19. The precise removal of tumor cells with minimally
affecting the normal tissues is achieved by the advancements in the radiation treatment
technologies such as intensity modulated radiation therapy (IMRT)20, image guided
radiation therapy (IGRT) 21, stereotactic body radiation therapy (SBRT)22 and Delta4
Discoverer16. These technologies offer precise and controlled damage of tumor site
leaving a large portion of normal cells. Moreover, advancement in imaging technologies
such as positron emission tomography-computed tomography (PET-CT)23,24, MRI 25,26
and pretreatment CT enhanced the efficacy of radiation therapy 27 Radiation therapy is
used in combination with surgery or chemotherapy to treat cancer patients.
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1.2.3.

Chemotherapy. While surgery and radiation therapy can treat localized

tumors spreading over a smaller area and are unable to treat metastasized tumors,
chemotherapy can reach to every organ in the body in an effort to cure cancer.
Chemotherapy is the major form of treatment method for both the localized and
metastasized cancer across all cancer types28. Conventional chemotherapeutic drugs are
associated with poor aqueous phase solubility, non-specificity and multi drug resistance.
Because of the lack of solubility the chemotherapeutics are required to administer with
solvents causing severe toxicity. The non-selective chemo drugs affect the fast growing
healthy cells in the body and cause poor survival rate following the treatment. Moreover,
multi drug resistance mechanism causes transport of the drug molecules out of the cancer
cells through enhanced activity of efflux pump molecules such as P-glycoproteins in
cancer cell membrane which causes partial therapeutic response or cancer recurrence.
Despite the therapeutic limitations and severe toxicity chemotherapeutic drugs are being
used ubiquitously in cancer treatment as a first line of defense and in some cancers non
targeted chemo drugs are the only treatment option because of lacking of any targetable
surface biomarker. For example, in triple negative breast cancer non targeted
chemotherapy is still the sole option for treatment 29. Several chemotherapeutic drugs
have been approved by FDA and are being used clinically either alone or in combination
with another chemotherapeutic drug. Chemotherapeutic drugs have wide range of
mechanisms of action. The alkylating agent drug class impair cancer cell growth by
alkylating specific sites on protein molecules, DNA and RNA30. Their activity mostly
depends on the relatively fast duplication rate of the cancer cells. The common clinically
used alkylating agent drugs include nitrogen mustards, platinum complexes (Cisplatin,
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Carboplatin), nitrosoureas and many others 31. Hyperactive DNA repair mechanism and
efficient glutathione conjugation in cancer cells cause resistance to alkylating agent
drugs32. The antimetabolites, for example, 5- fluorouracil interfere with the DNA
synthesis and inhibit the cancer cell growth 33. Bleomycin, a member of antitumor
antibiotics drug class intercalates DNA, forms free oxygen radicals causing DNA breaks
and cell growth inhibition34,35. The anthracycline antibiotics such as Doxorubicin cause
intercalation between the base pairs of DNA and specifically inhibit the DNA
topoisomerases I and II resulting in cell growth arrest 36. The epipodophyllotoxin drugs
inhibit the cell growth by stabilizing the DNA topoisomerase II complex37. Vinca
alkaloid chemo drugs dissemble the microtubule assembly and block the polymerization
of microtubules resulting in cell growth inhibition38. In contrast to the mechanisms of
vinca alkaloids which cause microtubule disassembly, Taxanes such as Paclitaxel and
Docetaxel promote microtubule assembly and stabilization resulting in cell growth arrest
in mitosis phase 39,40. Alkaloid camptothecin semi-synthetic analogs such as Irinotecan
and Topotecan cause interruption in DNA replication elongation phase and inhibit
topoisomerase I resulting in cell growth inhibition 41,42.
1.2.4. Cancer Immunotherapy. Cancer immunotherapy is a relatively recent
therapeutic strategy that involves activating, boosting or engineering the immune cells to
recognize malignant tumor cells and fight them43. Immune cells are programmed to kill
any malignant cells or foreign they encounter. However, as the cancer cells evolve from
normal cell phenotype of our own body, the immune system cannot see them as foreign
or malignant. Sometimes the cancer cells impose a brake on the activity of these immune
cells. Moreover, the aggressive form of cancer tissue surpasses the capability of immune

7

cells to fight them. Several strategies have been adopted over the years to stimulate the
activity of immune cells to fight against cancer. The checkpoint inhibitor
immunotherapeutic drugs (e.g., anti-PD1/PDL1, anti-CTLA4) take the brakes off the
immune cells and help them recognize and attack the cancer cells44-47. In chimeric antigen
receptor (CAR)-T cell therapy, cytotoxic T cells from patients’ blood are drawn,
modified in the laboratory condition to recognize specific marker on the malignant cell
surface and reintroduced into the individual again. The modified T cells now attack only
the malignant cells that they were trained to attack43. However, the CAR-T therapy is
currently not therapeutically effective in treatment of solid tumors and limited to
refractory hematological malignancies48. There are drugs that boost the immune cells to
fight against cancers known as immunomodulatory drugs, are widely used in cancer
treatment. Targeted therapeutic mAb e.g., Trastuzumab recognize a specific antigen or
biomarker and inhibit the growth of cancer cells49. Therapeutics involving cancer
vaccines, oncolytic viruses, and cytokine delivery are also novel immunotherapeutic
strategies to fight cancer50.

1.3. NANOPARTICLE BASED THERAPEUTICS IN CANCER TREATMENT
Therapeutic molecules including small molecule drugs, chemotherapeutic drugs,
RNA interference molecules are being integrated with nanosized drug delivery vehicle
systems and utilized for cancer treatment. The drug encapsulated nanocarriers facilitate
the entry of therapeutics into the tumor tissue by providing with improved solubility in
physiological conditions inside the blood vessel, enhanced bio-availability and bio
distribution. The selective targeting of cancer tissue with minimal effect on the healthy
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cells can be achieved by utilizing the concepts of “passive” and “active” targeting
principles of cancer therapeutics (Figure 1.2).

Figure 1.2. A representation of passive and active targeting of nanoparticle based
cancer therapeutics 51

•

Passive targeting and EPR effect: In passive targeting approach, nanocarriers

utilize the defective “leaky” tumor blood vessels and poor lymphatic drainage system in
the vicinity of solid tumor. These characteristics of the tumor microenvironment allow
the preferential accumulation of nanoparticles in the tumor site, a phenomenon known as
enhanced permeability and retention (EPR) effect 52.
•

Advantages and limitations of passive targeting: The nanocarriers used in drug

formulation provide the system with a better pharmacokinetics profile, enhanced
solubility of drugs, improved toxicological profile. For example, the polymeric
nanoparticle formulations used in clinically approved drugs showed the characteristics of
water solubility, non-toxicity and biodegradability. Moreover, the EPR mechanism
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allowed the formulation to selectively accumulate in the cancer site. Polymeric micelles
have been proven to be a suitable carrier of the water insoluble drug. The self-assembling
system is easy to modify, biocompatible, biodegradable and has a good targeting
potential. Liposomes are another class of cancer drug nanocarrier having a self
assembling colloidal structure composed of lipid bilayers. The drug nanocarrier system is
biocompatible, easier for surface modification and has good potential for selective
targeting of tumor cells. Dendrimers nanocarriers can provide high ligand density,
tunable pharmacokinetics and bio-distribution profile. The system is convenient to
functionalize and has high structural and chemical homogeneity. Taken together,
integration of nanotechnology in the drug delivery system has shifted the paradigm of
cancer drug design and development. However, only 15 passively targeted nanoparticle
based drugs were in clinical practice till 2018. Instability in circulation, premature drug
release, toxicity to normal cells, poor oral bioavailability, insufficient accumulation of
drugs at the cancer site have caused hindrances in clinical translation of nanoparticle
based cancer therapeutics. Moreover, the understanding is limited by the poorly known
mechanisms of complex nano-bio interactions in the tumor microenvironment. The other
potential causes limiting the therapeutic efficacy of nanoparticle based drugs can largely
be attributed to the heterogeneity in permeability in tumor blood vessels, poor tumor
penetration, hypoxia and angiogenesis, and poor intracellular endosomal escape
capability of the drug. In addition to that, a major portion of the nanoparticle therapeutics
are cleared by the phagocytic systems, hepatocytes, kupffer cells while some physically
cannot get through the sinusoids of the liver.
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•

Current passively targeted nanoparticle based therapeutics: Till November,

2018, only 15 passively targeted drugs got approval for cancer treatment 53. Doxil
(PEGylated liposomal doxorubicin, liposomal system), approved in 1995 by FDA is the
first clinically used passively targeted nanoparticle based drug for cancer treatment 54
The promising characteristics of the drug formulation include prolonged blood circulation
time, avoidance of reticuloendothelial system (RES) or phagocytic elimination and high
doxorubicin loading 54 Other examples of clinically approved passively targeted
nanoparticle based drugs include Abraxane 55,56(albumin-taxol, polymer drug conjugate
system), Marqibo 57(vincristine sulfate, liposomal system), DaunoXome 58(liposomal
daunorubicin, liposomal system), Onivyde 59,60(irinotecan, liposomal system), Vyxeos 61(
cytarabinee-daunorubicin combination, liposomal system), Myocet 62,63(Non, PEGylated
liposomal doxorubicin, liposomal system), Mepact 64,65( mifamurtide, liposomal system) ,
Genexol-PM 66( PEG-PLA-taxol, polymeric micelles system), and SMANCS 67,68(
neocarzinostatin, polymer drug conjugate system). While most of the formulations
mainly focus on improving the drug pharmacokinetics, drug solubility and toxicological
profile, some nanoparticle based cancer drug formulations have enhanced therapeutic
response in patients and improved the overall survival percentage compared to the
standard non-formulated chemo drugs. For example, Abraxane (albumin-Paclitaxel)
polymer drug conjugate formulation significantly enhanced the therapeutic response in
metastatic breast cancer patients in phase III clinical trial compared to the standard
Paclitaxel treatment 55,69.
•

Active targeting: The “active” targeting involves binding of affinity ligands

functionalized on the nanocarrier surface to the specific overexpressed biomarkers or
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receptors on the target cells improving selective tissue homing and enhanced retention
at the tumor vicinity 70. The targeted biomarker enhances the internalization of
nanoparticles upon binding with nanoparticle surface functionalized ligands.
•

Advantages and limitations of active targeting: Actively targeted nanoparticle

based drugs showed greater potential in cancer treatment by utilizing the enhanced tumor
localization and most crucially by the selective inhibition of cancer cells minimizing the
side effects in cancer treatment 71,72. In fact, integration of actively targeting mechanism
with optimization in nanocarrier design will allow for the design of a more efficacious
nanotherapeutic platform for cancer treatment 73. Ligands employed on the actively
targeted nanocarrier surface enhance the nanoparticle accumulation in the intravascular
tumor cells or endothelial cells of tumor blood vessels70,74. Moreover, the internalization
of ligand functionalized targeted drug nanoparticle can be mediated through a specific
pathway by a specific antigen overexpressing tumor cells and the intracellular
accumulation can be increased 75. However, the greater potential is associated with more
complex challenges. The first barrier comes with the transport process of the nano-drug
delivery systems. The protein coating formed around the surface of the nanoparticles,
known as the “protein corona” limits the blood circulation time of the particles by
altering the stability and surface architecture of the particle76-79 though longer blood
circulation time for nanoparticles might not be so crucial considering a high pressure
blood flow in the tumor microenvironment blood vessels53. The protein coating alters the
pharmacokinetics and helps elimination by immune systems of the delivery system 80.
The protein corona also hinders the receptor targeting, intracellular uptake, intracellular
trafficking of the actively targeted nanoparticle based drugs77. The challenge also remains
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in predicting the correlations between nanoparticle size and the binding affinity or
tissue specific accumulation of drugs. Such a mechanistic model predicts that the
nanoparticle size >50 nm does not enhance the accumulation of drugs at the malignant
tumor site when compared to the non-targeted nanotherapeutic system81. Endosomal
escape into the cytosol is one of the major barriers of the actively targeted nanoparticle
based drug delivery systems. Nanoparticles internalized or uptaken by the tumor cells in
clatherin mediated endocytic pathway enter the endosomes and are subsequently
degraded in lysosomes by a intracellular degradative mechanism often driven by the pH
of these subcellular compartments82. One of the ingenious mechanisms to enhance
endosomal escape efficiency is “proton sponge effect” that utilizes the pH buffering
substances for endosomal escape83. Exocytosis, the cellular recycling process is another
major limitation for actively targeted nanoparticle based drugs. It has been demonstrated
that 70% of the uptaken endosomal siRNA encapsulated lipid nanoparticle were rejected
by the tumor cells through exocytosis84. The current drug delivery vehicles targeting a
single biomarker or mechanism of action often develop tumor resistance and promotes
tumor relapse because of the partial and non-sustainable therapeutic outcome85.
Moreover, the choice of specific biomarker ligands, conjugation of ligands with
nanoparticle and complex manufacturing process impose great hindrance on the efficacy
of actively targeted nanoparticle based therapeutic drug delivery vehicles 2.
•

Current actively targeted nanoparticle based cancer therapeutics: None of

the actively targeted therapeutics have been approved for clinical use in cancer treatment
till November, 20 18 53. However, a number of drugs have entered in clinical trials. Table
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1.1 summarizes the all intravenous actively targeted nanoparticle based cancer
therapeutics that are in different stages of clinical trials as of August 2019 86.

Table 1.1. Current intravenous nanoparticle based actively targeted therapeutics in
clinical trials 86
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cancer,siRNA; small interfering RNA
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MCC-465 being the first actively targeted nanoparticle based drug showed
selective accumulation in stomach cancer tissues over the normal cells 87 SGT-53, a
transferrin receptor targeted and p53 plasmid DNA encapsulating cationic liposome
nanocarrier has been shown to sensitize cancer cells to the subsequent treatment with
radiation therapy and systemic chemotherapy88,89. The first polymer based targeted
nanotherapeutic drug to enter the clinical trial is CALAA-01 which encapsulates small
interfering RNA molecule (siRNA), has shown RNA interfering mechanisms in patients
and also showed enhanced accumulation in tumor cells intracellularly 75. These examples
show promising insights towards future clinical success of actively targeted nanoparticle
based cancer drugs.

1.4. COMBINATION THERAPY TO OVERCOME
RESISTANCE IN CANCER TREATMENT

THE

THERAPEUTIC

Treatment with a single drug often causes partial response in cancer treatment.
The cancer cells often acquire resistance to the treatment and hence cause disease
recurrence. Old age chemotherapeutic drugs, mAb-based targeted drugs, small molecule
kinase inhibitors have been proven to improve the therapeutic response in cancer patients
when used in combination with other suitable drugs90,91. In fact, the combination therapy
is the key treatment strategy for most cancer treatments now 92. For example,
Trastuzumab is used to treat early stage HER2- positive breast cancer as a first line of
treatment. However, the complete response of the treatment is not achieved in 20-60%
cases of the HER2- positive and HER2-enriched breast cancer patients93. The treatment is
also associated with the risk of therapeutic resistance and tumor recurrence after a certain
period of the treatment. The lower risk of tumor recurrence and better outcome can be
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expected when Trastuzumab is administered with another chemotherapeutic drug in
combination94,95. Till 2013, four phase III clinical trials involving more than 8,000
patients showed that the risk of recurrence was decreased by 50% in when Trastuzumab
was administered with or after chemotherapy in combination91,96-99. The American
Society of Clinical Oncology (ASCO) guideline updated in 2018, recommended anti
HER2 therapy in combination with chemotherapy or a taxane (Paclitaxel and Docetaxel
are most common in practice) as a first line of treatment for metastatic HER2-positive
breast cancer. Trastuzumab treatment has been shown to sensitize the breast cancer cells
to the microtubulin polymerization agent especially to the taxols and the drugs synergize
improving the therapeutic outcome in vivo 100-102. Combination therapy with Paclitaxel
and Trastuzumab for adjuvant HER2- positive breast showed promising long term
clinical outcome in recent years. In 2015, after a median follow up period of 4 yr,
adjuvant Paclitaxel and Trastuzumab combination treatment trial involving 406 node
negative HER2-positive breast cancer patients reported the 3 yr disease free survival rate
(DFS) to be 98.7%103. In 2019, after 7 yr follow up period, the DFS was 93% with an
overall survival rate (OS) of 95% 104

1.5. ANTIBODY DRUG CONJUGATES
Antibody Drug Conjugates (ADCs) are the combination therapeutic system
consisting small molecule cytotoxic drugs covalently bound to the mAb via a stable
linker (Figure 1.3).
The coupled antibody directs towards a specific antigen that is highly expressed
on the cancer cell surface.
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Figure 1.3. Schematic structure of ADC 105

Antigen binding initiates downstream signaling pathways to inhibit the cancer cell
growth. Eventually, the antibody is internalized in the intracellular endosomes with the
conjugated therapeutic drug molecule through a clathrin or caveolae mediated
endocytosis 106 and pinocytosis pathway 107 . The endosomes containing the ADC
subsequently mature into lysosomes 108,109. In the lysosome, the linker is cleaved and the
drug molecule released in the cytosol exerts the therapeutic effect following reaching to
its target either binding with cytosolic microtubules or nuclear DNA 110 (Figure 1.4).
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1.5.1.

Advantages and Challenges Associated with ADCs. ADCs have the

novel advantages of utilizing mAb to specifically target cancer tissue site while also
delivering cytotoxic potential anti-cancer drug molecule. The system can potentially
enhance the tumor site specific accumulation of drugs with low or no cytotoxic effects on
the normal cells111,112. There are major limitations involved along with the ingenuity of
the ADC combination therapeutic system. Selection of target antigens, drug
hydrophobicity, insufficiently low therapeutic payload, off target toxicity due to unstable
linker conjugation in physiological system, drug efflux and multidrug resistance
constitute the major limitations of ADC therapeutic system113-118. Till 2017, the two third
of the cytotoxic small molecule drugs in the ADC systems that were on clinical trials
came from only auristatins and maytansinoids family which inhibit the tubulin
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assembly119. This suggests that there still lies limitations keeping from using
diversified drug molecules in ADC system. High susceptibility to multi drug resistance is
a common barrier in successful formulation of ADCs. Cancer cells often become
resistant to multiple drugs through enhanced drug efflux mechanism. The upregulation of
multidrug resistance protein encoding genes including MDR1, MRP1 and MRP3 promote
the efflux transporter activity in cancer cells and result in drug resistance 120. In vitro
therapeutic efficacy of Mylotarg drug on acute myeloid leukemia (AML) cell lines
showed that P-glycoprotein expression significantly altered the therapeutic potency of the
drug molecule and treatment with efflux transporter inhibitor restored the potency of the
payload 121. An ADC system AVE9633 comprising the anti CD33 linked with a
cytotoxic maytansine analog molecule DM4 has also been shown to be dependent on Pglycoprotein expression level for its therapeutic efficacy in vitro 122. Hydrophobic nature
of ADC reduces the pharmacokinetics and therapeutic index of the system.
Hydrophobicity also induce antibody aggregation causing small shelf life and clearance
by immune cells 112. Moreover, the conventional drug to antibody ratio (DAR) in ADC
system is 3.5-4.0 106,113. The in vitro therapeutic efficacy of ADC system increases with
increasing DAR value113. Site specific highly loaded ADC system showed enhanced in
vivo therapeutic efficacy in a system with low antigen expression at the target site 123. In
the same system, no or low therapeutic effect was observed when treated with similarly
loaded conventional molecule or with the similar ADC having low payload. This
suggests that a conventional therapeutic payload might not be sufficient for achieving
satisfactory outcome while targeting cancer cells with lower abundance in antigen
expression 124 However, high DAR value has been showed to positively correlate with
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enhanced ADC plasma clearance resulting in reduced in vivo efficacy 125. So,
balancing between the enhanced payload and best achievable therapeutic index in the
conventional ADC platform is both a dilemma and a compromise 126. Again, lower
abundance of target antigens on the tumor cell surface results in further therapeutic
inefficacy, often causing treatment resistance. These limitations have hindered the
clinical success of methotrexate, doxorubicin and alkaloid based ADCs119,127.
Optimization in linker conjugation and stability is another challenge in developing ADCs.
Premature release of drug molecule in the blood circulation cause toxicity to normal
tissue and poor therapeutic index. Hydrophobic linker molecule has been showed to
promote enhanced efflux transporter activity in cancer cells resulting in drug resistance.
Non polar linker molecule in maytansinoid-based ADC system showed low potency in
MDR1 overexpressed cancer cells in vitro due to enhanced transport of hydrophobic
molecule by MDR1 activity 113. Moreover, majority of the ADCs have maleimide type
conjugation chemistry and often undergo deconjugation, causing off target toxicity 113.
1.5.2. Strategies for Developing Efficacious ADCs. Diversification in the drug
selection, linking chemistry and alternative form of mAbs are brought into the
development of ADCs.
•

Selection of drugs: For designing efficacious ADC system, the selected drug

molecule must possess good aqueous phase solubility, potent toxicity, specified site for
linker conjugation and maintenance of potency after conjugation110,128,129 . In selection of
potent cytotoxic drugs, lowering the minimum effective dose of cytotoxic drugs should
be considered to reduce off target toxicity and improve the therapeutic index of ADCs. In
case of malignant tissue selectivity, the therapeutic index can be improved by focusing on
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increasing the maximum tolerated dose. The drugs must retain the efficacy and have
aqueous phase stability after modification by linker chemistry. The drugs should be
synthetically available and the manufacturing process should be cost effective 129.
Moreover, a better understanding of the toxicity profile of ADCs as a combination drug
system should be addressed in the development of next generation ADCs.
•

Bystander effect: The target antigen expression in solid tumor tissue is

heterogeneous in nature. The designed ADC selective for a specific antigen might not
affect a large cell population with low or no antigen expression. This might cause partial
therapeutic response in cancer treatment. The design consideration or characterization of
ADCs that allow the system to affect the neighboring malignant cells with low or no
antigen expression is called bystander effect. For example, the FDA approved ADC
brentuximab vedotin contains neutral monomethyl auristatin E (MMAE) drug molecule.
Upon protease mediated cleavage of ADC, MMAE is released, crosses the bio
membranes and kills the neighboring epithelial cancer cells130-134. Other example of
ADCs that have been reported to possess bystander effect include trastuzumab
duocarmazine ( kills HER2- negative cells though targeted against HER2+ breast cancer
population in vitro )135 , coltuximab ravtansine (targets CD19, phase II clinical trial,
2017)136 , anetumab ravtansine (targets mesothelin, phase I clinical trial , 2017) 137
•

Selection of linkers and conjugation chemistry: The mechanisms of drug release is

an important consideration for developing ADCs. This is mostly achieved by the
appropriate selection of linkers. The physiological stimuli such as pH, glutathione
concentration, and proteolytic degradation are responsible degradation of cleavable
linkers while the non-cleavable linkers rely on mAb degradation in the lysosomal
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compartment to release the drug after internalization. ADCs comprising the both type
of linkers were approved by FDA or are currently in clinical trials. For example, The
ADC brentuximab vedotin (marketed as Adcetres) which was approved in 2011 by FDA
for anaplastic large cell lymphoma, utilizes the degradation of cleavable linker valinecitrulline (vc) by lysosomal proteases such as cathepsin B 138. Another FDA approved (in
2013) ADC Ado-trastuzumab emtansine (marketed as Kadcyla, popularly known as TDM1) for HER2-positive metastatic breast cancer treatment comprised a non-cleavable
linker lysine-SMCC that utilized the proteolytic degradation of mAb to release the drug
molecule 139. Each strategy has their own merits and demerits and optimization is needed
considering the comprising drug, antibody and targeted site. The conventional
thiosuccinimide linkage involving the reaction of thiols and alkyl maleimides are being
replaced by novel site specific conjugation chemistries including engineered cysteines ,
unnatural amino acid engineering, enzyme assisted ligation , glycan remodeling and
glycoconjugation, amino terminal engineered serine , ligation to Fab nucleotide -binding
sites, cysteine rebridging, among many others 112.
•

Selection of alternative forms of antibody: Alternative configurations of full length

mAbs are also being investigated in state of the art ADC systems. This include
nanobodies, tumor tissue specific novel probodies, single chain variable fragments
(scFvs), antigen binding fragments (Fabs), ADCs with biparatopic activity (binds two
different epitopes on the same antigen) and other formats.
As discussed, the use of diverse clinically approved chemo therapeutic drugs such
as methotrexate, taxoids, anthracyclins and alkaloids is still a challenging task to
incorporate in the ADC platform due to hydrophobic nature, insufficient drug delivery to
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the tumor tissue and off target toxicity in the normal tissue resulting in poor therapeutic
index 113,129. In this work, these limitations have been addressed by integrating the
concepts of nanotechnology, actively targeted drug delivery and combination therapy in a
single novel therapeutic platform. The conventional ADC system was remodeled into an
actively targeting nanosized therapeutic platform ADN designed for combination
treatment in HER2-positive breast cancer. Rod shaped nanoparticles were synthesized
using pure chemotherapeutic drug. The drug nanoparticles were covalently conjugated
with mAb to target an actively expressed biomarker on the cancer cell surface. The
engineered ADN showed enhanced in vitro selectivity and a synergistic therapeutic
efficacy on the HER2-positive breast cancer cells compared to the single drug treatments.
The therapeutic efficacy of the ADN was also mechanistically determined at the protein
expression level. In a following study, the deep genetic mechanism and transcriptional
regulation determining the treatment response with engineered ADN were investigated.
The objective of the study was to identify the novel genetic pathways that might cause
enhanced treatment response or potential therapeutic resistance in breast cancer cell lines
upon treatment with ADN. Taken together, the work presented the development and
therapeutic efficacy of ADN system for targeted cancer treatment with synergistic
efficacy. The work also investigated the mechanisms of ADN therapeutic efficacy at
cellular, molecular and gene expression levels. Figure 1.5 shows the schematic diagram
of the primary works presented in the dissertation.
In addition, the dissertation also presents a study on the design and therapeutic
efficacy of a multifunctional polymer coated superparamagnetic NIR responsive
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nanosized therapeutic platform harnessing both the integrity of diagnostics and
therapeutics in a single platform for cancer treatment.
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Figure 1.5. An overview of the primary works presented in the dissertation

Finally, the work presents a study on therapeutic efficacy of a natural
cyanobacterial extract glycoglycerolipid molecule MGDG, that was investigated for
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potential anti-cancer application. The sequential overview of the dissertation is shown
in the following block diagram (Figure 1.6).

Paper I

Paper II

Design of HER2-positive breast
cancer targeted Antibody Ding
Nanoparticle (ADN)
High drag payload
Higher aqueous stability than
standard chemo drug
>80% HER2-positive breast
cancer cell growth inhibition in
vitro

Synergistic therapeutic efficacy
G2/M phase cell cycle arrest
and caspase dependent cell
death in HER2-positive breast
cancer cells

Paper III

Review of major cell
signaling pathways
Overview of cell cycle
regulation
Overview of intrinsic and
extrinsic programmed cell
death pathways
Discussion on molecular
interplay between cell cycle
progression and cell death
pathways

ADN induced gene
expression analysis in
HER2-positive breast cancer
cells
Analysis of gene regulatory
pathways for apoptosis
mechanism
Analysis of possible genetic
mechanisms of ADN
resistance in HER2-positive
breast cancer cells

Paper V

Paper IV
• Design of a multifunctional
superparamagnetic
nanomedicine platform
• Diagnostics and therapeutic
application in cancer
• NIR responsive nanoparticle
• MRI contrast agent
• >40% HER2-positive breast
cancer cell growth inhibition
in vitro following nanoparticle
uptake and subsequent remote
NIR laser treatment

• Isolation of a natural anti
proliferation molecule from
ocean cyanobacteria
• >65% cell growth inhibition
in HER2-positive breast
cancer cells in vitro
• Caspase mediated
programmed cell death in
HER2-positive breast cancer
cells
• No significant toxicity in
human normal cell lines in
'

vitro

V____________________>V__________________ /
Figure 1.6. Overview of the dissertation
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PAPER

I. ANTIBODY-DRUG NANOPARTICLES INDUCES SYNERGISTIC
TREATMENT EFFICACIES IN BREAST CANCER CELLS

ABSTRACT

Chemotherapeutic drugs suffer from non-specific binding, undesired toxicity, and
poor blood circulation which contribute to poor therapeutic efficacy. In this study,
antibody-drug nanoparticles (ADNs) are engineered by synthesizing pure anti-cancer
drug nanorods (NRs) in the core of nanoparticles with a therapeutic monoclonal antibody,
Trastuzumab on the surface of the NRs for specific targeting and synergistic treatments
of breast cancer cells. The ADNs were designed by first synthesizing ~95 nm diameter x
~500 nm long paclitaxel (PTX) NRs using the nanoprecipitation method. The surface of
PTXNRs was functionalized at 2' OH nucleophilic site using carbonyldiimidazole and
conjugated to TTZ through the lysine residue interaction forming PTXNR-TTZ
conjugates (ADNs). The size, shape, and surface charge of ADNs were characterized
using scanning electron microscopy (SEM), SEM, and zeta potential, respectively. Using
fluorophore labeling and response surface analysis, the percentage conjugation efficiency
was found >95% with a PTX to TTZ mass ratio of 4 (molar ratio « 682). In vitro
therapeutic efficiency of PTXNR-TTZ was evaluated in human epidermal growth factor
receptor 2 (HER2) positive BT-474 and HER2 negative MDA-MB-231 breast cancer
cells using MTT assay. PTXNR-TTZ inhibited >80% of BT-474 cells at a higher
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efficiency than individual PTX and TTZ treatments alone after 72 h. A combination
index analysis indicated a synergistic combination of PTXNR-TTZ compared with the
doses of single drug treatment. The molecular mechanisms of PTXNR-TTZ were
investigated using cell cycle and Western blot analyses. The cell cycle analysis showed
PTXNR-TTZ arrested >80% of BT-474 breast cancer cells in the G2/M phase, while
>70% of untreated cells were found in the G0/G1 phase indicating that G2/M arrest
induced apoptosis. A similar percentage of G2/M arrested cells were found to induce
caspase-dependent apoptosis in PTXNR-TTZ treated BT-474 cells as revealed using
Western blot analysis. PTXNR-TTZ treated BT-474 cells showed ~1.3, 1.4, and 1.6-fold
higher expressions of cleaved caspase-9, cytochrome C, and cleaved caspase-3,
respectively than untreated cells, indicating up-regulation of caspase-dependent
activation of apoptotic pathways. The PTXNR-TTZ ADN represents a novel nanoparticle
design that holds promise for targeted and efficient anti-cancer therapy by selective
targeting and cancer cell death via apoptosis and mitotic cell cycle arrest.

1. INTRODUCTION

Engineering nanoscale drug delivery systems have been studied extensively
because of several advantages including high drug payloads,1-5 improved drug release,6,7
enhanced bioavailability,8,9 and increased multivalence effects through receptor-ligand
interactions.10-13 The use of a ligand allows direct delivery of the cytotoxic agent to target
cells, however, the clinical success of targeted antibody-drug conjugates is limited due to
poor bioavailability and low therapeutic efficacy.14-16 Improvements in drug design in
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combination with active targeting are shown to enhance cellular uptake, targeting, and
higher therapeutic efficacy which have led to the design of antibody-drug nanoparticles
(ADNs). ADNs are comprised of an anticancer drug core nanoparticle conjugated with a
therapeutic monoclonal antibody on the nanoparticle surface for targeted delivery and
enhanced therapeutic efficacy. Trastuzumab (TTZ) is used to treat early-stage human
epidermal growth factor receptor 2 (HER2) positive breast cancer as the first line of
treatment. However, the complete response of the treatment is not achieved in 20-60%
cases of the HER2 positive and HER2 enriched breast cancer patients.17 The TTZ
treatment is associated with the risk of therapeutic resistance and tumor recurrence after a
certain period of the treatment. The lower risk of tumor recurrence and the better
outcome can be expected when TTZ is administered with another chemotherapeutic drug
in combination.18,19 Till 2013, four Phase III clinical trials involving more than 8,000
patients showed that the risk of recurrence was decreased by 50% when TTZ was
administered with or after chemotherapy in combination.20-24 The American Society of
Clinical Oncology (ASCO) guideline updated in 2018, recommended anti-HER2 therapy
in combination with taxane as the first line of treatment for metastatic HER2 positive
breast cancer.25
Combination therapy using paclitaxel (PTX) and TTZ for adjuvant HER2 positive
breast cancer showed promising long-term clinical outcomes in recent years. In 2015,
after a median follow up period of 4 yr, adjuvant PTX and TTZ combination treatment
trials reported that the 3 yr disease-free survival rate is 98.7% in HER2 positive breast
cancer patients.26 In 2019, after 7 yr follow up period, the disease-free survival rate was
93% with an overall survival rate (OS) of 95%.27 While the combination therapy of PTX
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and TTZ are promising, the following challenges still have to overcome in terms of
synergy between the drugs, toxicity and therapeutic efficacy.28 The current clinically used
intratumoral concentration of PTX (1-9 ^M) is shown to be insufficient for breast cancer
treatment.29 Moreover, PTX is poorly soluble in aqueous phase causing a great limitation
and trade-off in terms of toxicity in intravenous administration. The high concentration of
TTZ used in clinical trials have always been associated with the risk of severe cardiac
arrest.26-28
To overcome the limitations of toxicity and off-site targeting, nanoparticles have
been engineered with advanced chemical composition,14-16,30 surface functionalization,3135 and geometric modification.35-38 Nanoparticles made of human serum albumin
(Abraxane™) have been used for the delivery of PTX to breast cancer cells.39 Another
example of a nanoparticle-based drug delivery system is liposome-based doxorubicin
(Doxil) for the treatment of ovarian cancer40,41 and breast cancer.42 However, the
efficiency of these nanoparticles is controversial due to the lack of active targeting and
controlled drug delivery. Currently, a large number of nanoparticles such as liposomes,43
polymers,44 micelles,45 solid lipid nanoparticles,46 and other organic and inorganic
nanoparticles have been explored to improve the therapeutic efficiency by active
targeting of cancer cells through the design of nanoparticle size, shape and surface
charge.
Nanoparticle size in the range of 50-500 nm size nanoparticles is desirable for
enhanced blood circulation, tissue penetration, and cellular interaction.36,47,48 Size less
than 10 nm is cleared by renal excretion, while larger particles are cleared by
phagocytosis.11,12,49,50 Non-spherical nanoparticles have been reported to be less clearance
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by macrophages than spherical nanoparticles as dictated by the contact angle of
nanoparticles with the macrophage membrane.51 Nanoparticle also leads to a dramatic
increase in surface area for surface functionalization with targeting ligands such as
monoclonal antibodies, affibodies, peptides, and aptamers. For example, binding of rod
shaped nanoparticles can be high if the particle aligns with its major axis parallel to the
cell membrane increasing the multivalence effects of receptor-ligand interactions.10-13
In this study, we synthesized PTX nanorods (PTXNRs) of the size (96.8 ± 33) x
(503.4 ± 210) nm using the nanoprecipitation method. TTZ was used as a HER2 targeting
antibody for specific PTX delivery to HER2 positive breast cancer cells. The surface of
PTXNRs was conjugated via carbonyldiimidazole (CDI), a highly reactive crosslinker to
form an active N-acyl imidazole group capable of coupling with amine-containing TTZ
and formed a stable amide linkage. Flow cytometry analysis of a fluorophore-labeled
PTXNR-TTZ and response surface analysis confirmed the TTZ conjugation efficiency of
>95%. A combination approach of PTXNR-TTZ ADNs was explored in exploiting the
therapeutic efficacy of the ADNs towards HER2 positive breast cancer cells. It is
hypothesized that a combination system using PTXNR-TTZ ADNs enhances therapeutic
payloads and treatment efficiency by selective targeting of HER2 positive breast cancer
cells.
2. MATERIALS AND METHODS

2.1. SYNTHESIS OF PTXNRs
PTXNRs were prepared using the nanoprecipitation method (SI Figure 1).10,52,53
Briefly, PTX powder (>99.5%, Alfa Aesar) was dissolved in 5 ml of ethanol at a
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concentration of 3 mg/ml. The solution was homogenized at 1000 rpm, sonicated, and
injected to 20 mL deionized (DI) water at a flow rate of 2 ml/min to form PTXNRs.
PTXNRs were washed three times using DI water by centrifuging at 18,000 rcf for 2 h,
suspended, and lyophilized (Labconco) overnight to obtain the dried particles.

2.2. CHARACTERIZATION OF PTXNR
The size and shape of PTXNRs were analyzed using a scanning electron
microscope (Hitachi S4700 FESEM). The images were obtained at 10.0 KV accelerating
voltage with 4.5 mm working distance and 40,000X magnification. The size distribution
of NRs was analyzed using Fiji image processing software( Image J; Win 64 Java 1.8.0).
The surface charge of PTXNRs was measured in DI water and phosphate-buffered saline
(PBS) using zeta potential (Nano series Zetasizer, Malvern).

2.3. ACTIVATION OF 2' OH NUCLEOPHILIC SITE OF PTXNR
TTZ (Genentech) was conjugated with the 2O H nucleophilic site group of PTX
using the CDI activation reaction (SI Figure 2). Briefly, 1 mg of dry PTXNRs was
suspended in 1 ml of PBS. 5 mg CDI was added directly to the NR suspension with a
continuous stirring speed of 600 rpm. The reaction was carried out at 4oC for 20 min to
form the amine-reactive PTX-carbamate (PTXNR-CDI). The PTXNRs-CDI were
centrifuged at 16,000*g for 30 min and washed five times using DI water to remove the
unreacted CDI or imidazole. The particles were lyophilized for subsequent TTZ
conjugation reaction.
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2.4. *H-NMR ANALYSIS OF ACTIVATED PTXNR
To confirm the linkage of the activated carbamate group at the 2O H site of
PTXNR, the 'H-NMR experiment was carried out. In carrying out the experiment, 2 mg
of each unmodified PTXNR and surface functionalized PTXNR particles were dissolved
in 600 |il of chloroform-d solvent (Alfa Aesar). The solvent was used as the internal
reference to determine chemical shifts (5) in ppm. !H-NMR spectra were then recorded
using Bruker advanced III 400 MHz Liquid-State NMR instrument at R.T.

2.5. CONJUGATION OF TTZ WITH ACTIVATED PTXNR THROUGH THE
LYSINE RESIDUE INTERACTION
The CDI activated PTXNRs were subsequently reacted with the s-amino group of
lysine residues of TTZ (pKa 10.53) for subsequent conjugation.54 100 |ig of TTZ powder
was dissolved in 100 |il carbonate buffer at pH 9.3-9.5 and added to the CDI activated
100 |il of 1 mg PTXNR-CDI particle suspension. The reaction was allowed to proceed
for 48 h at room temperature (~22°C). The resulting TTZ conjugated PTXNR (PTXNRTTZ) particles were centrifuged at 16,000*g for 25 min and washed using carbonate
buffer at pH 9.3-9.5 (3* 1 ml). The supernatant was collected after each washing for
quantifying the unbound TTZ. The concentrate was collected by centrifuging the
membrane filter at 1,000*g for 2 min. The concentrated PTXNR-TTZ particles were
finally re-suspended in 300 |il of PBS (pH 7.5). The amount of PTXNR in PTXNR-TTZ
was quantified by measuring absorbance at 230 nm (BioTek Synergy 2; BioTek,
Winooski, VT, USA) using a PTX calibration curve (SI Figure 3). The amount of
unbound antibody was quantified using a BCA protein Assay (Pierce Biotechnology,
Rockford, IL, USA) and a TTZ calibration curve (SI Figure 4). The size and shape of
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PTXNR-TTZ particles were investigated using SEM (10.0 kV; accelerating voltage with
5.6 mm working distance and 20,000X magnification). The surface charge of the
PTXNR-TTZ was measured in DI water and PBS using a Nano series Zetasizer
(Malvern).

2.6. FLUORESCENCE DATA ANALYSIS TO CONFIRM THE CONJUGATION
OF TTZ WITH PTXNR
To confirm the successful conjugation of TTZ with PTXNR, TTZ was tagged
with Alexa 594 red fluorescent dye molecule (Invitrogen) according to the
manufacturer’s protocol before conjugating with PTXNR. The fluorescence data of both
unconjugated bare PTXNR and conjugated Alexa 594 tagged PTXNR-TTZ particles
were obtained using a flow cytometer (BD Accuri C6 plus). The fluorescence signal of
the particles was acquired using a 585/40 bandpass filter with 488 nm laser excitation.

2.7. OPTIMIZATION OF TTZ CONJUGATION USING RESPONSE SURFACE
ANALYSIS
The optimum conditions for maximum TTZ conjugation efficiency were
investigated by the response surface analysis method using JMP statistical modeling
software. The design of the experiment involved two factors, initial PTXNR, and initial
TTZ concentration. Three levels were assigned to each of the two factors. For initial
PTXNR concentration the levels were 5, 10, 15 mg/ml and for initial TTZ concentrations
the levels were 0.5, 1.0, 1.5 mg/ml. Each experimental design unit was replicated three
times resulting in a total 27 experimental units. For each experimental unit, a random
number was assigned using JMP. The experiments were performed according to a
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complete randomized design in three days with nine randomly assigned experiments in a
single day. Conjugation efficiency of TTZ was chosen to be the yield or response of the
experimental design. TTZ conjugation efficiency was calculated using Equation (1):
% conjugation efficiency =

2.8. IN

V IT R O

(initial am ount of TTZ )—(unbound am ount of TTZ )
(initial am ount of TTZ)

x 100

(1)

THERAPEUTIC EFFICACY

BT-474 and MDA-MB-231 cells were cultured in hybricare medium and RPMI1640, respectively supplemented with 10% fetal bovine serum (FBS) and 1% penicillinstreptomycin at 37oC and 5% CO2 . Approximately, 10,000 cells per well were plated in
96-well plates and treated with different doses of PTXNR-TTZ, PTXNRs, TTZ alone,
and PTX solution alone. After 72 h of incubation, cell viability was assessed using MTT
(3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide, MW 414) assay. MTT
reagent was added to each well to convert into an insoluble formazan from water-soluble
MTT. After 4 h, sodium dodecyl sulfate (SDS) solution prepared in 0.01 N HCl was
added to each well to solubilize the formazan. The percentage of live cells relative to
untreated control wells was quantified by measuring the absorbance at 570 nm (BioTek
Synergy 2). Cell viability was calculated as a means of six wells containing BT-474 and
MDA-MB-231 cells by subtracting the mean background level of wells containing
medium only. Nonspecific formation of formazan due to the presence of medium was
determined from triplicate wells. The number of viable cells was calculated as follows
(Equation (2)):
-^ 570 o f sample
-^ 570 o f medium
. „ „
% ceZZ vtafriZity = ------- ------ ------- ----- ------------x 100
•™570 o f live cells
^ 570 o f medium

(2)
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2.9. QUANTITATIVE ANALYSIS OF SYNERGISTIC EFFECTS OF PTXNR-TTZ
We investigated the quantitative effects of PTXNR-TTZ using combination index
analysis (CI) by the Chou-Talalay method 55,56. The CI of PTXNR alone, TTZ alone, and
conjugated PTXNR-TTZ were calculated using Equation (3) and plotted as CI versus the
fraction of cells being affected.
_ ( Dosage o f PTXNR in PTXNR - TTZ)
^
(Dosage o f PTXNR)
(Dosage o f TTZ in PTXNR - TTZ)
+
(Dosage o f TTZ)

( 3)

2.10. CELL CYCLE ANALYSIS
The effect of the PTXNR-TTZ on the cell cycle of BT-474 cells was investigated
after 24, 48, and 72 h of treatments. BT-474 cells without any treatments, PTXNR alone
treatment, and TTZ alone treatment were used as controls. The cell cycle analysis
protocol was developed by modifying the previously reported method 57,58. For each
sample of the analysis, 2 x 106 cells were seeded in a T25 cell culture flask. After 12 h,
PTXNR-TTZ, PTXNR alone, and TTZ alone were added and incubated for 24, 48, and
72 h. The untreated sample was incubated with 1 ml of PBS solution. Before harvesting
the cells, 100 |il of 5'-Bromo-2'-deoxyuridine (BrdU) (Alfa Aesar) stock solution per 5
ml of media was added to an active concentration of 40 |iM and incubated for 1 h at
37oC. The culture media was removed completely, and the cells were collected in 15 ml
centrifuge tubes. The cells were centrifuged, and the cell pellets were fixed by adding 1
ml of 100% ice-cold ethanol. The cells were stored at 4oC at least for 30 min. Ethanol
was removed after centrifugation at 500*g for 5 min and was resuspended in 1 ml of
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0.5% Triton X-100 prepared in 2N HCl. After 30 min of incubation at room temperature,
cells were pelleted down to mix with 1 ml of 0.1 M Na2B4O7.10 H2 O (pH 8.5) solution
and was incubated for at least 30 min at room temperature. The cells were pelleted down
again and washed with PBS containing 1mg/ml Bovine Serum Albumin (BSA) and 0.1 %
Tween-20 (PBST) solution. After washing, cells were resuspended in 50 |il prediluted
mouse anti-BrdU monoclonal antibody (Novus Biologicals, Cat. NBP248373) stock
solution. After 30 min of incubation in dark, 0.5 ml PBST stock solution was added and
washed. A 50 |il prediluted FITC conjugated rabbit anti-mouse secondary antibody
(Sothern Biotech, Cat. 617002) stock solution was added to cell pellets and were
incubated for 30 min at room temperature in dark. After washing again with PBST
solution, cells were resuspended in 100 |il of 1 mg/ml RNAse A (Alfa Aesar) stock
solution and incubated for at least 20 min. Finally, 300-500 |il of 35 |ig/ml propidium
iodide (PI) (Alfa Aesar) was added to cell pellets and incubated in the dark at 37oC for 45
min. Before analyzing the cells in a flow cytometer (BD accuri C6 Plus), cells were
passed through a 40-micron cell strainer (Thermo Scientific) to remove the cell
aggregates. For flow cytometry analysis, cells were gated to sort out the singlet cells and
only the singlets were gated for subsequent analysis. For acquiring the fluorescent data,
530/30 and 585/40 bandpass filters were used to acquire the BrdU positive and PIpositive cells, respectively with a 488 nm of laser excitation.

2.11. WESTERN BLOT ANALYSIS
BT-474 and MDA-MB-231 cells were treated with PTXNR-TTZ, PTXNR alone,
and TTZ alone for 48 h at 10,000 nM each for Western blot analysis. The cells were
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harvested and lysed at 4oC using 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, and 0.1%
Triton X-100, 0.5% sodium deoxycholate and 0.1% sodium dodecyl sulfate (SDS). The
lysate protein was quantified using the BCA assay and the BSA calibration curve (SI
Figure 5). For each experiment, 40 |ig of each sample was taken and added to an equal
volume of 2X Laemmli sample buffer. The cell lysate in the sample buffer was heated at
86oC for 5 min before running the SDS-PAGE electrophoresis process. Novex TrisGlycine SDS gels (8-16% and 16%) (Invitrogen) were used for gel electrophoresis. The
electrophoresis was performed for 45 min to 1h at 200 V. The separated proteins were
transferred from gel to nitrocellulose membrane using a Power Blotter (ThermoFisher
Scientific) according to the manufacturer’s protocol. After the transfer process, the
membrane was blocked for 5 h with moderate shaking using 3% BSA protein in TBST
buffer (20 mM Tris (pH 7.5), 150 mM NaCl, and 0.1% Tween 20). The membrane was
incubated with a primary monoclonal antibody overnight at 4oC. GAPDH (ThermoFisher,
Cat. MA5-15738, 1: 5000) monoclonal antibody was used as a loading control. Actin
(ThermoFisher Cat. MA5-11869, 1: 2000), Caspase -9 (ThermoFisher, Cat PA5-16358,
1:500), Caspase-3 (ThermoFisher, Cat. 43-7800, 1:500), cleaved caspase-3
(ThermoFisher Cat. PA5- 23921, 1:1000), XIAP (ThermoFisher, Cat. PA1-84846,
1:1000) and Cytochrome-C (ThermoFisher, Cat. MA5-11674, 1:400) primary
monoclonal antibodies were used to observe the corresponding proteins of interest. After
primary antibody incubation, the membrane was washed 3-5 times for 5 min each with
TBST buffer. The membrane was incubated in Horseradish peroxidase (HRP) enzymeconjugated secondary anti-mouse (ThermoFisher Cat.A27025, 1:10000 or anti-rabbit
monoclonal antibody (Cell Signaling Technology, Cat.7074P2, 1:10000) depending on
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the primary antibody host species for 1 h followed by washing with TBST washing
buffer. The electro-chemiluminescent substrate (Super Signal West Dura, ThermoFisher,
and Cat. 34075) was added on the membrane and incubated for 5 min. The electro
chemiluminescent signal was captured using a Bio-Rad gel imager. The signals were
analyzed by image processing using Fiji (Image J) software.

2.12. STATISTICAL ANALYSIS
To observe the statistically significant differences in protein expressions
compared to controls, we performed the one-tailed (either overregulation or
downregulation) t-test with a 95% confidence level. All other hypothesis testing was
performed using a two-tailed t-test. The TTZ conjugation efficiency analysis was
performed using a complete randomized (CR) model. The final conjugation efficiency
data was predicted using a response surface analysis using JMP statistical software.
P<0.05 was considered statistically significant.

3. RESULTS

3.1. SYNTHESIS OF PTXNRs
The SEM images of PTXNRs as shown in Figure 1(a) confirms the elongated rod
shape PTX drug NRs. The average diameter and length of PTXNRs were (96.87 ± 33.08)
and (503.42 ± 210) nm, respectively (Figure 1 (b)). The size distribution plots (Figure 1
(c), Figure 1 (d)) confirm the moderately narrow dispersity of the particle diameter and
length. The polydispersity index (pDI) of the particles was measured as 0.20 ± 0.02.
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PTXNRs showed high colloidal stability in DI water having a zeta potential value of (
32.60 ± 4.82) mV (Figure 1(e), SI Table 1). In 0.15 M PBS solution, the zeta potential
value was measured (-13.40 ± 2.81) mV, indicating the stability of nanoparticles even in
high salt concentrations (SI Table 1).

Figure 1. Characterization of PTXNRs. (a) Scanning electron microscopy (SEM) image
of PTXNRs; (b) Particle size percentile plot of the PTXNR-TTZ particle length and
diameter; (c) Size distribution of PTXNR particle length; (d) Size distribution of PTXNR
particle diameter as calculated analyzing SEM images. The number ‘n’ denotes the
particle population count for the analysis; and (e) Zeta potential (^) of PTXNR is 32.6±4.8 mV in water. Three colors indicate three different experiments

3.2. CONFIRMATION OF LINKER CONJUGATION WITH PTXNRs USING JH
NMR ANALYSIS
We activated the 2O H site of PTXNR to form an imidazole carbamate
intermediate for subsequent conjugation step with the 8- amino group in the lysine side
chain of TTZ (SI Figure 2). In 1H NMR analysis, imidazole carbamate intermediate
linkage was confirmed by the peak of the imidazole ring proton in ‘a’ position (Ha) at
8.35 ppm (Figure 2).59,60
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Figure 2. 1H-NMR analysis to characterize PTX-imidazole carbamate formation. 1HNMR spectra of hydrolyzed carbonyldiimidazole (CDI), PTX-imidazole carbamate
(PTXNR-CDI), and PTXNR. The NMR spectra were acquired at room temperature. For
characterization of PTXNR and PTXNR-CDI deuterated chloroform (CDCI3 , 5 7.24) and
for hydrolyzed CDI deuterated oxide (D2 O, 5 4.65) were used as reference carrier
solvents

In a parallel side reaction, CDI hydrolyzes in the aqueous phase of conjugation
reaction with TTZ. Hydrolyzation of CDI produces free imidazole ring and might
interfere in the NMR analysis as a free surface-bound residuals. To further confirm the
linkage of the imidazole carbamate with the PTXNR, we performed the NMR analysis of
hydrolyzed CDI residuals. Residual imidazole group was identified by the peak of the
imidazole proton in “a'” position (Ha') at 7.6 ppm.59 So, the shift of NMR peak at 8.35
ppm represents only the Ha proton and hence confirms the successful linkage of
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imidazole carbamate at 2 OH site of PTXNR particles forming the PTX-imidazole
carbamate intermediate (PTXNR-CDI) particles.

3.3. CONFIRMATION OF TTZ CONJUGATION WITH PTXNR-CDI
The s-amino group in lysine residue of TTZ acts as an active electrophile at the
reaction pH and attacks the CDI activated site of PTXNR through nucleophilic
substitution reaction. Attack by the electrophile amine group releases the imidazole ring
but leaves the carbonyl group resulting in a one-carbon spacer forming a stable carbamate
linkage. To confirm the TTZ conjugation, Alexa 594 fluorescent molecule was
conjugated with TTZ. The bare unconjugated PTXNR showed a mean autofluorescence
intensity of 42.60 a.u. (arbitrary unit). The Alexa 594 fluorophore bound PTXNR-TTZ,
the mean fluorescence intensity was measured 13889.46 a.u. (Figure 3(a)) that is 326
fold higher than the mean fluorescence intensity of bare PTXNR confirming a successful
conjugation of TTZ with PTXNRs (Figure 3(b)). PTXNR-TTZ showed good
dispersibility in both water and PBS (SI Figure 6).

3.4. OPTIMIZATION OF TTZ CONJUGATION EFFICIENCY
The SEM image of the PTXNR-TTZ particles confirms the consistency in the size
and shape of the particles after lyophilization (Figure 4(a)). The zeta potential of the
PTXNR-TTZ in DI water was measured -17.1±3.83 mV (Figure 4(b), SI Table 1). In
PBS, the zeta potential was measured -9.5± 0.02 mV (SI Table 1).
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Figure 3. The fluorescence intensity of PTXNR-TTZ confirms the conjugation of TTZ on
the surface of PTXNRs. (a) The F.I. of bare PTXNRs (grey) and Alexa 594 fluorophore
bound TTZ conjugated PTXNR (PTXNR-TTZ) (green) shows a significant increase in
emission spectra; (b) The quantitative mean F.I. of PTXNR-TTZ increases by ~14,000
fold (2.54 logarithmic fold ) compared to bare PTXNRs indicating TTZ is effectively
conjugated on the surface of PTXNRs using a CDI linker

The conjugated particles had a pDI of 0.21±0.11 showing significant
homogeneity in size and shape. Optimization of TTZ conjugation efficiency was
performed using response surface analysis (Figure 4(c)). The surface plot shows that the
vicinity of lower concentrations of both initial PTXNR and TTZ result in 90-95% of
conjugation efficiency, whereas the higher initial concentrations predict lower
conjugation efficiency. The analysis suggests that the higher concentration of PTX results
in precipitation of nanoparticles and less available surface for conjugation as well as
several vacant reactive sites on the nanoparticle surface, whereas the higher concentration
of TTZ produces excess unbound TTZ in the reaction medium. The maximum
conjugation efficiency of TTZ to PTXNR was calculated 95.24 ± 1.40 % (SI Table 2),
and hence, considered the optimum amount to use for subsequent experiments. The
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optimum condition for the maximum conjugation efficiency was 5mg/ml and 0.5 mg/ml
initial concentrations of PTXNR and TTZ, respectively. The drug to antibody ratio
(DAR) of the conjugated particle was 4.0 ± 0.53 on a weight basis (molar ratio=681.67 ±
90.23) (SI Table 2).

Figure 4. Characterization of PTXNR-TTZ ADNs. (a) SEM image of PTXNR-TTZ
ADNs; (b) The zeta potential (^) of PTXNR-TTZ was observed -17.1±3.83 mV in DI
water; (c) Contour plot of response surface analysis showing % conjugation efficiency of
TTZ on the surface of PTXNRs. In response surface analysis, two factors PTXNR
concentration and TTZ concentration were optimized for the highest conjugation
efficiency. Each concentration factor had three levels. For PTXNR, the concentration
levels were 5, 10, and 15 mg/ml and for TTZ the levels were 0.5, 1.0, and 1.5 mg/ml.
Each level was replicated at least three times resulting in a total 27 experimental units.
The maximum ~95% conjugation efficiency was obtained with PTXNR concentration 5
mg/ml and TTZ concentration 0.5 mg/ml. The experiment was designed according to a
Complete Randomized (CR) model using JMP statistical software

3.5. IN

V IT R O

ANTICANCER EFFICACY

To determine the anti-cancer efficacy in vitro, the dose-response cytotoxicity was
measured using PTXNR-TTZ, PTX NR alone, TTZ alone, and PTX solution alone in BT474 and MDA-MB-231 cells (Figure 5). PTXNR-TTZ was found to exert more
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therapeutic efficiency in BT-474 cells than the individual effect of PTXNR, TTZ, and
PTX solution treatments (Figure 5(a)) confirming the HER2 specificity of the ADNs.
PTXNR-TTZ inhibited >83% and 51% of BT-474 (Figure 5(a)) and MDA-MB-231
(Figure 5(b)) cancer cells, respectively suggesting specific targeting and more therapeutic
efficiency in HER2 positive BT-474 cells than MDA-MB-231 cells.

(a)

Figure 5. In vitro anti-cancer efficiency of PTXNR-TTZ ADNs. The cytotoxic effects of
PTXNR-TTZ (closed circle), PTXNR (triangle), PTX Solution (diamond), and TTZ
(square) on the growth of (a) BT-474, and (b) MDA-MB-231 cells. Each experiment was
replicated at least n=6 times, and the average data is presented with mean ± standard
deviation
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(b)

Figure 5. In vitro anti-cancer efficiency of PTXNR-TTZ ADNs.The cytotoxic effects of
PTXNR-TTZ (closed circle), PTXNR (triangle), PTX Solution (diamond), and TTZ
(square) on the growth of (a) BT-474, and (b) MDA-MB-231 cells. Each experiment was
replicated at least n=6 times, and the average data is presented with mean ± standard
deviation (cont.)
The half-maximal inhibitory concentration (IC50), as defined as the concentration
needed to kill 50% of cells, was found 106, 609 and 9000 nM for PTXNR-TTZ, PTX NR
alone and TTZ alone, respectively in BT-474 cells indicating a synergistic therapeutic
efficiency using ADNs compared to the individual treatments. MDA-MB-231 cells were
resistant to PTXNR-TTZ exhibiting an IC50 >3,000 nM indicating intrinsic trastuzumab
resistance in vitro. PTXNR alone and TTZ solution alone inhibited roughly 40% and 30%
of the MDA-MB-231 cell growth, respectively. The cytotoxic effects of PTX solution
were similar in both cell lines showing a dose-dependent cytotoxicity from 30-50%.
PTXNR effectively killed more BT474 cells from 20-60% in a dose-dependent manner
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than that in MDA-MB-231 cells from 10-30%. All these results suggest that PTXNRTTZ exerts specific cytotoxicity in HER2 positive breast cancer cells.

3.6. THE EFFECTS OF PTXNR-TTZ IS SYNERGISTIC IN HER2 POSITIVE
BREAST CANCER CELLS
The combination effects of PTXNR and TTZ were evaluated in BT-474 and
MDA-MB-231 cells using the combination index (CI) analysis (Figure 6). The effects of
the drugs were analyzed to determine whether a synergistic effect occurred in that cell
line. On the plot, any point showing CI < 1 indicates a synergistic effect, and the values
showing CI>1 is considered antagonistic. It is found that PTXNR-TTZ shows a
synergistic effect in BT474 cells by decreasing CI values <1 with increasing fraction
affected cells (Figure 6(a)). Very different CI vs. fraction affected line was observed in
MDA-MB-231 cells showing increased CI values with increasing fraction affected cells
up to 0.8 beyond which antagonistic effects were observed indicating a combination of
PTX NR and TTZ is irrelevant in this cell line (Figure 6(b)).

3.7. PTXNR-TTZ ARRESTS HER2 POSITIVE BREAST CANCER CELLS IN THE
G2/M PHASE
We quantified the population of BT-474 cells arrested in G0/G1, S, and G2/M cell
cycle phases after treatment with PTXNR-TTZ, PTXNR alone, and TTZ alone (Figure 7
and SI Figures 7-9). PTXNR-TTZ arrested 39.90, 62.56, and 83.55% of BT-474 cells in
the G2/M phase after 24, 48, and 72 h treatments, respectively. Conversely, it decreased
the proportion of the G0/G1 phase from 43.70 to 30.6 to 15.39% at 24, 48, and 72 h,
respectively.
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(a)

(b)

Figure 6. Combination Index (C.I.) analysis of PTXNR-TTZ ADNs. The C.I. plot as a
function of each fraction of cells affected by PTXNR-TTZ particles in (a) BT-474, and
(b) MDA-MB-231 cells. A C.I. value =1; additive effect, < 1; synergistic effect, > 1;
antagonistic effect. The downward and upward curves in BT-474 and MDA-MB-231
cells indicate synergistic and antagonistic effects, respectively
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PTXNR alone caused 39.76, 60.31, 76.18% arrest in the G2/M phase after 24, 48,
and 72 h, respectively. TTZ alone treatment arrested 56.25, 53.39, 57.83% of BT-474
cells in the G1 phase after 24, 48, and 72 h, respectively. The cell cycle data confirms
that PTXNR modulates the mitotic cell cycle arrest, or cell growth inhibition, and
eventually apoptosis in BT-474 breast cancer cells.

(a)
24 l

U n tre a te d
P T X N R T rea te d
T T Z T r e a te d
P T X N R -T T Z T re a te d
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G0/G1

G2/M

Figure 7. Cell cycle analysis. BT-474 cells were treated with PTXNR-TTZ, PTXNR
alone, and TTZ alone. Cell cycle analysis was performed by flow cytometry after (a) 24
h, (b) 48 h, and (c) 72 h of treatment. Each experiment was replicated at least n=2 times
and the average cell count data are presented as mean ± standard deviation
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(b)

(c)

Figure 7. Cell cycle analysis.BT-474 cells were treated with PTXNR-TTZ, PTXNR
alone, and TTZ alone. Cell cycle analysis was performed by flow cytometry after (a) 24
h, (b) 48 h, and (c) 72 h of treatment. Each experiment was replicated at least n=2 times
and the average cell count data are presented as mean ± standard deviation (Cont.)
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3.8. PTXNR-TTZ DOWNREGULATES ANTI-APOPTOTIC PROTEIN AND
INDUCES APOPTOSIS IN A CASPASE-DEPENDENT INTRINSIC
PATHWAY
We found that >80% of BT-474 cells were inhibited and arrested in the G2/M
phase by PTXNR-TTZ ADN treatments. We investigated if the prolonged cell cycle
arrest in the G2/M phase induced programmed cell death or apoptosis in cancer cells and
the mechanisms of apoptotic induction by PTXNR-TTZ ADNs. PTXNR-TTZ induced
apoptosis in HER2 positive BT-474 cells in an intrinsic cytochrome-C mediated pathway
(Figure 8(a) and Figure 8(c)). In BT-474 cells, after 48 h of treatment using PTXNRTTZ and PTX NR, we observed a significant release of cytochrome-C than that of
untreated cells. We further observed a significantly higher expression of initiator
apoptotic protein fully cleaved caspase-9. The lower expression of procaspase-3 was
correlated with the upregulation of cleaved or active form of caspase-3. The observation
is in agreement with the time-dependent expression study of caspase-3 on taxane treated
HER2 positive SK-BR-3 cell line.61 In BT-474 cells, the anti-apoptotic protein XIAP was
significantly downregulated by PTXNR-TTZ treatment than the individual drug
treatment. XIAP is a natural inhibitor of caspase-3 and caspase-9. 47,62-64 High XIAP
activity may cause the inactivation of early apoptotic protein caspase-9 and inactivation
of active caspase-3 at the later phase of apoptosis. The significant downregulation of
XIAP by PTXNR-TTZ treatment facilitates the late apoptosis by overexpressing the
effector caspase-3 apoptotic protein that attributes to the synergistic cytotoxic effect in
BT-474 cells. The high concentration of PTXNR and PTXNR-TTZ significantly
downregulated the actin production in BT-474 cells compared to MDA-MB-231 cells. In
MDA-MB-231 cells, although cytochrome-C release was observed for both PTXNR-TTZ
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and PTXNR treatments, there was no significant change in the expression of active
caspase-9 suggesting that the apoptosome was not activated in the cytosolic area (Figure
8(b) and Figure 8(d)). The procaspase-3 expression in PTXNR-TTZ treated cells was not
statistically different from that of untreated cells. Eventually, the cleaved form of the
caspase-3 signal was not observed at all with the individual drug treatment and PTXNRTTZ treatment. XIAP activity was observed in individually treated cells as well as in
PTXNR-TTZ treated cells. XIAP activity in the drug-treated cells was found to be as
high as that in untreated MDA-MB-231 cancer cells. XIAP is a potent anti-apoptotic
protein and abnormal expression of XIAP can block the cell death pathways 47

Figure 8. Western blot analysis. The cell signaling protein expressions of (a) BT-474
and (b) MDA-MB-231 cells using PBS, PTX alone, TTZ alone, and PTXNR-TTX
treatments. The relative intensity of XIAP, actin, cleaved caspase-9, caspase 3, cleaved
caspase 3 and cytochrome C is analyzed after 48 h of treatment in (c) BT-474 and (d)
MDA-MB-231 cells. For each protein expression the experiment was replicated at least
n=2-4 times and the average data is presented as mean ± standard deviation. The relative
protein expressions are normalized to the untreated control cells and to the housekeeping
GAPDH protein expression (hypothesized expression mean, g=1). The p-value for
overexpression or downregulation of cytochrome-C, cleaved caspase-3 and XIAP in (d)
BT-474 is 0.039, 0.003, and 0.000049, respectively. The p-value for the overexpression
of cytochrome-C in MDA-MB-231 is 0.047
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and (b) MDA-MB-231 cells using PBS, PTX alone, TTZ alone, and PTXNR-TTX
treatments. The relative intensity of XIAP, actin, cleaved caspase-9, caspase 3, cleaved
caspase 3 and cytochrome C is analyzed after 48 h of treatment in (c) BT-474 and (d)
MDA-MB-231 cells. For each protein expression the experiment was replicated at least
n=2-4 times and the average data is presented as mean ± standard deviation. The relative
protein expressions are normalized to the untreated control cells and to the housekeeping
GAPDH protein expression (hypothesized expression mean, |i=1). The p-value for
overexpression or downregulation of cytochrome-C, cleaved caspase-3 and XIAP in (d)
BT-474 is 0.039, 0.003, and 0.000049, respectively. The p-value for the overexpression
of cytochrome-C in MDA-MB-231 is 0.047

4. DISCUSSION

Many chemotherapeutic drugs including PTX is a water-insoluble drug that
results in low circulation time, poor bioavailability in the tumor tissue, and higher
administrative dosage.65-67 Nano-sized drug carriers, liposomes, polymeric nanoparticles,
and micelles have been designed over the past decades to improve water dispersibility,
stability and blood circulation half-life of chemotherapeutic drugs.68-71 However, most
nanoparticles suffer from poor specificity targeting only 1.6% of the administered dose of
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the linked small molecule drug to be delivered in the targeted tumor vicinity.72,73 In this
study, we designed ADNs by conjugating TTZ monoclonal antibody on the surface of
PTXNRs through a single carbonyl group spacing with >95% conjugation efficiency.
PTXNR-TTZ was synthesized in two steps. First, PTX NRs were synthesized by phase
separation of PTX drug solution from ethanol into water. This method is simple and
scalable. Secondly, PTXNRs were reacted with CDI linker in water to form intermediate
PTXNR-carbamate followed by coupling with the amine groups of TTZ using
carbodiimide chemistry that forms PTXNR-TTZ ADN.74,75 The reaction is chemically
defined, efficient, and scalable with an overall yield of >80% and a high PTX: TTZ w/w
ratio « 4 (molar ratio « 682). The cytotoxic payload in ADNs is 170-fold more than
conventional antibody-drug conjugates (molar ratio « 4) which improves the ability to
deliver more active drugs at the target site and greater in vitro potency. The PTXNR-TTZ
ADN showed greatly enhanced water dispersibility (>1 mg/ml) compared to PTX
aqueous solution, indicating little aggregation in water.52
PTXNR-TTZ ADNs are designed to target HER2 receptors overexpressed in
breast cancer cells so that the ADN binds to target cells, are internalized via endocytosis
and exerts apoptosis mediated therapeutic effects.10,48,50,76-90 The NRs, when coated with
TTZ, exhibit high binding toward HER2-overexpressing breast cancer cells.53,91 The
adhesion strength of NRs has been shown high both experimentally and by theoretical
modeling.87,92-95 After targeting and internalization, PTXNR-TTZ ADNs activated
intrinsic apoptosis pathways and inhibited >83% of HER2 positive BT-474 cells which
was 43% more than the cytotoxicity in HER2 negative MDA-MB-231 cells. No
difference in cytotoxicity was observed for PTXNR-TTZ, unconjugated PTXNR, PTX
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solution alone, and TTZ alone treatments in MDA-MB-231 cells, indicating non-specific
cell death. The IC50 of PTXNR-TTZ in BT-474 cells is lower than single drug treatments
which is consistent with the previously published literature. The IC 50 s of PTX vary
between 2-200 nM in breast cancer cells due to differential basal level expressions of Ptubulin subunits of microtubules,96-98 sensitivity of PTX toward binding with P-tubulin,96
the expression of tau proteins involved in microtubule polymerization,99 and HER2
expression levels.100 PTXNR-TTZ inhibits tubulin polymerization and microtubule
formation, blocks the cell cycle in G2/M, and induces apoptosis.
The CI analysis showed that PXNR-TTZ augments apoptosis in BT-474 cells
synergistically indicating an induction in apoptosis through multiple pathways including
intrinsic caspase-dependent pathway and cell cycle arrest. PTX and TTZ arrest cells in
G2/M and G0/G1 phase, respectively by disrupting the microtubule dynamics and
binding with HER2 extracellular domain.101-105 In this study, individual treatment using
PTXNR alone and TTZ alone arrested 76% and 57% of BT-474 cells in G2/M and
G0/G1, respectively after 72 h of treatment. In contrast, PTXNR-TTZ arrested 83.5% of
BT-474 cells in G2/M after 72 h of treatment indicating dominant effects of PTX in
sensitizing and synchronizing cells in the G2/M phase which correlates with the
percentage of apoptotic dead cells after PTXNR-TTZ treatment.106-108 The cleaved
caspase-3 and cytochrome C were significantly increased, while anti-apoptotic XIAP was
decreased in BT-474 cells after 72 h of PTXNR and PTNR-TTZ treatments compared
with untreated control. Cytochrome-C binds to apoptosis protease-activating factor-1
(APAF1), inducing its oligomerization to form apoptosome that recruits and activates an
apoptosis initiator protein, caspase-9, cleaves caspase-9 into its active small subunits and
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initiates the late apoptotic caspase cascade reactions.47,64,109,110 The cleaved caspase-9
eventually activates the late apoptotic protein caspase-3.111"113 The overexpression of
cleaved or active form of caspase-3 ultimately confirms the late phase of apoptosis in BT474 cells using PTXNR-TTZ treatment.111,114-116 In the late phase, apoptosis is facilitated
by two-fold downregulation of anti-apoptotic XIAP protein after PTXNR-TTZ treatment
compared to that in the untreated control. In contrast, MDA-MB-231 cells did not show
any sign of mid- or late phase apoptosis though having overexpression of the
cytochrome-C protein. No changes in XIAP expression was observed in MDA-MB-231
cells treated with PTXNR-TTZ. XIAP, a key member of the inhibitor of apoptosis protein
(IAP) family,117 has been shown to be a direct inhibitor of caspase-3 and to interfere with
the cytochrome-C pathway by inhibiting caspase-9 in lung cancer cells,118-120 and
leukemia cells.121-124 In this study, the downregulation of XIAP and activation of caspase
cascades in BT-474 cells by PTXNR-TTZ has proven to be an effective approach for the
treatment of HER2 positive breast cancer cells.

5. CONCLUSION

The first synthesis of PTXNR-TTZ ADNs and its therapeutic efficiency in vitro
are presented which induces higher apoptosis responses than single drug treatments in
HER2 positive breast cancer cells. The use of PTXNR of ~95 nm in diameter and 500 nm
in length remove the compromising need for toxic organic carrier solvent for intravenous
administration of PTX alone. The particles are stable in the aqueous phase that makes it
suitable for intravenous administration without any need for any organic solvent. The
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surface of PTXNR was functionalized by CDI activation reaction in the aqueous phase
and successfully conjugated TTZ without altering the size and shape of the nanoparticles.
PTXNR-TTZ synergistically inhibited HER2 positive breast cancer cells. The IC50 of
PTXNR-TTZ is 106 nM in BT-474 cancer cells which facilitates lower dose, and hence,
fewer side effects than individual treatments. PTXNR-TTZ arrested >83% of the
proliferating cells in the G2/M phase of the cell cycle after 72h of the treatment, which
was well corroborated with cell cycle analysis. The higher number of cells (>80%)
arrested in the G2/M phase after PTXNR-TTZ treatment than individual treatments using
PTXNR and TTZ (arrests in the G0/G1 phase) confirms the synergistic crosstalk between
PTX and TTZ. The Western blot analysis demonstrates that PTXNR-TTZ activates the
effector caspase proteins in HER2 positive breast cancer cells, and downregulates the
anti-apoptotic XIAP facilitating caspase-dependent apoptosis followed by the cell cycle
arrest in G2/M phase. Taken together, it is envisaged that the results from this study will
facilitate the rational design of combination therapy through a novel design of ADNs.
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II. THE ROLE OF INTRINSIC SIGNALING PATHWAYS IN CELL
PROLIFERRATION

ABSTRACT

Programmed cell death, or apoptosis, and controlled cell division, or mitosis are
two highly regulated processes in the cell cycle. A balance between apoptosis and mitosis
is critical for multiple distinct states including embryonic development, immune cell
activation, stem cell differentiation, tissue formation (wound healing), and tumor
prevention, among others. A cell undergoing apoptosis shows a series of characteristic
morphological changes similar to normal mitosis and an aberrant form of mitosis. During
each of these processes, nuclear chromatin condenses, the nuclear lamina and
cytoplasmic membranes disintegrate, and cells decrease in volume. The morphological
resemblance among cells undergoing these processes suggests that the underlying
intracellular signaling pathways influence the mitotic cell fate. In this review paper, the
relationship of intracellular signaling pathways, cell cycle dynamics, and apoptotic cell
signaling pathways are discussed. The MAPK/Ras/Raf/ERK, PI3K/Akt, JAK/STAT,
Wnt, and TGF-P are major cell signaling pathways that transmit signals from multiple
cell surface receptors to transcription factors in the nucleus. The pathways are stimulated
by cytokines, growth factors, and external stimuli, i.e., reactive oxygen species which
induce signal transduction pathways and regulate complex processes such as cell cycle
progression, cell proliferation, cellular growth, differentiation, and apoptosis. Aberrant
mutations in particular genes and proteins of these pathways contribute to cancers usually
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by inhibiting pro-apoptotic proteins and stimulating anti-apoptotic proteins. The cell
cycle is regulated by intracellular signaling pathways such as the MAPK/Ras/Raf/ERK
and PI3K pathways to synthesize cyclin D and other mitosis regulating proteins (Myc and
Jun). Cyclin D1 binds to CDK4/6 to form an effective complex, activate several
substrates, and initiate the cell cycle. The prominent molecules that regulate signaling
pathways in normal and cancer cells are described.

1. INTRODUCTION

Cell death and cell proliferation are coordinated in the cell cycle to maintain
tissue function and tissue homeostasis.1-4 The mammalian cell cycle is a regulated
process that monitors the replication of genetic information and the division of cells. This
regulation involves growth - regulatory signals and protein signals that ensure the genetic
sequence of the cell receives no damage.5 The cell cycle consists of four phases including
a GO or quiescence phase, G1 or Gap 1, S or DNA synthesis phase, a G2 or Gap 2 phase
with mitosis or M phase at the end (Figure 1 (a)). These cell cycle phases are tightly
controlled by a series of cell cycle proteins cyclin/cyclin-dependent kinases (CDKs) and
cyclin inhibitors.6 There are four cyclin groups (cyclin D, E, A, and B) that once bound
activate specific cyclin-dependent kinase (CDK) pathways. The CDK pathways act as
checkpoints that regulate the structure and property of the cellular chromosomes to either
allow or deny entry into the next phase. Once the cyclin/CDKs of cyclin D1 to CDK
4/CDK 6 are bound and activated, the complex phosphorylates the retinoblastoma (Rb)
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proteins and releases the activated E2F. At E2F this protein family determines whether
the cells will reenter the cell cycle or eliminate the cell completely.7

Figure 1. The cell cycle. (a) The cell cycle comprises four phases: G1, S, G2, and M.
Extracellular signals received during the G1 phase lead to the production of D-type
cyclins that interact with their dependent kinases. If the concentration of these cyclins is
sufficient, the cell will pass the R phase, and E-, A-, and B-type cyclins will trigger DNA
synthesis, a second gap phase to perform DNA repair, and mitosis. The cell is only
responsive to extracellular signals in G1. (b) Cyclin levels during the cell cycle. The
concentration of different types of cyclins varies with cell cycle progression. When a cell
enters a new phase, a new type of cyclin associates with CDKs, ensuring the cycle only
moves in the forward direction. The figure is reproduced with permission from Robert A.
Weinberg (The Biology of Cancer, second edition) (2013)

Entry into the cell cycle is regulated by the mitogenic signaling pathways. The
signaling pathways activate the downstream growth-promoting transcription factors
including Myc, activator protein (API), P-catenin. Such transcription factors induce
several cell cycle proteins such as cyclin D. D-type cyclins are typically present in the
cell in extremely low concentrations. Unlike other cyclins, D-type cyclins are responsive
to extracellular signals including mitogens. The E, A, and B-type cyclins are regulated in
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a preprogrammed cyclic fashion to maintain the cell cycle in a unidirectional way
(Figure 1 (b)). In response to the appropriate signals, the concentration of D-type cyclins
increases in the cell. D-type cyclins bind to and activate CDK4 and CDK6.8 Formation of
active cyclin D-CDK4/6 complex is inhibited by the inhibitor of CDK-4 (INK4) family
CDKIs (Figure 2 (a)). CDKIs act in response to growth factors, DNA damage, and other
stressors. Two families of CDKIs exist p21 family members and INK4 proteins. p21,
p27, and p57 belong to the p21 family and act by binding to cyclin-CDK complexes to
block their active and binding sites.8 Proteins of the INK4 family include p16, p15, p18,
and p19 which bind to the catalytic subunit of CDK4/6 to bind D-type cyclins from
activating them. The CDK inhibitors are activated in response to senescence inducing or
growth-inhibitory signals including DNA damage, transforming growth factor-P (TGFP), forkhead box protein 01/ O3 (FOXO1/ FOXO3) signaling pathways.

Figure 2. The pRb-E2F pathway. (a) pRb in a hypo- and hyperphosphorylated state.
CDKIs act on CDKs and CDK-cyclin complexes to prevent pRb from becoming
phosphorylated. (b) In the absence of CDKIs, CDK-cyclin complexes are free to
phosphorylate pRb. This induces a conformational change that allows pRb to release E2F
proteins
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The retinoblastoma protein (pRb) normally exists in a hypophosphorylated
state. Hypophosphorylated pRb binds E2F proteins. Upon the formation of active cyclin
D-CDK4/6 complex and subsequent hyperphosphorylation of pRb, E2Fs are released
which stimulate the transcription of several genes involved in cell cycle progression and
cell division (Figure 2 (b)). D-type cyclin-CDK4/6 complexes begin the process of
phosphorylating pRb. Among the many genes stimulated by E2Fs encode E-type cyclins.
E-type cyclins form cyclin-CDK complexes with CDK2 and phosphorylate pRb. This
positive feedback loop allows pRb to become hyperphosphorylated and allows the cell to
progress from the G1 phase to the S phase.8,9
E2Fs activated the transcription of S phase promoting genes including CCNE1
and CCNE2, translating into cyclin E proteins. Cyclin E proteins pairs with CDK2
proteins. The cyclin E-CDK2 complexes remain in an inactivated state by the interactions
with p27KIP1 and p21CIP1 cyclin-CDK complex inhibitor proteins. These inhibitor proteins
are regulated by the p53 dependent DNA damage checkpoint protein molecules and
growth-inhibitory signals. The sequestration of p27KIP1 and p21CIP1 inhibitory proteins by
cyclin D-CDK4/6 complex and phosphorylation of p27KIP1 by cyclin E-CDK2 complex
activates the cyclin E-CDK2 complex. Upon activation of the cyclin E-CDK2 complex
and further phosphorylation of pRb and other target proteins, the cells enter the S phase
(Figure 3 (a)).
Entering the S phase, D type cyclins is exported to the cytoplasm from the
nucleus where its level is no longer influenced by the extracellular growth factors. DNA
replication occurs during the S phase while A-type cyclins replace E-type cyclins. The S
phase is followed by G2, a second gap phase.
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Figure 3. Representation of G1-S, G2-M cell cycle phase transition. The figure shows the
regulation of (a) G1-S and (b) G2-M transition in the cell cycle. The cell cycle machinery
is controlled by multiple proteins including cyclins, CDKs, CDKIs, and several
transcription factors
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This ensures that the cell has adequate time to complete DNA replication and
repair any DNA damage that occurred during replication. During the late G2 phase,
several G2 phase regulator proteins including B type cyclin proteins are translated
replacing the A-type cyclins. The translation requires the association of multi-vulval class
B protein (MUVB) complex with the forkhead box M1 (FOXM1) transcription factor.
Together they bind with the cell cycle genes homology promoter region (CHR) and
induce the transcription of G2 phase regulatory genes including cyclin B genes. Cyclin B
pairs with CDK1 for cell cycle progression. The Cyclin B-CDK1 complex is activated in
the following mechanism: CDK1 requires phosphorylation at threonine (Thr161) by the
cyclin H-CDK7 protein complex and dephosphorylation at threonine 14 (Thr14) and
tyrosine 15(Tyr15) kinase sites by cell division cycle 25 (CDC25) phosphatase enzyme.
CDK7 is known as CDK activating kinase (CAK). The activation of the cyclin A/BCDK2 complex promotes the cell cycle progression to the mitosis or M phase. This
progression can be halted by checkpoint kinase-1 (CHK1) dependent G2 phase
checkpoint upon DNA damage (Figure 3 (b)).
The events of mitosis include prophase, prometaphase, metaphase, anaphase, and
telophase, resulting in two identical cells. After the M phase, the cell returns to G1 where
it is once again receptive to internal and external signals and must divide whether to enter
G0 or repeat the cell cycle. In this review, we will emphasize the major growth and anti
growth signals that stimulate the cells to take the exit from or retrieve to their quiescence
phase. Aberrations in these signaling pathways can lead to two closely related hallmarks
of cancer: evading growth suppressors and self-sufficiency in growth signals.10 Pathways
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of interest reviewed in this study are the MAPK, PI3K, Jak-STAT, Wnt, and TGFP
signaling pathways.

2. CELL SIGNALING PATHWAYS

2.1. MAPK/Ras/Raf/ERK SIGNALING PATHWAY
The MAPK pathway is a kinase cascade, also known as the extracellular signalregulated kinase pathway (ERK). The first step in this pathway is Ras activation (or
activation of other Ras family proteins). Ras activation begins when specific growth
factors bind to transmembrane receptors, primarily receptor tyrosine kinases.11 These
receptors most commonly phosphorylate growth factor receptor-bound protein 2 (Grb2)
or Shc. If Shc is phosphorylated, it will phosphorylate Grb2. Grb2 contains two
functional domains: SH2 and SH3.9 Upon phosphorylation, the SH2 domain binds to Shc
or the receptor, and the SH3 domain is available for Sos binding.9 This brings Sos into
close proximity to Ras.12
Ras (and related Ras family proteins) are membrane-bound GTPases that function
as G proteins. G proteins act as molecular switches that cycle between being GDP and
GTP bound depending on extracellular signals such as growth factors and survival
signals.13 Sos can activate Ras by inducing it to convert GDP to GTP (Figure 4).
Ras binding and activation lead to Raf kinases including ARAF, BRAF, and
CRAF, thus beginning the kinase cascade (Figure 5). Rafs are MAPKKKs which activate
MAPKKs MEK1 and MEK2. MEK1/2 activates MAPKs ERK1 and ERK2.
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Figure 4. The Ras activation pathway. Growth factors bind to their respective receptors
allowing them to bind Shc or Grb2. Grb2 binds Sos bringing it in proximity to Ras. This
induces Ras to switch from an “off’ to an “on” conformation, converting GDP to GTP

These MAPKs translocate to the nucleus and phosphorylate several proliferation
promoting transcription factors including Myc.14 Myc is a major regulator of cell cycle
progression and pRb.9 Myc is a transcription factor that elevates the expression of D-type
cyclins, CDK4/6, and several E2F proteins. Myc also signals the expression of C ull, a
protein which phosphorylates the CDKI p27 for subsequent ubiquitination and
degradation.13 Myc is also capable of repressing p15 and p21 expression by associating
with Myc-interacting zinc finger protein 1 (Miz-1).9
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Figure 5. The MAPK signaling pathway. Ras activation initiates a kinase cascade.
Eventually, MAPK proteins ERK1 and ERK2 enter the nucleus to phosphorylate and
activate several pro-mitotic transcription factors including Myc

2.2. MAPK PATHWAY ASSOCIATED TARGETS FOR CANCER THERAPY
Extensive studies have been conducted targeting the Ras-Raf-MEK-ERK pathway
alterations in cancer. The pathway is altered in almost 40% of all types of human
cancers.11,15 RAS point mutations are found in up to 30% of all human cancers and 90%
of pancreatic adenocarcinomas.11 These mutations often render Ras insensitive to
inactivation leading them to remain activated in the absence of pro-mitotic factors.11
BRAF mutation accounts for almost 10% of all human cancers.16 In metastatic
melanoma, BRAF mutation is altered in almost 50-60% of the cases and is considered to
be the most prevalent acquired hallmark in melanoma.15 Mutations resulting in
hyperactive Raf proteins are also common among thyroid17-19 and colon cancer,20,21,
among other types.11 The prevalence of these mutations in cancer has led to considerable
research into treatments and mechanisms of resistance targeting this pathway.15
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One of the major strategies of targeting and blocking the MAPK signaling
pathway includes the use of MEK inhibitors.11 MEK inhibitors are small molecules that
inhibit MEK1/2 either by inhibiting Raf phosphorylation activity or by allosterically
blocking the conformational shift of MEK1/2 typically induced by phosphorylation.22
Cobimetinib (brand name Cotellic) is an FDA approved MEK inhibitor which may be
used in combination with Vemurafenib to treat melanoma. Vemurafenib (a Raf inhibitor)
was previously approved for patients with a BRAF V600E mutation.22 Dabrafenib and
Encorafenib are also approved for advanced melanoma patients with BRAF V600E
mutation. In combination, Cobimetinib has been shown to improve progression-free
survival and response to the drug compared to Vemurafenib alone.23 Two other MEK
inhibitors, Trametinib (Mekinist) and Binimetinib (Mektovi) have been approved by the
FDA to treat melanomas with mutations in the BRAF genes in combination with Raf
inhibitors. The epidermal growth factor receptor (EGFR) inhibitors Gefitinib and
Lapatinib are two approved drugs to inhibit the MAPK pathway in cancer treatment.
Though MEK inhibitors showed tremendous potency and high selectivity to
inhibit this pathway, their success was limited by the acquired resistance upon treatment
with single-arm MEK inhibitor.24-26 Upon perturbation by the MEK inhibitor, a negative
feedback loop mechanism inactivates the Raf protein in the pathway causing the drug to
be ineffective on the MEK eventually. This negative feedback loop mechanism results in
the restoration of the ERK signaling pathway. Hence, targeting the inhibition of both Raf
and MEK is now a standard therapy in metastatic melanoma treatment. Inhibition of
restoration of ERK pathway upon therapeutic intervention by Raf or MEK inhibitors is a
major challenge in dealing with drug resistance.27-29 The mechanisms of restoration often
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impinge on the dimerization of Raf kinases,30 though dimerization is a part of
physiological Raf activation.31 Raf kinases are frequently dimerized in tumors with
mutated RAS. The dimerized Raf is drug-resistant can paradoxically reactivate the ERK
pathways causing therapeutic resistance. Inhibitors targeting the inhibition Raf
dimerization may overcome such resistance. Furthermore, the therapeutic resistance in
this pathway is also attributed to the role of Jun N-terminal kinase (JNK) and p38 MAPK
pathway mediated drug resistance.31-35

2.3. PI3K/Akt SIGNALING PATHWAY
The PI3K/Akt pathway influences cell proliferation (Figure 6). Extracellular
cytokines bind to transmembrane receptors which activate PI3K via two mechanisms.
Some receptors bind the regulatory subunit of PI3K (p85), recruiting the catalytic subunit
(p110) of PI3K.36 Ras can also activate the p110 subunit of PI3K in addition to its
function in the MAPK signaling pathway.14,36 Once activated, PI3K causes
phosphatidylinositol-dependent kinase-1 (PDK1) to localize at the membrane.36 PDK1
phosphorylates and activates Akt. Akt is known to phosphorylate a number of substrates,
many of which have implications in controlling the cell cycle regulation.9 Notably, it
phosphorylates glycogen synthase kinase 3 beta (GSK-3P), tagging it for degradation.9
GSK-3P, a major player in the Wnt signaling pathway described below, is responsible for
phosphorylating P-catenin (an upstream regulator of Myc and cyclin D) for ubiquitination
and degradation.9,37 Akt also phosphorylates the CDK inhibitor p21.
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Figure 6. The PI3K signaling pathway. Ligand-receptor binding activates and associates
p85 with p110 to form PI3K. PI3K activates PDK1 which phosphorylates Akt.
Phosphorylated Akt can inhibit anti-mitotic proteins including GSK-3P or phosphorylate
them for subsequent ubiquitination and degradation. Akt also has anti-apoptotic effects

Upon phosphorylation, p21 moves from the nucleus to the cytoplasm where it
actually exhibits anti-apoptotic functions. The third substrate for Akt involved in
proliferation is FOXO4. FOXO4 induces CDKI p27 expression; however, upon
phosphorylation, FOXO4 is transported to the cytoplasm like p21.9
It is also interesting to note that Akt phosphorylates substrates directly related to
the apoptotic machinery. Akt inhibits the pro-apoptotic proteins Bad and caspase 9 and
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activates mouse-double minute 2 homolog (MDM2). Thus, Akt drives cell survival and
proliferation by transmitting anti-apoptotic and pro-mitotic signals within the cell.
Because of its role in regulating cell death and proliferation, it is perhaps unsurprising
that aberrations in the PI3K pathway have been found in several cancers. Notably, a
mutant p85 has been identified in Hodgkin’s lymphoma cells and has been linked to
breast cancer, lung cancer, melanomas, and leukemia.36

2.4. PI3K/Akt PATHWAY ASSOCIATED TARGETS FOR CANCER THERAPY
The PI3K/Akt pathway is an attractive therapy for chemotherapy due to its role in
so many cancer types. PI3K inhibitors act via various mechanisms to inhibit members of
the PI3K/Akt pathway, primarily PI3K or Akt.36 Wortmannin was the first PI3K inhibitor
to be approved by the FDA.36 Wortmannin is not selective and binds to PI3K as well as
several related proteins.38 Wortmannin irreversibly inhibits PI3K by covalently binding to
a lysine residue in the protein’s catalytic subunit.38 Wortmannin has good efficacy but is
somewhat unstable; following its development other PI3K inhibitors have been
developed.
Two more recently approved drugs include Aleplisib and Idelalisib. Alpelisib
(Piqray) was approved by the FDA to treat HER2 negative breast cancer with mutant
PI3K. Idelalisib (Zydelig) has been approved for solo or combination treatment of
chronic lymphocytic leukemia and two types of Non-Hodgkin lymphomas. PIK3CA is a
mediator of HER2 targeted treatment resistance. PIK3CA mutation accounts for almost
20% of HER2 positive breast cancer patients and imposes the insufficiency of HER2
blockade strategy to suppress the downstream PI3K signaling pathway. PI3K activation
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pathway is most often accompanied by loss of tumor suppressor gene PTEN in breast
cancer.

2.5. Jak-STAT SIGNALING PATHWAY
The Jak-STAT signaling pathway offers another method for cytokines and growth
factors to directly influence cell proliferation (Figure 7).39

Figure 7. The Jak-STAT signaling pathway. Associated growth factors bind receptors to
activate Jak family proteins. These proteins phosphorylate each other followed by their
receptor. This leads to the binding and phosphorylation of STAT proteins. STAT proteins
dimerize and translocate to the nucleus to activate pro-mitotic genes that encode for Dtype cyclins, CDK4/6, and Myc

Upon the binding of their extracellular ligands, receptors in the Jak-STAT
pathway dimerize and associated Janus kinases (Jaks) phosphorylate tyrosines on the
opposing receptors. Activated Jaks can then phosphorylate STATs (signal transducers
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and activators of transcription). Upon phosphorylation, STAT proteins dimerize and
translocate from the cytoplasm to the nucleus. STATs activate several target genes
involved in cell proliferation including those encoding for Myc and two D-type cyclins.
This pathway offers a simple opportunity for signal transduction between extracellular
signals and the cell cycle; however, this pathway also interacts with some of the more
complex pathways described above. For example, Jaks are capable of phosphorylating
tyrosines on receptors in the MAPK or PI3K pathway as well as their own pathway. This
phosphorylation leads to the same activation of Ras (in MAPK signaling) and p85 (in
PI3K), enabling those pathways to send proliferative signals to the nucleus as well.39,40

2.6. Jak-STAT PATHWAY ASSOCIATED TARGETS FOR CANCER THERAPY
In healthy cells, STAT proteins are only active upon phosphorylation by Jaks. In
some cancers, constitutively active STAT proteins have been found, signaling for
proliferation in the absence of cytokines and growth factors. Notably, STAT3 (a protein
in the STAT family) has been found to be constitutively active in 40% of breast cancers
and T-cell large granular lymphocytic leukemia cases, as well as many cases of prostate,
glioblastoma, thyroid, and non-small cell lung cancer.40 The Jak-STAT pathway also
regulates components of the immune response; several mutations resulting in hyperactive
Jak or STAT proteins are known to influence immune diseases.40,41 Because of this, Jak
and STAT inhibitors have been studied for many cancers and immune diseases.42 Several
Jak inhibitors have been approved to treat immune disorders such as psoriasis,
myelofibrosis, and rheumatoid arthritis.41,43 While many of these agents are also being
investigated to treat different cancer types, none have yet passed clinical trials.41,43
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2.7. Wnt SIGNALING PATHWAY
The Wnt signaling pathway can also influence cellular proliferation (Figure 8).37

Figure 8. The Wnt signaling pathway. Wnt binds to the transmembrane receptor
Frizzled to activate Disheveled. Disheveled inhibits GSK-3P preventing P-catenin
degradation. Instead, B-catenin translocates to the nucleus, associates with Tcf/Lef, and
induces the transcription of D-type cyclins and Myc

Wnts are secreted glycoproteins that interact with several signaling pathways that
are not fully understood.37,44 The most well-known is the canonical pathway which
influences cell cycle progression.9,37,44 P-catenin is normally present in the cell in very
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low concentrations with a half-life of 20 minutes.9 Cytoplasmic P-catenin forms a
complex with axin, adenomatous polyposis coli protein (APC), and GSK-3P.9 This
multiprotein complex enables GSK-3P to phosphorylate P-catenin, tagging it for
ubiquitination and subsequent degradation, thus maintaining its short half-life and low
intracellular concentration.9 However, the canonical Wnt signaling pathway prevents this
degradation from occurring. Wnts associate with low-density lipoprotein receptor-related
protein (LRP) 5 and 6, Wnt ligand co-receptors, and bind to transmembrane receptors of
the Frizzled gene family.44 This binding, in turn, inhibits GSK-3P.44 With GSK-3P unable
to phosphorylate P-catenin, it accumulates in the cytoplasm before translocating to the
nucleus.44 There it binds to and activates the T-cell factor/lymphoid enhancer factor
(Tcf/Lef) transcription factors.9 This complex is responsible for the transcription of many
genes, including Myc and cyclin D1, both of which are involved in cell cycle
44
progression.44

2.8. Wnt SIGNALING PATHWAY ASSOCIATED TARGETS FOR CANCER
THERAPY
Colorectal cancers (CRC) are the most commonly affected cancers by the
dysregulation in the Wnt signaling pathway. A sequencing study on 1134 CRC samples
identified that almost 96% % of the human CRC was associated with Wnt oncogenic
activity.45 Loss of function mutation in APC is the most common in colorectal cancers,4650 followed by alterations causing inhibition of the proteasomal degradation or
downregulation of P-catenin.51-54 Due to the acquired resistance upon conventional
therapeutic intervention, a few Wnt/P-catenin inhibitors have been identified as useful
agents in treating any type of cancer with Wnt pathway dysregulation. Krishnamurthy

86

and Kurzrock summarized 35 therapeutic drugs that inhibit the Wnt signaling
pathway.55 Of those, three off label drugs were FDA approved: Niclosamide, a drug
traditionally used to treat tapeworm infestations, thought to downregulate disheveled;
Sulindac, a nonsteroidal anti-inflammatory drug, also thought to target disheveled; and
Pyrvinium, an anthelmintic, thought to target the Wnt inhibitor CK1a.55 The wide domain
of Wnt signaling dysregulation across the cancer types has led to the identification of
cancer-specific therapeutic targets in the Wnt signaling pathway. The list of Wnt/ Pcatenin inhibitors in the past and present clinical trials and potential therapeutic target in
this pathway beyond the P-catenin destruction pathways are well summarized in a recent
review by Jung et. al.56 In addition to the malignant progression caused by the aberrant
Wnt signaling pathway emerging evidence suggests that Wnt pathway also alters the
cancer-immune system surveillance and offers resistance to the immunotherapeutic
drugs.57-59

2.9. TGF- p SIGNALING PATHWAY
The above-mentioned signaling pathways all rely on growth signals to stimulate
proliferation. When those pathways acquire mutations resulting in constitutively active
components, they fire and signal for cell cycle progression, whether or not growth signals
are present. This is known as “self-sufficiency in growth signal,” a hallmark of cancer.10
However, cells do not rely solely on the presence of growth signals to stimulate
proliferation. Anti-growth signals also regulate proliferation by commanding a cell not to
progress through the cell cycle.
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Transforming growth factor-beta (TGF-P) is the best studied growth-inhibitory
signal (Figure 9).5

Figure 9. The TGF P signaling pathway. TGF P inhibits cell cycle progression by
binding Type I (blue) and Type II (green) receptors. Binding induces Smad2/3
phosphorylation. Smad 2/3 then dimerizes with Smad 4 and translocates to the nucleus to
associate with Miz-1. The Smad dimer-Miz-1 complex acts as a transcription factor for
the CDKIs p21 and p15

When the TGF-P ligand binds receptors on the cell’s surface, type I and II
receptors associate leading to the phosphorylation of Smad2 and Smad3. Phosphorylated
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Smad 2/3 is capable of dimerizing with Smad4.9 These Smad dimers translocate to the
nucleus where they associate with Miz-1.9 Upon binding with Miz-1, Smad complexes
act as transcription factors for CDKIs p15 and p21.9
In healthy cells, Smad complexes and Myc compete to bind with Miz-1 to control
the expression or repression of these CDKIs.9 To prevent proliferation, Smad3 is capable
of binding to the promoter site of the MYC gene, blocking its expression and favoring
binding between Miz-1 and Smads.9 Many cancer cells develop strategies to avoid TGFP’s growth inhibitory effects, known as “insensitivity to antigrowth signals”.10
Overexpression of Myc will favor Miz-1 binding to Myc rather than Smad
dimers, preventing the expression of p21 and p15.9 It is common among cancer cells for
mutations in the MYC promoter site to prevent TGF-P induced repression.5 In other cells,
pRb is lost and the MAPK pathway is no longer the main pathway signaling to advance
in the cell cycle.9 Since TGF-P primarily inhibits Myc and the MAPK signaling pathway,
this renders TGF-P ineffective as other signaling pathways continue to trigger
activation.13 In colon cancers, mutations in the TGFP pathway are common. These take
the form of mutations in the gene which encodes Smad2 or through the presence of Ski
and Sno, proteins that bind to and inhibit Smad dimers.9 Other colon cancers acquire
mutations which inactivate the transmembrane receptors in the TGF-P pathway.9

2.10. TGF-p SIGNALING PATHWAY ASSOCIATED TARGETS FOR CANCER
THERAPY
In premalignant state, TGF P maintains the tissue homeostasis by cytostasis,
differentiation, induction of apoptosis, suppression of tumorigenic inflammation and
stroma derived mitogens. The malignant cells can adulterate the suppressive pathway of
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TGF P promoting tumor growth and invasion, deceiving the immune surveillance, and
finally causing metastasis. There are two ways to do that. The first one is the upstream
inactivation of the core component in the pathway, for example, mutations in the
receptors. Secondly, the downstream alterations in the tumor-suppressive arm in the
pathway such as defective cytostatic response in tumorigenesis. The consequence of the
first type of malignancy in the cancer cells removes the chance for tumor suppression
upon suppressive growth signals. The second type of malignancy is more aggressive as it
allows the cancer cells to aberrantly use the TGF P regulatory functions, produce
autocrine mitogens, release prometastatic cytokines and hence, create a pro-tumorigenic
microenvironment along with deactivation of growth suppression capability.
Additionally, TGF-P may contribute to invasion and metastasis.60 Cancer cells TGF-P has
been shown to induce Smad 2/3 dependent epithelial-mesenchymal transition (EMT).60
EMT is a critical acquired ability in metastatic cancers. The therapeutic targets in this
pathway include antisense oligonucleotides for TGF-P production inhibition, anti-TGF-P
antibodies, and anti-receptor antibodies to inhibit the ligand-receptor interactions, small
molecules targeting TGF-P receptor kinases and TGF-P trapping receptor codomain
proteins.61-64

3. CELL CYCLE PROTEINS: CYCLINS, CDKs AND CDK INHIBITORS

In the following sections, the main molecules participating in the signaling
pathways of the cell division and cell cycle are described.
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3.1. CYCLINS
Cyclin Ds are important for the cell entry into the G1 phase of the cell cycle and
the transition to the S phase. There are three members of the cyclin D family: D1, D2,
and D3. Cyclin D1 plays an important role in cell cycle progression. Cyclin D1 conducts
specific functions to regulate gene expression in the context of chromatin, cellular
migration promotion, and chromosomal instability promotion.65 Once the cyclin D family
activates the kinases, CDK4 and CDK6, the cells can transition into the S phase. The
cyclin E family plays an important checkpoint that allows the cells to transition from the
G1 phase to the S phase. There are two members of the cyclin E family: E1 and E2. The
cyclin E family limits the number of cells that enter the S phase and the G0 phase. Cyclin
E also plays an important role in replication of DNA, the genomic stability, and the
centrosome cycle. Once the cyclin E family activates the kinase CDK2, the cells can
transition into the S phase. The cyclin A family regulates the cell proliferation through
the S phase. The cyclin A family activates the kinase CDK2, during the S phase and will
activate the kinase CDK2 at the checkpoint, to determine if the cell will transition to the
G2 phase or remain in the S phase. Lastly, the cyclin B family regulates the last
checkpoint that allows the cell to transition from the G2 phase to the M phase to complete
division. The cyclin B family activates the kinase CDK1 to further allow entry of the cell
into the M phase.

3.2. CYCLIN DEPENDENT KINASES
CDK4 and CDK6, activated by the cyclin D family, promote the cell transitioning
by two major mechanisms; they sequester the CDK inhibitors p21 and p27, and they
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phosphorylate the RB family to code for the p107 and p130 proteins.5 The proteins p21
and p27 are responsible for the cell’s progression through the G1 to the S phase by
inhibiting the activity of CDK4/6. The proteins p107 and p130 are responsible for
monitoring the activity of the E2F family by limiting the genetic material needed for the
cell’s transition through the cell cycle. Another way to describe the p107 and p130
proteins are as “pocket proteins”.66
CDK2 can be activated by either cyclin E or cyclin A family. CDK2 is a
serine/threonine protein kinase that is the key regulator in the cell phases of G1/S and
S/G2.67 In the transition from the G1/S phases, CDK4/6 phosphorylates the Rb proteins
from the activation caused by cyclin D. CDK2, activated by cyclin E, further completes
the phosphorylation of Rb to activate the E2F family. CDK2 is also required for mini
chromosome maintenance proteins that are essential for the initiation of replication.67
Overall CDK2 is responsible for the drive of the progression through the cell cycle.
CDK1 can be activated by either the cyclin A or cyclin B family. CDK1 is
responsible for the successful completion of the M phase in the cell cycle. CDK1
activated by cyclin A, regulates the cell’s entry into mitosis and proceeds until cyclin A
eliminates the ubiquitin - proteasome system that starts in the early stages of
prometaphase.68 When CDK1 is activated by cyclin B, the cell is signaled to proceed
onward through mitosis to complete the DNA replication to divide.

3.3. CYCLIN DEPENDENT KINASE INHIBITORS (CDKIs)
CDKIs are proteins that inhibit the activated CDKs of the cell cycle. Seven CDKI
proteins can cause the cell’s progression to be delayed including p15, p16, p18, p19, p21,
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p27, and p57. p15 targets CDK4 by the CDKN2B gene to prevent the activation of the
cyclin D family in the G0/G1 phase.69 Thus, the p15 protein inhibits the cells progression
in the early phase of the cell cycle. p16 delays the proliferation of the cell through the G1
and S phase by targeting CDK4/6 and is encoded by the gene CDKN2A. When
CDKN2A is deleted, it can cause the p16 to be non-functional and result in an
acceleration of the cell cycle.70 p18 is encoded by the CDKN2C gene to target the
activation of CDK4/6 in the early phase of cell progression. p19 also targets CDK4/6 in
the early phase of cell progression by the CDKN2D gene. As mentioned in the cyclin dependent kinase section, p21 and p27 can be sequestered by CDK4/6. p21 and p27 are
encoded by the genes CDKN1A and CDKN1B to target CDK2 and CDK4. By inhibiting
the activity of CDK4/6, p21 and p27 are responsible for the cell’s progression through the
cell cycle. Lastly, p57 is encoded by the gene CDKN1C to target CDK2 in the cells
transition from the G1 phase to the S phase. Each CDKI protein acts as a tumor
suppressor to delay the activity of the tumor formation.

3.4. THE ROLE OF p53 IN CELL CYCLE REGULATION
p53 is a nuclear transcription factor that targets genes involved in the induction of
cell cycle arrest and/or apoptosis.71 DNA damage usually involves the activation of p53
in response to damages to the DNA and stresses. Once p53 is activated, there are two
pathways the cell can go. The first is cell cycle arrest and the second is apoptosis. The
p53 pathway can signal to p21 that will mediate the binding to CDK2 and CDK1 to lead
the arrest at specific stages in the cell cycle due to various stimuli.72 On the other hand,
p53 can activate either Bax or Puma for cell apoptosis. Bax is an apoptosis regulator that
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is part of the Bcl-2 family of proteins that are the main regulators of cell death. BAX is
the central mediator and contains BH1, BH2, and BH3 domains with a hydrophobic
membrane.72 Puma is a potent killer among the Bcl-2 homology 3 that transduces
apoptosis signals primarily to the mitochondria.73 PUMA indirectly responds with BAX
to promote apoptosis of the cell.

3.5. THE ROLE OF Bax AND Puma IN p53 - MEDIATED THERAPY
Bax is one of two nuclear encoded proteins that mediate cell death. Bax was the
first death inducing member of the Bcl-2 family due to studies that involved protein
purification with Bcl-2. Bax is a globular protein that contains nine helices; Alpha 1 to
Alpha 8 are the inhibitors of apoptosis.74 Bax can be activated by cleavage of caspases,
inhibition of protein kinases, activation of phosphates, and an increase in intracellular
pH.75 Specifically, to p53, under stress signals cytochrome c is released, inducing
apoptosis. Puma is essential for apoptosis and is activated due to DNA damage on p53.
Puma p53-mediated apoptosis includes the neuronal cell death induced by 6 hydroxydopamine,76 and cancer cell death induced by proteasome inhibitors.77 Oncogenic
stress can also activate Puma to function as a safeguard against neoplastic
transformation.73 Puma- induced apoptosis requires interactions with the Bcl-2 family
proteins such as Bax and once triggered, mitochondrial dysfunction and caspase
activation is induced. In cancer, Puma can be compromised due to p53 mutations caused
by irradiation and chemotherapy drugs, overexpression of the Bcl-2 family proteins, and
poor levels of Puma detection.73 Even with the compromises, it is important to note that
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Puma in p53-mediated therapies is still emerging and deciphering the different
signaling pathways will contribute to targeting Puma p53-mediated therapies.

3.6. CYCLIN, CDK AND CDKI TARGETS FOR CANCER THERAPY
The CDK4/6-Rb pathway is frequently deregulated in cancer that influences the
tumor cells to enter the restriction (R) point at the late G1 phase and complete the cell
cycle.5 The deregulations of major cell cycle proteins in this pathway in terms of
deletions, amplifications and point mutations are summarized by Otto et.al.5 In this
pathway, the tumor suppressor CDK4/6 inhibitor p16INK4Aprotein is often silenced by
promoter methylation or the p16INK4Aencoding gene CDKN2A is frequently deleted
across all human cancer types.78 The frequent deletion of RB1, the pRb encoding gene
also causes the proliferation of tumor cells irrespective of their cyclin D-CDK4/6
catalytic activity.78
The cyclin D1 gene (CCND1) is the second most frequently amplified gene in all
cancer types.5,78 The overexpression of cyclin D1 increases the catalytic activity of their
binding partner CDK4/6 and hence increases the proliferation rate of tumor cells. In a
transgenic mice model overexpression of cyclin D1 induced hyperplasia and carcinoma
in mammary glands.79 Carcinogen induced skin tumorigenesis was induced by the
overexpression of cyclin D1 protein, cyclin D2 gene, and CDK4 protein
overexpression.16,80,81 Cyclin D1 protein is overexpressed in 50-70% of the breast cancer
cases and is most frequent in Luminal B type and human epidermal growth factor
receptor-2 (HER2) positive breast cancer.82,83 Cyclin D1 promotes tumorigenesis in
HER2 positive breast cancer.84 The amplification in the CCND1 gene copy number is
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present in only 9-30% of the cases suggesting underlying mechanisms of protein
overexpression other than the copy number amplification.83 An integrative study of
CCND1 amplification in 2305 breast tumors found that CCND1 amplified tumors
induced the co-expression of proliferative gene MKI67 across all of the PAM50
classified breast cancer subtypes including HER2 positive breast cancer.83 The same
study also suggests that CCND1 amplification is independent of CDK4/6 gene
upregulation and could be a poor predictive biomarker for the prediction of response to
CDK-4/6 inhibitors. CDK4 is constitutively amplified in glioblastomas.85 CDK4 is most
commonly mutated by an R24C point mutation in melanomas and becomes insensitive to
the INK4 members of CDKIs promoting unhalted growth.86 CDK4 promotes
tumorigenesis in HER2 positive breast cancer cells.87,88 An oncogenic KrasG12Vdriven
lung cancer showed selective sensitivity to CDK4 inhibition indifferent to CDK2 or
CDK6.89 Altogether the data suggest that the CDK4/6-Rb pathway is a crucial target for
cell cycle targeted therapeutic trials. The CDK 4/6 inhibitors Palbociclib, Ribociclib, and
Abemaciclib have been approved for the treatment of Herceptin receptor-positive
(HER2+) and Herceptin receptor-negative (HER2-) breast cancer treatment. Several other
CDK 4/6 targeted therapeutic trials are ongoing for breast cancer,90-92 and other solid
tumors.5,93
Cyclin E1 encoding gene CCNE1 is commonly amplified in ovarian94 and breast
cancer.95 CCNE1 copy number amplification or Cyclin E overexpression and
corresponding CDK2 activity is associated with worse clinical benefit, poor progressionfree survival with statistical significance. In a study on 395 breast cancer patients, Cyclin
E expression was the most powerfully negatively correlated with patients overall and
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disease-free survival.96 CDK2 mutation is rare but the Cyclin E protein overexpression
causes the hyper catalytic activity of Cyclin E-CDK2 complex.5 CDK2 activity is
normally kept inactivated by the association of CDK inhibitors p21CIP1 and p27KIP1
protein molecules. Degradation of these molecules has been shown to increase the
activity of CDK2 and cyclin E-CDK2 complex and promote tumor formation.97-99
Cyclin A2/B-CDK1 catalytic activity is required for entry into the mitotic phase.
CDK1 is rarely deregulated in cancer. But there is some evidence that CDK1 activity is
required for tumorigenesis. For example, CDK1 inhibition induced apoptosis in Myc has
driven mouse lymphomas, liver tumors,100 and human triple-negative breast cancer
cells.101 In a KRas mutant colorectal cancer xenograft model, CDK inhibition blocked the
tumor growth.102 Despite of these evidence the inhibition of CDK1 is a tricky target as
normal cells also require CDK1 for regular cell cycle progression.5 103

4. APOPTOTIC SIGNALING PATHWAYS

Apoptosis, programmed cell death, is used to regulate tissue development and
homeostasis.104 In healthy cells, this critical process is regulated by internal and external
signals. The intrinsic pathway can be triggered by a myriad of events including severe
DNA damage, anoxia, or other internal signaling imbalances. The extrinsic pathway is
primarily triggered by death receptor ligands.
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4.1. INTRINSIC PATHWAY
p53 is the primary regulator for triggering apoptosis in response to internal stress.
p53 is always present in the cell at extremely low levels.105 This is maintained by MDM2
which ubiquitinates p53 for degradation.105 Stresses including but not limited to DNA
damage, oncogene activation, anoxia, radiation, heat shock, oxidative stress, osmotic
stress, and nutrient deprivation can increase the expression of p53 through various
mechanisms.
For example, while small levels of DNA damage will trigger DNA repair
pathways, extreme DNA damage will trigger apoptosis. The Mre11-Rad50-Nbs1(MRN)
complex binds to double-stranded breaks in DNA.106 MRN then recruits and activates
ataxia telangiectasia protein (ATM). Similarly, ATR interacting protein (ATRIP) binds to
single-stranded DNA exposed due to damage and recruits ATM-related protein (ATR).106
ATM and ATR phosphorylate and activate p53.107 Additionally, the ARF protein battles
with MDM2 to regulate p53 levels in the cell. However, the insertion of an additional
exon between the CDKIs INK4A and INK4B leads to the translation of an alternate
reading frame (ARF).108 The resulting protein, ARF, binds to MDM2 and prevents it
from ubiquitinating p53.108 Oxygen levels also influence p53 levels in the cell. Though
not fully understood, the mechanism by which hypoxic conditions stabilize p53 in the cell
involved hypoxia-inducible factor 1 alpha (HIF-1a) and von Hippel-Lindau tumor
suppressor (VHL).109 Under normal conditions, VHL interacts with and degrades HIF-1a.
Under hypoxic or anoxic conditions, this interaction is disrupted. This allows HIF-1a to
bind to p53, preventing ubiquitination by MDM2.109
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Figure 10. Examples of p53 activation via DNA damage, hypoxia, and ARF activation
mechanisms,(1) MRN and ATRIP interact with exposed double-stranded and single
stranded DNA, respectively. Upon binding, MRN activates ATM and ATRIP activates
ATR. ATM and ATR phosphorylate and activate p53. (2) Hypoxia disrupts the
interaction between VHL and HTF-1a to prevent VHL from inhibiting HTF-1a. HIF-1a
then phosphorylates and activates p53. (3) ARF interacts with MDM2 to prevent the
ubiquitination and degradation of p53

Additionally, p53 is also capable of inhibiting MDM2, driving a positive feedback
loop further stabilizing it in the cell. Through these and other pathways, p53 escapes
degradation by MDM2 and triggers apoptosis (Figure 10). In this capacity, p53 primarily
acts in the nucleus as a transcription factor for many apoptotic proteins (Figure 11).109
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Figure 11. The Intrinsic apoptotic pathway. Upon activation, p53 acts as a transcription
factor for several pro-apoptotic genes including those transcribing Noxa, Puma, and Bid.
These proteins inhibit Bcl-2 from maintaining the mitochondrial membrane. Bid also acts
with cytoplasmic p53 to activate Bax and related proteins to poke holes in the
mitochondrial membrane. This releases cytochrome c to the cytoplasm where it interacts
with Apaf-1 and caspase 9 to form the apoptosome. The apoptosome cleaves and
activates caspase 3 to further stimulate bid and act on several death substrates to carry out
apoptotic events

This begins with several members of the Bcl-2 family. Bcl-2 and related antiapoptotic proteins keep the membrane of the mitochondria closed.110 P53 acts as a
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transcription factor for Puma and Noxa.109 These two BH3 only proteins inhibit Bcl2. Other transcriptional targets include Bax, Bid, and Bim. Bid acts like Puma and Noxa
to inhibit Bcl-2 and other anti-apoptotic family members.110 Bid and Bim also directly
bind to and activate Bak and Bax which poke holes in the mitochondrial membrane.110
p53 is capable of transporting to the cytoplasm to directly activate Bax, Puma, and
Noxa73,111,112 As the mitochondrial membrane opens, cytochrome c is released.110
Cytochrome c is a member of the electron transport chain (ETC) and is normally
involved in ATP production; however, when it is present in the cytosol it associates with
Apaf-1. Together, they form the apoptosome, also known as the “wheel of death,” which
activates caspase 9. This is the first caspase activated in a caspase cascade. Caspases
comprise a family of cysteine proteins which initiate apoptosis by activating downstream
caspases or by directly carrying out apoptotic functions.113
Caspase 9, an initiator caspase, cleaves pro-caspase 3 to activate caspase 3, an
execution phase caspase.113 Caspase 3 activates downstream caspases by cleaving their
respective pro-caspases, eventually triggering caspases which carry out functions to
induce an apoptotic phenotype such as destruction of intracellular structures and
organelles.9,10,113

4.2. MOLECULAR TARGETS OF THE DEFECTIVE INTRINSIC PATHWAY
Oxaliplatin (diaminocyclohexane) and other platinum-containing drugs also
damage nuclear DNA.114 Oxaliplatin binds to DNA to block replication and transcription,
form lesions, and cause single-stranded breaks. These particular lesions are poorly
recognized by DNA repair proteins in the cell so damage accumulates. An accumulation
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of damaged DNA in the cell causes stress signals within the cell which activate the
intrinsic apoptotic pathway.114
Oxaliplatin (brand name Eloxatin) has been approved by the FDA to treat
colorectal and stage three colon cancer. Like most current small molecule cancer
therapies, Oxaliplatin alone is not specific to cancer cells and has many undesirable side
effects.114,115 Shad et. al. investigated a strategy to encapsulate Oxaliplatin in folate
conjugated hyaluronic acid-coated alginate nanogels.115 In this system, folate is used for
specific targeting to folate receptors which are overexpressed in many types of colorectal
cancers and hyaluronic acid and alginate are natural, biocompatible polymers.115 In this
study, HT29 colorectal cancer cells were treated with encapsulated Oxaliplatin. Cells
treated with encapsulated Oxaliplatin showed a higher ratio of apoptosis to necrosis,
higher gene expression of Bax, and lower expression of Bcl-2 compared to untreated cells
or cells treated with unencapsulated Oxaliplatin.115 This suggests that novel drug delivery
systems may improve treatment with Oxaliplatin and other platinum-based
chemotherapeutics; however, further testing in animal models and clinical trials is
required to determine if the encapsulation strategy employed here will improve efficacy
and specificity and decrease negative side effects.
The function of p53 is lost in more than half of all human cancer cases.71 Since
cancer is typically the result of an accumulation of genetic mutations that occur over the
years or decades, loss of the enzyme responsible for suicide in cells with damaged DNA
greatly enables this process. A majority of p53 mutations occur in its reading frame and
cause conformational changes.71 Many mutations disable the catalytic site of p53 but
allow it to still bind other p53 proteins and form the homotetramer required for its
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activity. In this way, mutant p53 is an inhibitor to wild type p53 since the
homotetramer requires four wild-type p53 proteins in order to function.105 The use of
small molecules and peptides to activate a p53-dependent process in cells with mutant
forms of p53 are being investigated for clinical use.116,117 However, p53 reactivation has
proved difficult clinically.
While the loss of function of p53 is the most common mutation across human
cancers, it is also common that p53 is still functional but its regulators such as MDM2 are
overexpressed.9,116"118 Nutlins, small molecule inhibitors that bind to MDM2, are
currently being investigated as potential chemotherapeutics.118 The first MDM2 inhibitor
to undergo clinical trials was RG7112 which demonstrated high selectivity and efficacy
in preclinical studies.118 However, Clinical trials revealed that the necessary dose to
activated p53 had severe side effects including death.118 Now, second-generation MDM2
inhibitors such as Idasanutlin, which are thought to have more desirable toxicity profiles,
are undergoing clinical trials.118 These trials primarily investigate the use of MDM2
inhibitors in combination therapies or alongside radiation therapy.

4.3. EXTRINSIC PATHWAY
Apoptosis can also be triggered externally via the extrinsic or receptor-activated
apoptotic pathway (Figure 12). The cell membrane contains several transmembrane
proteins including death receptors which share a common “death domain”. Members of
the tumor necrosis factor (TNF) family known as “death receptor ligands” can bind to
this domain.
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Figure 12. The extrinsic apoptotic pathway. Death receptor ligands such as FasL bind
death receptors at the cell surface. Fas activates FADD, which in turn activates DISC.
Disc cleaves and activates initiator caspases 8 and 10 which act on executioner caspases
3, 6, and 7. These caspases act on death substrates to achieve an apoptotic phenotype.
Additionally, caspase 3 can activate Bid to activate the internal pathway

The most common death receptor ligand is the Fas ligand (FasL) which binds to
the death receptor Fas (Apo-1 or CD95).119 Ligand binding induces activation of the Fasassociated death domain (FADD) protein within the cytosol.119 FADD triggers the deathinducing signaling complex (DISC) which in turn cleaves and triggers initiator caspases 8
and 10. At this point, the extrinsic pathway converges on the intrinsic pathway by
activating the execution phase caspases 3, 6, and 7. Caspase 3 is also capable of cleaving
and activating Bid to act on Bcl-2, amplifying pro-apoptotic signals and recruiting
additional members of the intrinsic pathway.
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4.4. MOLECULAR TARGETS OF THE DEFECTIVE EXTRINSIC PATHWAY
Several existing and potential cancer treatments attempt to kill cancer cells by
taking advantage of apoptotic machinery in the cells. For example, all trans retinoic acid
(ATRA) is a naturally occurring derivative of vitamin A that can be used to target
apoptotic pathways in cancerous cells.120 ATRA binds to the retinoic acid transmembrane
receptors retinoic acid receptor (RAR) and retinoid x receptor (RXR), causing them to
form a heterodimer.121 This binding activates apoptosis through the external apoptotic
pathway.121 NB4 cells treated with ATRA showed decreased viability due to the
activation of the apoptotic pathway.113 ATRA has been shown to treat acute
promyelocytic leukemia (APL).122 Ades et al analyzed data from elderly patients at
European centers who were treated for APL with ATRA in combination with
chemotherapy122. Combination of ATRA with other chemotherapeutics improved the
survival of elderly patients compared to traditional chemotherapy.122
ATRA is now also being investigated to treat other types of cancer. ATRA has a
low solubility in water which makes delivery a challenge.121 Ravichandran et al.
encapsulated ATRA in liposome carriers to improve distribution.9 The lipo-ATRA
system reduced tumors in mice.121 Another possible therapeutic agent is oxymatrine.
Oxymatrine is derived from marine, an active in the Chinese herb Sophora flavecens.123
Several laboratory studies have shown that oxymatrine inhibits cellular proliferation by
inducing apoptosis.123-125 Although the exact mechanism is not fully understood,
Oxymatrine was shown to increase caspases associated with apoptosis in T24 cells
(human bladder cancer) 123 and in A549 cells (human lung cancer).125 It has also been
shown to increase expression of p53 and Bax, and decrease expression of Bcl-2 in
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DU145 cells (human prostate cancer), PC3 cells (human prostate cancer), and PNT1B
cells (human prostate).124 These effects on p53, Bax, and Bcl-2 were also seen in mice
xenograft models.124 Additionally, tumor weight stopped increasing in these mice, though
the tumors did not shrink.124

5. DISCUSSION

Healthy cells depend on internal and external signals to decide whether to live or
die, proliferate, or become quiescent entering the G0 phase. These signals are interpreted
through signaling pathways within the cell to stimulate the production of proteins to carry
out these actions. The cells get a license for the division at the late G1 phase or R point,
and the later phases follow more or less the same mechanisms as normal cells unless
there are major genetic and molecular alterations in cell cycle-associated genes or
therapeutic intervention. So, the G0/G1 transition and early G1 phase are of much interest
in cancer research. There is growing evidence that the R point deregulation is the
determinant of abnormal cell growth and accompanies the tumorigenesis process in
almost all the cancer types.126-129
For cell cycle targeted therapy, CDK4/6-Rb is one of the most critical pathways to
target as it provides the cells license to enter the R point. In addition to the active
targeting of molecules involved in the G1-S transition of the CDK4/6-Rb pathway, the
cell cycle targeted therapy has already been shifted towards the inhibition of key players
of the S and G2 checkpoints. Several chemo and radiotherapy target the alterations of the
DNA as a mechanism of action against cancer progression. Cancer cells can manipulate
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the cell cycle checkpoints to halt the progression allowing them time for DNA repair
in response to the damage caused. The rationale for targeting the checkpoints is that
inhibition of these regulatory proteins in cancer cells prevents cell cycle arrest in S and
G2 phase allowing the cells to enter the mitosis phase with a defective genetic component
and become susceptible to apoptosis or permanent arrest during mitosis, a mechanism
known as a mitotic catastrophe.130,131 Such indirect therapeutic strategy includes
inhibition of ATM and ATR (inhibition of DNA damage response),106,132-135 Aurora A
and B kinases (inhibition of spindle machinery during mitosis),136-141 PLK1 (inhibition of
chromosome segregation, the permission of mitotic entry upon DNA damage),142-145
BRCA1/2 (inhibition of homologous recombination), 146,147 MPS1,148-151 CHK1
(induction of aberrant replication, chromosome fragmentation, mitotic death),152-155 and
WEE1 (induction of premature mitosis) molecules.156-160 One of the major concerns in
targeting the cell cycle targeted therapy is selectivity. To address the challenge, the cell
cycle targeted therapeutic regimen can benefit to a great extent by incorporating the
personalized treatment approach. The genomic signature tools can identify the subsets of
patients who will get a maximum therapeutic response to the intervened cell cycle
targeted treatment.
The role of major molecular circuitries responsible for cell proliferation, cell
cycle, and apoptosis are interlinked and also share common molecular machinery.2,161,162
There are evidence that apoptosis can be triggered by the genes that are involved in cell
cycle progression. For example, Myc regulates several genes that control both cell cycle
progression and apoptosis and metabolism in tumorigenesis.163-171 Similarly, p53 is
involved in molecular signaling circuitries for cell cycle arrest and cell death,172,173 DNA
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damage response,174-176 and increasing evidence as a regulator of cell homeostasis
and metabolism in cancer cells.177 Cancer cells manipulate such interlinked cell signaling
pathways for the acquisition of major hallmarks in cancer such as self-sufficiency in
growth signals and suppressing or insensitivity to the death signals and tissue invasion
and metastasis.10,178 Thus, a comprehensive understanding of the linkage between the cell
proliferation and apoptosis pathways will unveil the underlying causes of imbalanced
tissue homeostasis and is critical to discover new therapeutic strategies to defeat cancer.
Such elucidations help to behold cancer in a more logical way.

6. CONCLUSION

In this review, intracellular signaling pathways such as MAPK/Ras/Raf/ERK,
PI3K/Akt, Jak-STAT, and Wnt regulating the cell proliferation and apoptosis are
discussed. Growth factors activate the MAPK/Ras/Raf/ERK, PI3K, and Wnt pathways to
synthesize cyclin Ds and other mitosis regulating proteins (Myc and Jun). Cyclin D1
binds to CDK4/6, forms CDK complexes, activates several substrates, and initiates the
cell cycle. In contrast, TGFP prevents the cells from initiating the cell cycle by
expressing CDKIs and p53. p53 stops the cell cycle when DNA is not replicated correctly
during the S phase, producing p21 proteins and promoting the transcription of apoptotic
proteins. Alterations in the signaling pathways lead to diseases including cancer,
cardiovascular diseases, immunological disorders, neurodegenerative diseases, and many
other infectious diseases. As cancer therapy is becoming more and more personalized
through precision medicine, understanding the intercorrelated cell signaling pathways and
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identification of key regulatory molecules are so important to prescribe the effective
individual molecular therapies.
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III. TRANSCRIPTIONAL REGULATION ACTIVITY OF A TARGETED
ANTIBODY DRUG NANOROD IN BREAST CANCER CELLS

ABSTRACT

Transcriptional activity in cancer cells is a key factor for determining the
therapeutic outcome in patients. Therapeutic drugs with diverse mechanisms regulate
certain gene expression activity in cancer cells causing enhanced tumor cell death.
However, the aberrant gene regulation activity during the tumor evolution process or
even following the therapeutic drug treatment significantly causes drug resistance and
disease recurrence. Hence, such genomic instability in tumor cell population has to be
comprehensively unfolded for better treatment response. In this study, we investigated
the transcriptional regulation activity of a Trastuzumab conjugated Paclitaxel drug
nanorod system (PTXNR-TTZ) in breast cancer cell lines. We investigated the gene
regulation activity of DNA metabolism, cell cycle checkpoint and inflammatory
pathways that might determine the therapeutic response or drug resistance in PTXNRTTZ treatment. Hyperactivity in DNA repair pathways can offset the effect of therapeutic
drugs and cause treatment resistance. In HER2-positive breast cancer cells, we found that
PTXNR-TTZ did not alter the DNA repair pathways although a significant
downregulation in this pathway was observed in individual treatment with Trastuzumab.
PTXNR-TTZ also induced significantly high expression of NR4A3 gene. The
upregulation of nuclear NR4A3 gene has role in inducing enhanced apoptosis mechanism
by activating the pro-apoptotic and inhibiting the anti-apoptotic gene regulation activity.
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The pathway enrichment analysis showed a significant upregulation of the Rho
GTPase signaling network following PTXNR-TTZ treatment. The effector genes in this
pathway are associated with spindle assembly checkpoint (SAC) regulation in mitosis
phase and hyperactivation of this pathway is responsible for cell cycle progression and
aberrant exit from mitosis phase of the cell cycle potentially causing poor treatment
outcome. PTXNR-TTZ also induced oncogenic CDC20 gene expression activity that
functions in mitosis phase and promotes the cell cycle progression. In HER2-negative
breast cancer cell line, PTXNR-TTZ significantly upregulated a set of tumorigenic
chemokine and cytokine encoding genes IL6, CXCL1, CXCL2, CXCL3, CXCL8, IL1A
and IL1B suggesting an induction of enhanced survival signaling and aggressive
tumorigenic behavior in cancer cells.

1. INTRODUCTION

Chemotherapeutic drugs can be categorized into the cell cycle phase specific or
non-specific drugs based on their therapeutic effect window1-4. For example, the DNA
damaging drugs have almost no therapeutic effect on the cells that are in the resting phase
2. Rather, the effect is maximum when the cells are actively replicating their genetic
contents in the synthesis phase5-7. Similarly, the taxanes (e.g., Paclitaxel) depend on the
active mitosis cell cycle phase for exerting their therapeutic efficacy 8. Such variations in
treatment outcome are due to the alterations in gene expression in different cell cycle
phases 2,4 In combination chemotherapy, cell cycle mediated drug resistance is
minimized by appropriate scheduling of different cell cycle targeted chemotherapeutic
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agents 4 In our recent study, we designed an actively targeted nanoparticle based
combination therapeutic system ADN that induced apoptosis in HER2-positive breast
cancer cell lines by arresting the cells in the G2/M phase. In this study, we investigated
the alterations in gene expressions in breast cancer cells induced by ADN. We
hypothesized that the cell cycle plays a critical role in determining the therapeutic
efficacy of ADN in HER2-positive breast cancer treatment.
The cell cycle and apoptosis are two complementary mechanisms for tissue
homeostasis and normal functioning of the tissues to perform a specific task in a
coordinated way 9"15. Most cells rest at the quiescent phase (G0) and perform tissue
specific tasks. At the same time, these cells keep receiving the mitogenic signaling via
several growth factors from the cellular environment and enter the cell cycle phase Gap
1(G1) when they commit to divide 16. In the synthesis (S) phase, the cells start replicating
their genetic contents and progress through the Gap 2/Mitosis (G2/M) phase resulting in
cell division. During the cell cycle, the cells progress through a subsequent series of
regulatory checkpoints17-20. These regulatory cell cycle checkpoints make sure that the
genetic materials of the dividing cells are kept intact before the distribution to the
daughter cells 2. Failure to maintain the intact nature of the genetic materials causes the
initiation of a programmed cell death or apoptosis mechanism to maintain the normal
tissue functioning 15. Mutations and aberrant growth signaling pathways cause the cancer
cells to respond more frequently to these external mitogenic signaling and unregulated
progression through the cell cycle. Evading the apoptosis mechanism and unregulated
division with aberrant genetic contents are the major acquired hallmarks of cancer 21,22.
The cell cycle targeted drugs alter the regulatory machineries of the cells causing forced
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apoptosis or halt the cellular growth. The cancer cells also activate a series of
molecular machinery e.g., DNA metabolism 23-26, cell cycle checkpoints 27-29,
inflammatory pathways30-32 upon any genotoxic stress on the cells to maintain the
aberrant genomic and phenotypic integrity resulting in partial treatment response or
therapeutic resistance.
We previously synthesized targeted ADN using rod shaped Paclitaxel
nanoparticles (PTXNR) of 500 nm length and 100 nm diameter. We covalently
conjugated the nanorods with therapeutic monoclonal antibody (mAb) Trastuzumab
(PTXNR-TTZ). The current study extends our investigation in understanding the effects
of PTXNR-TTZ on breast cancer cells at the gene expression level. For the investigation,
we treated HER2-positive BT-474 and HER2- negative MDA-MB-231 breast cancer
cells with PTXNR-TTZ. The cells were also treated by different cell cycle targeted drugs
e.g., Trastuzumab and Rapamycin targeting the early G1 phase, 5-Fluorouracil targeting
the S phase, and Paclitaxel, Doxorubicin targeting the G2/M phase of the cell cycle. The
untreated cells mostly arrested in the G0/G1 phase were used as control. We performed
RNAseq analysis following the treatment with different cell cycle targeted drugs. The
study aims to investigate the PTXNR-TTZ induced gene regulation activity that might
determine the treatment response in breast cancer. We investigated the PTXNR-TTZ
induced transcriptional activity in DNA metabolism, cell cycle checkpoint, apoptosis and
inflammatory pathways in breast cancer cell lines to determine potential genetic means of
cell cycle dependent therapeutic response and drug resistance.
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2. METHODS

2.1. RNA EXTRACTION
BT-474 and MDA-MB-231 cells were cultured in hybricare medium and RPMI1640, respectively supplemented with 10% fetal bovine serum (FBS) and 1% penicillinstreptomycin at 37oC and 5% CO2 . Approximately, 1M cells were seeded in 25 cm2 cell
culture flask for each cell line and treated with IC 50 doses of 5-Fluorouracil, Doxorubicin,
Rapamycin, Paclitaxel, Trastuzumab and Trastuzumab conjugated Paclitaxel drug
nanorods (PTXNR-TTZ) (SI Table 1) . After 72 h of incubation, the total RNA was
extracted from the samples using TRIzol Plus RNA purification kit (Invitrogen) by
following the manufacturerer’s protocol. Briefly, 1 ml of TRIzol was used for 1 million
cells to lyse. The cell lysates were passed through an 18-21 gauge syringe needle for
homogenization. The cell lysates were kept at room temperature (RT) for 5 min for
complete dissociation of the nucleoprotein complex. To the lysate mixture 0.2 ml of
chloroform was added per 1 ml of TRIzol reagent . The mixture was centrifuged at
12,000*g for 15 minutes at 4oC. The mixture separates into two layers: the bottom red
phenol-chloroform layer, an interphase and colorless aquous layer containing the total
RNA. The upper phase ( ~600 |il) was then transferred to a new sterile RNase free tube
followed by addition of an equal volume of 70% ethanol. The mixtutre was vortexed well
and the total RNA was bound on the membrane provided by the manufacturer. In
subsequent steps, the RNA was washed on the membrane and eluted with RNase free
water by following the manufacturers protocol. The RNA quality was determined by
measuring the RNA integrity number (RIN) using Agilent Bioanalyzer .
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2.2. RNAseq ANALYSIS
The extracted RNA samples from BT-474 and MDA-MB-231 human breast
cancer cell lines were used for sequencing using the RNAseq technology. Briefly, the
mRNA was isolated from the total RNA extract using poly-A enrichment method. The
mRNA was fragmented and the fragmentation quality was confirmed using Agilent
Bioanalyzer. cDNA was synthesized from the fragmented mRNA and amplified using the
polymerase chain reaction (PCR) technique. The mRNA stranded RNAseq library was
prepared using TruSeq stranded mRNA library preparation kit (Illumina). The
constructed libraries were then sequenced using the NovaSeq 6000 Sequencing System
on a single NovaSeq S1 PE-50 flow cell. The samples were sequenced to an average read
count of 50 million paired end reads per sample. The library construction and sequencing
work was performed with the support of the University of Missouri DNA Core Facility.

2.3. GENOMICS DATA ANALYSIS OF ALTERATIONS IN BC
The Oncoprint analysis was performed in cBioPortal platform to investigate on
the DNA copy number alterations, overall survival and genetic co-expressions in HER2positive breast cancer patients. The clinical data were obtained from the Molecular
Taxonomy of Breast Cancer International Consortium (METABRIC) study. The study
comprised the genomics data of more than 2,000 primary breast cancer specimens that
were obtained from the tumor banks in the UK and Canada. Nearly none of the estrogen
receptor positive (ER+) and lymph node-negative (LN-) patients received any form of
chemotherapy. In our analysis, we screened 224 HER2-positive breast cancer patients’
genomics data from the study according to the PAM50 breast cancer subtype classifier
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method. None of the HER2-positive patients had gone through treatment with
Trastuzumab.

2.4. DATA NORMALIZATION
The RNAseq gene expression data sets were normalized using the BioJupies
RNAseq data analysis platform. For a specific drug treated sample the raw counts of a
specific gene expression were divided by the total sum of all gene expression counts and
multiplied by a factor of 106 and subsequent a log- 10 transform. The resulting
normalized unit becomes log10-Counts Per Million (logCPM).

2.5. DIFFERENTIAL GENE EXPRESSION
The differential gene expression table was generated for both BT-474 and MDAMB-231 breast cancer cell lines using the BioJupies RNAseq data analysis notebook
platform. The differential gene expression table was generated by normalizing the gene
expression levels of drug-treated samples to the gene expression levels in untreated
control samples for each cell line. The platform used the embedded limma R package for
generating the differential gene expression table. The heatmaps and hierarchical
clustering were generated by python Jupyter notebook (6.0.3) using the seaborn statistical
data visualization library. The pathway-specific signature gene sets were derived from the
Kegg gene sets database.

2.6. PRINCIPAL COMPONENT ANALYSIS
Principal component analysis (PCA) was performed to identify the similarity and
variance across the treatments for a specific gene signature or pathway. The PCA was
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generated using the differential G1, S and G2/M cell cycle signature gene expressions
obtained from the cell cycle treated drug samples for both BT-474 and MDA-MB-231
cancer cell lines. The analysis was performed using the MATLAB 2018 version. For the
analysis we obtained the statistical PC1, PC2 components from the differential cell cycle
gene expression signatures across all the drug treatments covering 58.06%, 38.97% of the
differentially expressed genes respectively, in BT-474 cells and 62.92%, 20.06%,
respectively in MDA-MB-231 cells.

2.7. GENE ONTOLOGY (GO) ENRICHMENT ANALYSIS
The GO enrichment analysis was performed to identify the collective functions of
genes or gene sets for a specific biological process. The database contains a large
collection of experimentally validated biological functions that correspond to a specific
set of genes. The database also contains predicted associations between genes and
biological terms. In this study, the GO analysis was generated using the Enrichr. The GO
terms were selected for analysis based on the statistical significance (p-value).

2.8. PATHWAY ENRICHMENT ANALYSIS
Pathway enrichment analysis was performed to identify the significant biological
or genetic interactions. The analysis aims to understand the intracellular response more
clearly following a therapeutic intervention. The Reactome database containing a myriad
of such biological or genetic interactions was used for this analysis. The enrichment
analysis was generated using Enrichr by leveraging the Reactome database. In this study,
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the upregulated or downregulated pathways were selected for analysis based on their
statistical significance (p-value).

2.9. GENE REGULATORY NETWORK ANALYSIS
Gene regulatory network analysis was performed to identify the set of genes that
are involved in specific intracellular biological functions. The analysis was performed
using the NetworkAnalyst platform. The significant differentially upregulated or
downregulated gene sets with the log2FC threshold value of 1.5 were used as input for
the analysis.
3. RESULTS

3.1. CELL CYCLE GENE SIGNATURES
The PCA was generated using the cell cycle signature (G1-S transition phase, S
and early G2 phase, G2/M phase) gene expression values of Rapamycin, 5-Fluorouracil,
Trastuzumab, Doxorubicin, Paclitaxel, and PTXNR-TTZ treated BT-474 (Figure 1a) and
MDA-MB-231 (Figure 1b) cells normalized to the untreated control cells . In BT-474
cells, the PCA plot showed that Paclitaxel and PTXNR-TTZ, 5-Fluorouracil, and
Trastuzumab formed two distinct clusters suggesting lower variance in cell cycle gene
expression between the samples in each cluster. Rapamycin and Doxorubicin treated cells
formed two distinct clusters suggesting high variance in gene expression between the
treatments. In MDA-MB-231 cell line, Paclitaxel and PTXNR-TTZ formed a cluster but
with larger variance than in BT-474 cells. This suggests that the alterations in cell cycle
gene expression by these drugs slightly vary between BT-474 and MDA-MB-231 cell
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lines. Trastuzumab and Rapamycin treated samples were almost invariant in cell
cycle gene expression and formed a cluster together. With a slight variance to this cluster,
5-Fluorouracil treated cells formed a distinct cluster. In similar to the BT-474 cells,
Doxorubicin treated MDA-MB-231 cells formed a distinctly variant cluster.

Figure 1. Cell cycle gene signature of cell cycle arresting drugs. PCA plot of cell cycle
related gene expression signatures following Rapamycin, 5-Fluorouracil, Doxorubicin,
Paclitaxel, Trastuzumab and PTXNR-TTZ drug treatments in (a) BT-474 and (b) MDAMB-231 cell line

3.2. PTXNR-TTZ DOES NOT ALTER THE DNA METABOLISM PROCESSES IN
HER2-POSITIVE BREAST CANCER CELL LINE
Therapeutic drugs that downregulate the DNA metabolism related genes might
augment the effect of platinum based therapeutics that induce hyperactivity in DDR
pathways causing therapeutic resistance. We investigated the PTXNR-TTZ induced DNA
metabolism related gene expressions in HER2-positive breast cancer cells. Paclitaxel or
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PTXNR-TTZ did not alter the regulation of DNA metabolism related genes compared
to the untreated cancer cells. In contrast, the gene ontology (GO) terms enrichment
analysis of the biological process showed that DNA metabolism processes were
significantly downregulated by the drugs that target either the G1 or the S phase cell
cycle arrest mechanism. In Figure 2a, the colored bubbles represent all the significantly
downregulated GO terms for individual treatment with Rapamycin, 5-Fluorouracil and
Trastuzumab. The GO terms are represented in a similarity based scatter plots with
arbitrary space, called semantic space (with no intrinsic meaning) where the distance
depicts the relative similarity between two GO terms. The size of the bubbles represents
the percentages of genes annotated with the GO term suggesting a more general GO term
(larger bubble ) and specific GO term (smaller bubble) . The color bar represents the pvalues of individual GO terms. In HER2-positive breast cancer, Rapamycin and
Trastuzumab (G1) and 5-Fluorouracil (S) significantly downregulated the DNA
replication and DNA repair mechanism in response to therapeutic intervention.
Transcriptional signatures of the major DNA repair pathways upon treatment with these
drugs were further investigated. Hierarchical clustering was generated for DNA repair
pathways with the normalized gene expression values for each treatment compared to the
untreated HER2- positive breast cancer cell gene expression. Most of the HR (Figure 2b)
and MMR (Figure 2c) pathway related genes were downregulated in response to
treatment with Rapamycin, Trastuzumab, and 5-Fluorouracil. Notably, Rapamycin
downregulated the HR and MMR pathways by significantly inhibiting the expressions of
BRCA2, RAD54B, RAD51, BLM, RAD54L, EMEI, RFC2, RFC3, RFC4, RFC5, MSH2,
EXO1, LIG1, and PCNA genes. A significant seven-fold upregulation of NHEJ pathway
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associated DNTT gene was overserved upon Doxorubicin treatment while no other
treatments showed the DNTT gene expression.
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Figure 2. The cell cycle targeted drug induced gene expression analysis in DNA repair
pathways. (a) The significantly downregulated GO terms are shown for treatment with
Rapamycin, 5-Fluorouracil, and Trastuzumab in BT-474 cell line. The colored bubbles
represent a specific GO term that is significantly downregulated in each treatment. The
distance between the bubbles represents relative similarity between the respective GO
terms. Hierarchical clustering showing alterations in (b) HR and (c) MMR pathways by
cell cycle arresting drugs in BT-474 cell line
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Figure 2. The cell cycle targeted drug induced gene expression analysis in DNA repair
pathways.(a) The significantly downregulated GO terms are shown for treatment with
Rapamycin, 5-Fluorouracil, and Trastuzumab in BT-474 cell line. The colored bubbles
represent a specific GO term that is significantly downregulated in each treatment. The
distance between the bubbles represents relative similarity between the respective GO
terms. Hierarchical clustering showing alterations in (b) HR and (c) MMR pathways by
cell cycle arresting drugs in BT-474 cell line (cont.)
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Figure 2. The cell cycle targeted drug induced gene expression analysis in DNA repair
pathways.(a) The significantly downregulated GO terms are shown for treatment with
Rapamycin, 5-Fluorouracil, and Trastuzumab in BT-474 cell line. The colored bubbles
represent a specific GO term that is significantly downregulated in each treatment. The
distance between the bubbles represents relative similarity between the respective GO
terms. Hierarchical clustering showing alterations in (b) HR and (c) MMR pathways by
cell cycle arresting drugs in BT-474 cell line (cont.)
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Figure 2. The cell cycle targeted drug induced gene expression analysis in DNA repair
pathways.(a) The significantly downregulated GO terms are shown for treatment with
Rapamycin, 5-Fluorouracil, and Trastuzumab in BT-474 cell line. The colored bubbles
represent a specific GO term that is significantly downregulated in each treatment. The
distance between the bubbles represents relative similarity between the respective GO
terms. Hierarchical clustering showing alterations in (b) HR and (c) MMR pathways by
cell cycle arresting drugs in BT-474 cell line (cont.)

3.3. PTXNR-TTZ MAY INDUCE NR4A3 MEDIATED INTRINSIC APOPTOSIS
PATHWAY IN HER2-POSITIVE BREAST CANCER CELL LINE
PTXNR-TTZ induces significant upregulation of PRKG1 and NR4A3
genes in HER2-positive BT-474 cell line (Figure 3).
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Figure 3. NR4A3 mediated apoptosis induced by PTXNR-TTZ in HER2-positive breast
cancer cell line. The gene regulatory network analysis showing the regulation of
apoptosis following the activation of PRKG1-NR4A3 axis induced by PTXNR-TTZ in
BT-474 cell line

The gene regulatory network showed that upregulation of PRKG1 positively
regulates the activation of CREB1, which subsequently regulates the orphan receptor
NR4A3 gene. The significantly upregulation of NR4A3 upon PTXNR-TTZ treatment can
possibly induce apoptosis in BT-474 cell line. The network showed that the NR4A3 gene
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can also be regulated directly by tumor suppressor gene TP53 for apoptosis induction.
The NR4A3 function in the gene regulatory network is consistent with the recent finding
that showed NR4A3 can induce apoptosis both in p53 dependent and independent manner
33

3.4. PTXNR-TTZ UPREGULATES DOWNSTREAM EFFECTORS OF RhoGTPase SIGNALING NETWORK
The Reactome pathway enrichment analysis generated by Enrichr showed
significant upregulation of Rho-GTPase signaling pathway (R-HSA-194315) induced by
PTXNR-TTZ treatment in BT-474 cell line. In total 37 genes related to this pathway were
upregulated with the p value 6.2 e-13, FDR 1.9 e-10 and a Z score of 4.03. A heatmap
was generated showing all the 37 upregulated gene expression by PTXNR-TTZ treatment
(Figure 4a). The effector proteins of the Rho-GTPase signaling pathway critically
regulates the mitosis and cell cycle progression. Cell division cycle protein -20
homologue (encoded by CDC20 gene) is one of the downstream effector proteins in this
pathway. The protein binds and activates the anaphase promoting complex APC/C.
Together the APC/CCDC20 protein complex promotes the exit from mitosis cell cycle
phase. The upregulation in CDC20 can promote an aggressive form of breast cancer. A
gene regulatory network was generated using all the significantly upregulated genes in
the Rho-GTPase signaling pathway. The upregulated genes are shown in red nodes in the
network. The network (Figure 4b) shows that CDC20 can be positively regulated by
PLK1 gene and subsequently activate the APC/C complex. We found that CDC20
overexpression is correlated with poor overall survival in HER2-positive breast cancer
patients. From the METABRIC study, we screened 224 patients with HER2-positive
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breast cancer according to PAM-50 plus claudin low subtype breast cancer classifier
method. Among 224 patients approximately 4% of the patients (8 patients) had CDC20
DNA copy number alteration. The rest of the 216 patients were considered to be in the
unaltered group for the analysis. The overall survival analysis (Figure 4c) showed that the
median overall survival for the unaltered group was 107.10 months while the median
survival was only 71.63 months in case of the CDC20 altered group (log-rank test pvalue 0.296). In the CDC20 altered group, out of 8 patients 6 patients were deceased.
Only 4% of the patients showed CDC20 DNA copy number alteration. The mRNA
expression shows that two more effector proteins encoding genes of this pathway KIF2C
and CDCA8, were also upregulated in most of the HER2-positive breast cancer patients
in METABRIC study. In the co expression analysis we observed that KIF2C (Figure 4d)
and CDCA8 (Figure 4e) gene expression highly correlated with the CDC20 gene
expression. The Spearman correlation factor was 0.86 (p=2.38 e-64) and 0.70 (9.9 e-34)
for KIF2C and CDCA8, respectively. We also found that the patients with KIF2C and
CDCA8 DNA copy number alterations completely overlapped with the CDC20 altered
group in the overall survival analysis. Out of 8 patients with CDC20 alteration, 6 of them
also had KIF2C alteration and 2 of them had alterations in CDCA8 DNA copy number.
This suggests that KIF2C and CDCA8 might also be a prognostic marker in HER2positive breast cancer patients along with CDC20. The Oncoprint analysis (Figure 4f)
showed that the most of the patients with HER2-positive breast cancer had high CDC20
mRNA expression along with a high expression of KIF2C and CDCA8, suggesting a post
transcriptional alteration in patients.
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(a)

Figure 4. Activation of Rho-GTPase signaling network by PTXNR-TTZ in HER2positive breast cancer cell line. Heatmap showing the upregulation of downstream
effectors in the Rho-GTPase signaling network. (b) Gene regulatory network showing the
activation of mitotic progression promoting APC/C complex following overregulation of
oncogenic CDC20 gene. (c) Overall survival analysis of HER2-positive breast cancer
patients in METABRIC study with CDC20 DNA copy number alterations. The median
overall survival of CDC20 altered group (n=8) was 71 months against 110 months in the
unaltered group (without CDC20 DNA copy number alteration). Correlation analysis
showing mRNA expression data of patients with CDC20 DNA copy number alteration
with (d) KIF2C (e) CDCA8 altered patients. The patients with either KIF2C or CDCA8
alterations completely overlapped with the CDC20 altered patients and also showed a
high correlation mRNA expression with CDC20 altered patients. The Spearman
correlation factor for KIF2C and CDCA8 mRNA expression against CDC20 mRNA
expression were 0.86 and 0.71, respectively. (f) The Oncoprint analysis showing the
DNA copy number and post transcriptional alterations in CDC20 , KIF2C and CDCA8
genes. The data are shown for individual 224 HER2-positive breast cancer patients in the
METABRIC study. The majority of the hER2-positive breast cancer patients showed
high mRNA expression for CDC20, KIF2C and CDCA8 though very few patients had
transcriptional alterations
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Figure 4. Activation of Rho-GTPase signaling network by PTXNR-TTZ in HER2positive breast cancer cell line.Heatmap showing the upregulation of downstream
effectors in the Rho-GTPase signaling network. (b) Gene regulatory network showing the
activation of mitotic progression promoting APC/C complex following overregulation of
oncogenic CDC20 gene. (c) Overall survival analysis of HER2-positive breast cancer
patients in METABRIC study with CDC20 DNA copy number alterations. The median
overall survival of CDC20 altered group (n=8) was 71 months against 110 months in the
unaltered group (without CDC20 DNA copy number alteration). Correlation analysis
showing mRNA expression data of patients with CDC20 DNA copy number alteration
with (d) KIF2C (e) CDCA8 altered patients. The patients with either KIF2C or CDCA8
alterations completely overlapped with the CDC20 altered patients and also showed a
high correlation mRNA expression with CDC20 altered patients. The Spearman
correlation factor for KIF2C and CDCA8 mRNA expression against CDC20 mRNA
expression were 0.86 and 0.71, respectively. (f) The Oncoprint analysis showing the
DNA copy number and post transcriptional alterations in CDC20 , KIF2C and CDCA8
genes. The data are shown for individual 224 HER2-positive breast cancer patients in the
METABRIC study. The majority of the hER2-positive breast cancer patients showed
high mRNA expression for CDC20, KIF2C and CDCA8 though very few patients had
transcriptional alterations (cont.)
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Figure 4. Activation of Rho-GTPase signaling network by PTXNR-TTZ in HER2positive breast cancer cell line.Heatmap showing the upregulation of downstream
effectors in the Rho-GTPase signaling network. (b) Gene regulatory network showing the
activation of mitotic progression promoting APC/C complex following overregulation of
oncogenic CDC20 gene. (c) Overall survival analysis of HER2-positive breast cancer
patients in METABRIC study with CDC20 DNA copy number alterations. The median
overall survival of CDC20 altered group (n=8) was 71 months against 110 months in the
unaltered group (without CDC20 DNA copy number alteration). Correlation analysis
showing mRNA expression data of patients with CDC20 DNA copy number alteration
with (d) KIF2C (e) CDCA8 altered patients. The patients with either KIF2C or CDCA8
alterations completely overlapped with the CDC20 altered patients and also showed a
high correlation mRNA expression with CDC20 altered patients. The Spearman
correlation factor for KIF2C and CDCA8 mRNA expression against CDC20 mRNA
expression were 0.86 and 0.71, respectively. (f) The Oncoprint analysis showing the
DNA copy number and post transcriptional alterations in CDC20 , KIF2C and CDCA8
genes. The data are shown for individual 224 HER2-positive breast cancer patients in the
METABRIC study. The majority of the hER2-positive breast cancer patients showed
high mRNA expression for CDC20, KIF2C and CDCA8 though very few patients had
transcriptional alterations (cont.)
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(e)

Figure 4. Activation of Rho-GTPase signaling network by PTXNR-TTZ in HER2positive breast cancer cell line.Heatmap showing the upregulation of downstream
effectors in the Rho-GTPase signaling network. (b) Gene regulatory network showing the
activation of mitotic progression promoting APC/C complex following overregulation of
oncogenic CDC20 gene. (c) Overall survival analysis of HER2-positive breast cancer
patients in METABRIC study with CDC20 DNA copy number alterations. The median
overall survival of CDC20 altered group (n=8) was 71 months against 110 months in the
unaltered group (without CDC20 DNA copy number alteration). Correlation analysis
showing mRNA expression data of patients with CDC20 DNA copy number alteration
with (d) KIF2C (e) CDCA8 altered patients. The patients with either KIF2C or CDCA8
alterations completely overlapped with the CDC20 altered patients and also showed a
high correlation mRNA expression with CDC20 altered patients. The Spearman
correlation factor for KIF2C and CDCA8 mRNA expression against CDC20 mRNA
expression were 0.86 and 0.71, respectively. (f) The Oncoprint analysis showing the
DNA copy number and post transcriptional alterations in CDC20 , KIF2C and CDCA8
genes. The data are shown for individual 224 HER2-positive breast cancer patients in the
METABRIC study. The majority of the hER2-positive breast cancer patients showed
high mRNA expression for CDC20, KIF2C and CDCA8 though very few patients had
transcriptional alterations (cont.)
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Figure 4. Activation of Rho-GTPase signaling network by PTXNR-TTZ in HER2positive breast cancer cell line.Heatmap showing the upregulation of downstream
effectors in the Rho-GTPase signaling network. (b) Gene regulatory network showing the
activation of mitotic progression promoting APC/C complex following overregulation of
oncogenic CDC20 gene. (c) Overall survival analysis of HER2-positive breast cancer
patients in METABRIC study with CDC20 DNA copy number alterations. The median
overall survival of CDC20 altered group (n=8) was 71 months against 110 months in the
unaltered group (without CDC20 DNA copy number alteration). Correlation analysis
showing mRNA expression data of patients with CDC20 DNA copy number alteration
with (d) KIF2C (e) CDCA8 altered patients. The patients with either KIF2C or CDCA8
alterations completely overlapped with the CDC20 altered patients and also showed a
high correlation mRNA expression with CDC20 altered patients. The Spearman
correlation factor for KIF2C and CDCA8 mRNA expression against CDC20 mRNA
expression were 0.86 and 0.71, respectively. (f) The Oncoprint analysis showing the
DNA copy number and post transcriptional alterations in CDC20 , KIF2C and CDCA8
genes. The data are shown for individual 224 HER2-positive breast cancer patients in the
METABRIC study. The majority of the hER2-positive breast cancer patients showed
high mRNA expression for CDC20, KIF2C and CDCA8 though very few patients had
transcriptional alterations (cont.)

3.5. PTXNR-TTZ SIGNIFICANTLY INDUCES INFLAMMATORY PATHWAYS
IN BREAST CANCER CELL LINES
The Kegg pathway enrichment analysis showed significant upregulation of the
TNF signaling pathway (HSA-04668) and NF- kappa B inflammatory signaling pathway
(HSA-04064) related genes in the MDA-MB-231 cell line induced by PTZNR-TTZ
treatment. In TNF pathway, 18 genes showed overlap in the analysis with p-value 2.6 e-
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10, FDR 7.5 e-08 and Z-score of 6.55. The heatmap (Figure 5a) shows the gene
expressions of significantly upregulated genes in this pathway. In the NF-kappa B
pathway, 12 genes in the analysis showed overlap with this pathway with p-value 3.5 e06, FDR 0.0002, and Z score of 5.16 and a heatmap was generated showing all the
overlapped upregulated genes (Figure 5b). A gene regulatory network was generated
using all the significantly upregulated genes in these pathways. All the red nodes in the
network represent the upregulated gene expression in our analysis for this particular
pathway. The gene regulatory network (Figure 5c) shows that the upregulated genes, in
turn, activate the NF-Kappa B p65/p50 signaling complex. The network also suggests
that NF-Kappa B p65/p50 signaling complex activation can subsequently induce IL6
expression. Induction of IL6 can positively regulate STAT-3 transcription factor and
cause inflammation in triple negative breast cancer cell lines. Such sequential activation
of NF-kappa B-IL6-STAT3 inflammatory circuit has been reported to be associated with
maintenance of cancer stem cell like population causing therapeutic resistance in breast
cancer both in vitro and in vivo. We further investigated the mRNA expression levels of
selected inflammatory genes (CCL20, CXCL1, CXCL2, CXCL3, CXCL8, IL6, IL1A and
IL1B) in response to PTXNR-TTZ treatment that has been previously reported to be
associated with enhanced inflammation, cancer cell progression or therapeutic resistance.
We found that all of these genes were highly upregulated in PTXNR-TTZ treated MDAMB-231 cell line (Figure 5d). In BT-474 cells, all of the genes except IL1A and CXCL8
were not differentially expressed at all. This suggests that PTXNR-TTZ treatment
significantly induced inflammatory pathways in the MDA-MB-231 cell line which might
induce therapeutic resistance in treatment.
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(a)

(b)

Figure 5. PTXNR-TTZ induces inflammatory gene expressions in triple negative breast
cancer cells. The heatmap shows the upregulation of (a) TNF (b) NF-kappa-B pathway
genes in MDA-MB-231 cell line induced by PTXNR-TTZ. (c) The gene regulatory
network showing the possible activation of the NF-kappa-B p65/p50 signaling complex
leading to potential activation of tumorigenic NF-kappa-B -IL6- STAT-3 signaling axis.
(d) Gene expression analysis of a set of selected tumorigenesis promoting inflammatory
genes in BT-474 and MDA-MB-231 cell line induced by PTXNR-TTZ
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Figure 5. PTXNR-TTZ induces inflammatory gene expressions in triple negative breast
cancer cells. The heatmap shows the upregulation of (a) TNF (b) NF-kappa-B pathway
genes in MDA-MB-231 cell line induced by PTXNR-TTZ. (c) The gene regulatory
network showing the possible activation of the NF-kappa-B p65/p50 signaling complex
leading to potential activation of tumorigenic NF-kappa-B -IL6- STAT-3 signaling axis.
(d) Gene expression analysis of a set of selected tumorigenesis promoting inflammatory
genes in BT-474 and MDA-MB-231 cell line induced by PTXNR-TTZ (cont.)
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Figure 5. PTXNR-TTZ induces inflammatory gene expressions in triple negative breast
cancer cells. The heatmap shows the upregulation of (a) TNF (b) NF-kappa-B pathway
genes in MDA-MB-231 cell line induced by PTXNR-TTZ. (c) The gene regulatory
network showing the possible activation of the NF-kappa-B p65/p50 signaling complex
leading to potential activation of tumorigenic NF-kappa-B -IL6- STAT-3 signaling axis.
(d) Gene expression analysis of a set of selected tumorigenesis promoting inflammatory
genes in BT-474 and MDA-MB-231 cell line induced by PTXNR-TTZ (cont.)

In our analysis, we observed significantly high expression of IL1A and IL1B in
triple negative MDA-MB-231 breast cancer cell line, whereas only IL1A was highly
overexpressed in HER2-positive BT-474 cell line upon PTXNR-TTZ treatment.
Recently, it has been reported that HER2-overexpression induces the expression of IL1-
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alpha (encoded by IL1A), promoting tumorigenesis and chemotherapeutic resistance
in HER2-positive breast cancer 34
4. DISCUSSION
Hyperactive DNA repair and replication mechanisms are the traits of therapeutic
drug resistance in cancer cells. Cancer cells activate the several DNA repair pathways in
a direct or indirect way in response to the stress caused by the chemo drugs. For example,
platinum based drugs inhibit the cancer cells by DNA damage and subsequent DNA
damage associated (e.g., p53) apoptosis pathways 35. In response, hyperactivity of DNA
repair pathways such as HR, NER cause the therapeutic resistance to these DNA
damaging chemotherapeutic drugs 35. In particular, mutations or inactivation in HR
pathway is influential and one of the major determinants of platinum based therapeutic
outcome in high grade serous cancer (HGCC)36. A study conducted on HGCC patients
who extraordinarily responded to platinum based treatment response showed that overall,
73% of the exceptional responder patients had disruption in HR DNA repair pathway 37
From the transcriptional analysis, we found that Paclitaxel molecule or PTXNR-TTZ do
not alter of affect the DNA metabolism pathways. On the other hand, Rapamycin, 5Fluorouracil and Trastuzumab downregulate the DNA repair pathways in HER2-positive
breast cancer cell line (Figure 2a). The hierarchical heatmap showed that Rapamycin, 5Fluorouracil, and Trastuzumab specifically altered majority of the gene expression in HR
and MMR pathways (Figure 2b, Figure 2c). This suggests that these G1/S cell cycle
arresting agents can be used in combination with platinum based chemotherapy for a
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possible synergistic outcome by suppressing the hyperactive treatment resistive DNA
repair pathways.
We found that PTXNR-TTZ might induce apoptosis in BT-474 cell line via
PRKG1- NR4A3 mediated intrinsic apoptosis pathway (Figure 3). Olga et al. recently
reported NR4A3 as a novel transcriptional target of p53 transcription factor and mediate
apoptosis 33. The protein p53 directly binds to the promoter region of NR4A3 gene and
induces the transcription. NR4A3 interacted with ant-apoptotic protein Bcl-2 for
sequestration and induction of apoptosis. Interestingly, the study also showed that the
orphan receptor NR4A3 gene also showed tumor suppressive function both in p53
dependent and independent way. In another recent study by Zhao et. al. showed that
microRNA miR-665 promoted epithelial-mesenchymal transition (EMT) , cancer cell
invasion, and metastasis by inhibiting the NR4A3 gene in MCF-7 and MDA-MB-231
breast cancer cell lines in vitro 38.
We found that Rho-GTPase signaling pathway genes were highly overregulated
by PTXNR-TTZ treatment in HER2-positive BT-474 breast cancer cell line (Figure 4a).
One of the major downstream effectors of this pathway CDC20 gene expression was
significantly upregulated in response to PTXNR-TTZ treatment. The gene regulatory
network shown in Figure 4b suggests that the overexpression of CDC20 further activates
the APC/C complex. The post translational over-regulation of CDC20 gene can
potentially cause aberrant mitotic exit and therapeutic resistance. The translated protein
Cdc20 is an essential regulator of mitosis and exhibits forced induction of cell cycle
progression by partnering with APC/C in subsequent downstream ubiquitination process
39. Ubiquitination has a critical role in cell cycle control and tumor initiation and
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transformation 40. APC/C binds and gets activated by Cdc20 (cell division cycle 20
homologue) and Cdh1 (Cdc20 homologue-1) forming two distinct multi subunit E3
ubiquitin ligase sub complexes APC/CCdc20 and APC/CCdh1, respectively to promote cell
cycle progression 41,42. Emerging evidences have suggested two distinct and opposing
roles of the closely related cell division cycle proteins Cdc20 and Cdh1 in tumorigenesis.
Cdc20 largely functions as an oncogene whereas Cdh1 has tumor suppressive role in the
tumorigenesis process 42. The oncogenic role of Cdc20 has been associated with a wide
range of cancer types including breast cancer, pancreatic cancer, prostate cancer,
colorectal cancer, lung cancer, glioblastomas and other types 41. The protein Cdc20
critically regulates the activation of APC/C in the mitosis cell cycle phase. The complex
APC/CCdc20promotes the metaphase to anaphase transition by degrading the cell cycle
regulatory proteins 43. Inhibition of Cdc20 protein has been showed to induce enhanced
apoptosis in skin tumor mouse model in vivo 44 The ablation of CDC20 gene in mice
caused aberrant mitotic arrest resulting in embryonic lethality suggesting possible role of
CDC20 gene in embryonic development 45. Moreover, inhibition of endogenous Cdc20
resulted in mitotic arrest and subsequent cell death in multiple human cancer cell lines.
Zeng et al. showed that inhibition of APC/CCdc20 and APC/CCdh1 by an IR-mimetic
inhibitor caused cell death in various cancer cell lines 46. In the survival analysis of
METABRIC data, 224 HER2 positive breast cancer patients showed that the patients who
had CDC20 DNA copy number alteration suffered from much worse overall median
survival compared to the unaltered group (71.10 vs 107.10 months) (Figure 4c).
Altogether, the increasing evidences suggest that CDC20 might be a potential therapeutic
in HER2-positive breast cancer treatment to overcome therapeutic resistance and aberrant
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mitotic exit upon Paclitaxel based drug treatment. In co-expression analysis, KIF2C
and CDCA8 were highly correlated with the CDC20 mRNA expression in METABRIC
HER2-positive breast cancer patients (figure 4d, Figure 4e). The patients with KIF2C and
CDCA8 DNA copy number alterations completely overlapped with the CDC20 altered
patients. Moreover, both KIF2C and CDCA8, along with CDC20, showed high mRNA
expression in 224 METABRIC HER2-positive breast cancer patients irrespective of their
DNA copy number alterations (Figure 4f). KIF2C and CDCA8 were also upregulated
following PTXNR-TTZ treatment. Kinesin family member KIF’s are involved in
cytoskeleton remodeling and take part in chromosomal segregation and spindle
orientation during mitosis47,48. Overexpression of kinesin family member 2C or mitotic
centromere associated kinesin, KIF2C is associated with detachment of microtubules
from the centromere by enhanced microtubule depolymerization. KIF2C has been
reported to be positively regulated by aurora-kinase B 49,50 and negative regulation by p53
tumor suppressor protein 51. KIF2C has been shown to have a role in correcting improper
kinetochore-microtubule attachment during mitosis 49,50. KIF2C overexpression has been
shown to induce mammary carcinogenesis, and suppression of KIF2C inhibited the
growth of breast cancer cell lines in vitro51. The cell division cycle associated protein-8,
encoded by CDCA8 gene translates a chromosomal passenger complex (CPC) which is
an essential regulator of mitosis 52. The CPC complex functions at the centromere regions
ensuring proper chromosomal segregation. The complex is cell cycle regulated and
essential for microtubule stabilization and spindle assembly. Overexpression of CDCA8
has also been showed to promote the malignant proliferation of melanoma cell lines in
vitro and correlated with poor prognosis 53. Moreover, a recent study leveraging the
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weighted gene co-expression network analysis (WCGA) and protein-protein
interaction network analysis from the Gene Expression Omnibus (GEO) database showed
that both KIF2C and CDCA8 are potential bio marker for metastatic breast cancer 54
Inflammation is well correlated with poor therapeutic outcomes and increased risk
of breast cancer recurrence. The pathway enrichment analysis showed PTXNR-TTZ
significantly upregulated the TNF and NF-kappa B inflammatory pathway related genes
in MDA-MB-231 cell line (Figure 5a, Figure 5b). We further investigated the induction
of these inflammatory pathways using the gene regulatory network generated with the
significantly upregulated gene expressions in this pathway. The gene regulatory network
showed that the upregulated genes might induce the activation of the NF-kappa Bp65/p50 signaling complex and possible sequential activation of NF-kappa B-IL6-STAT3
signaling axis (Figure 5c). We observed significant upregulation of IL6 in PTXNR-TTZ
treated triple negative MDA-MB-231 breast cancer cell line which further suggests the
possibility of activation of this signaling circuit. Overregulation of IL6 has been shown to
promote stem cell like phenotype in the breast cancer causing tumor progression and
therapeutic resistance55-58. NF-kappa B activation was shown to be required for the
elevated expression of Il6, IL8 and CXCL1 and concurrent inhibition of IL6 and IL8
inhibited the growth of triple negative breast cancer cell growth in vitro and in vivo59.
Altogether our transcriptomic analysis suggests that inhibition of IL6 might improve the
therapeutic outcome in the taxane based chemotherapeutic treatment of triple negative
breast cancer cells. We further investigated the PTXNR-TTZ induced selected
inflammatory gene expression signature in MDA-MB-231 cell line and BT-474 cell line.
The signature gene set is associated with enhanced inflammation and promotion of cell
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proliferation 34 In MDA-MB-231 cell line we found significantly high expression of
the signature genes suggesting a possible role in therapeutic resistance while most of the
genes were not expressed at all in BT-474 cell line (Figure 5d). In BT-474 cell line, we
also found that IL1A gene is overexpressed upon PTXNR-TTZ treatment. Recently, Liu
et. al. showed the role of IL1-alpha (encoded by IL1A gene) on tumorigenesis and
therapeutic resistance in HER2-positive breast cancer cell lines 34 The study showed that
HER2 overexpression induced the activation of IL1-alpha and IL6 for maintaining the
therapeutically resistant cancer stem cell like phenotype. More importantly, IL1A
knockdown depleted the cancer stem cell population, dampened the inflammatory
microenvironment and ultimately inhibited the HER2-induced tumorigenesis in HER2positive breast cancer cells in vivo. The study also showed that pharmacologic blockade
of IL1-alpha reduced the therapeutically resistant stem cell population and improved the
chemotherapeutic treatment response with Cisplatin and Paclitaxel in vivo. Hence, we
suggest IL1A might be a crucial therapeutic target to improve therapeutic response in
HER2-positive breast cancer.

5. CONCLUSION

The transcriptional regulation of PTXNR-TTZ was investigated in breast cancer
cells. PTXNR-TTZ treatment significantly overexpressed PRKG1 and NR4A3 genes in
HER2-positive breast cancer cells. It was concluded that the overexpression of the
PRKG1-NR4A3 axis might induce an intrinsic apoptosis pathway to inhibit the HER2positive breast cancer growth. The pathway enrichment analysis showed that the CDC20

157

was significantly overexpressed by PTXNR-TTZ treatment. CDC20 is a promoter of
mitotic exit and might act as an oncogene by activating the anaphase promoting complex
APC/C. Two other genes KIF2C and CDCA8 were also upregulated in this pathway
which have been reported to have role in cell growth progression. Moreover, KIF2C and
CDCA8 genes have recently been proposed as potential metastatic biomarkers in breast
cancer. Altogether, it was proposed that targeted inhibition of CDC20, KIF2C and
CDCA8 will enhance the therapeutic efficacy in HER2-posiitive breast cancer treatment.
PTXNR-TTZ induced high mRNA expression of selected tumorigenic inflammatory
genes in MDA-MB-231 cell line which suggests possible causes of drug resistance in
triple negative breast cancer cells.
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IV. POLYMER COATED GOLD-FERRIC OXIDE SUPERPARAMAGNETIC
NANOPARTICLES FOR THERANOSTIC APPLICATIONS

ABSTRACT

A multifunctional magnetic nanoparticle (NP) is designed to perform a near
infrared (NIR)-responsive remote control photothermal ablation for the treatment of
breast cancer. In contrast to the previously reported studies of gold (Au) magnetic
(Fe3 O4) core-shell nanoparticles (NPs), a Janus-like nanostructure is synthesized with
Fe3O4 NPs decorated with Au resulting in an approximate size of 60 nm mean diameter.
The surface of trisoctahedral Au-Fe 3 O4 NPs were coated with a positively charged
polymer, poly- i-lysine (PLL) to deliver the NPs inside cells. The PLL coating increased
the colloidal stability and robustness of Au-Fe 3 O4 NPs (PLL-Au-Fe3 O4) in biological
media including cell culture medium, phosphate buffered saline (PBS) and PBS with
10% fetal bovine serum. The PLL-Au-Fe 3 O4 NPs were characterized by transmission
electron microscopy (TEM), XRD, FT-IR and dynamic light scattering (DLS). The
unique properties of both Au surface plasmon resonance and superparamagnetic moment
result in a multimodal platform for use as a nanothermal ablator and also as a magnetic
resonance imaging (MRI) contrast agent, respectively. Taking advantage of the
photothermal therapy, PLL-Au-Fe 3 O4 NPs were incubated with BT-474 and MDA-MB231 breast cancer cells, investigated for the cytotoxicity and intracellular uptake, and
remotely triggered by a NIR laser of ~808 nm (1 W/cm2 for 10 min). It is revealed that
no significant (<10%) cytotoxicity was induced by PLL-Au-Fe 3 O4 NPs itself in BT-474
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and MDA-MB-231 cells at concentrations up to 100 ^g/ml. Brightfield microscopy,
fluorescence microscopy and TEM showed significant uptake of PLL-Au-Fe 3 O4 NPs by
BT-474 and MDA-MB-231 cells. The cells exhibited 40 and 60% inhibition in BT-474
and MDA-MB-231 cell growth, respectively following the internalized NPs were
triggered by a photothermal laser using 100 ^g/ml PLL-Au-Fe 3 O4 NPs. The control cells
treated with NPs but without laser showed <10% cell death compared to no laser
treatment control. Combined together, the results demonstrate a new polymer gold
superparamagnetic nanostructure that integrates both diagnostics function and
photothermal ablation of tumors into a single multimodal nanoplatform exhibiting a
significant cancer cell death.

1. INTRODUCTION

Assembly of the hyperthermia property of superparamagnetic nanoparticles (NPs)
with imaging function into a single nanostructure offers a promising way to dynamically
monitor the progress of the disease and enhance therapeutic efficacy. Unlike single
component materials, which usually contain only one unique property of the active
ingredient, the ingredients of multicomponent materials offer the possibility of
multimodal application of these functional components thereby increasing versatility of
these materials.1,2 The development of multicomponent materials as theranostic
nanosystems has a potential to establish a new therapeutic mode to combine imaging and
hyperthermia, which can greatly increase the therapeutic efficacy with real-time
monitoring in tissues. Normal tissues and tumors differ only slightly in relaxation time,
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and hence, cannot propagate proper diagnosis signals during magnetic resonance
imaging (MRI).3 The development of new MRI contrast agents based on NPs is a
fascinating field of research that focuses on improving MRI techniques for the early
detection of disease. Superparamagnetic NPs such as ferric oxide (Fe3 O4) have been
extensively employed as an MRI contrast agent,4-10 altering the magnetic resonance (MR)
signals by reducing the relaxivity through de-phasing of the transverse magnetization.11,12
A gold (Au) shell coating may be useful in this regard in order to enhance not only the
imaging contrasts for MRI but also the photothermal effect via the plasmon-derived
optical resonances of gold shells in the visible and near-infrared region (NIR).13 The
combination of Au-coated NPs has tremendous potential in improving optical properties,
thermal properties, tunable geometry, and imaging contrasts in MRI. As a bifunctional
NP, Au-Fe3 O4 can inherit excellent surface chemistry characteristics, unique optical
properties (attributed to Au) and superparamagnetic characteristics attributed to Fe3 O4 .
First of all, the NPs offer size controllability, ranging from few to hundreds of
nanometers with different and unique size-dependent properties. Second, the NPs can be
easily controlled and manipulated from outside with the help of external magnetic field
being operated from a distance. Third, the NPs can provide enhanced contrast in medical
imaging that can be used to diagnose the situation efficiently. These characteristics would
enhance and broaden the application of these nanoparticles for theranostic applications.
While only a few number of Au and magnetic NPs have been approved for
clinical and preclinical trials by the U.S. Food and Drug Administration (FDA),14-17
toxicity of both coated and uncoated magnetic NPs remain a serious concern.18-21 Both
Au and Fe3 O4 NPs exhibit toxicity to cells via numerous mechanisms including the
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disruption of cell membrane, DNA damage, induction of oxidative stress, generation
of free radicals, impairment of mitochondrial function and alteration in cell signaling
among others.22-24 The toxicity may not be caused by single NP, but rather due to the
aggregation of NPs in biological media and serum.25,26 Given the unstable nature of NP
formulation, it is hypothesized that an optimum dose of a cationic polymer coating onto
Au-Fe3 O4 NPs play a role in determining NP configuration on cellular cytotoxicity as
well as direct therapy. Coating the surface of Au-Fe 3 O4 NPs with suitable polymers may
offer several features: (i) reduced aggregation tendency of the particles; (ii) improved
dispersibility; (iii) enhanced colloidal stability; (iv) protected undesirable surface
oxidation; (vi) surface conjugation for targeting; (v) decreased cytotoxicity; and (v)
increased intracellular uptake by target cells. A charged polymer coating on the NP
surface enhances the electrosteric stabilization by attractive and repulsive forces. Poly- 1 lysine (PLL) is a biocompatible polycation that promotes cell adhesion by the presence of
amine (-NH 2) groups.27-29 PLL has been used to increase blood circulation, improve
solubility as well as enhance MRI imaging contrasts of gadolinium imaging chelates.27,2932 Steric stabilization has proven to be an effective method to improve NP colloidal
stability in ionic media.33 A uniform coating of Fe3 O4 NPs with polysaccharides leads to
a decrease in saturation magnetization as compared to uncoated particles.34 This drop in
saturation magnetization is undesirable due to poor signaling in MRI imaging. Therefore,
there is a need for a stable coating on the surface of Au-Fe 3 O4 NPs to prepare colloidal
dispersion in biological medium and attain high MRI imaging contrasts.
In this study, multifunctional Au-Fe 3 O4 NPs were designed for medical imaging
and hyperthermal treatments of breast cancer cells. To overcome the limitation of
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colloidal stability and low dispersity of NPs, a PLL polymeric coating was introduced
to the surface of Au-Fe 3 O4 as a physical barrier for preventing NP aggregation as well as
enhancing their intracellular uptake by breast cancer cells. Our results showed that the
PLL coating on Au-Fe 3 O4 enhanced it stability in biological fluids such as water,
phosphate buffered saline (PBS), cell culture medium and PBS containing 10% fetal
bovine serum (FBS). PLL coated Au-Fe 3 O4 NPs further enhanced the contrast of MRI
imaging signals, exhibited intracellular uptake across the breast cancer cell membrane
and decreased the cancer cell viability following photothermal treatment. The novelty of
this work is to generate a nanometer-thick PLL layer for the stable dispersion of AuFe3 O4 NPs in biological fluids that results in excellent optical, magnetic and therapeutic
properties for the cancer treatment.

2. MATERIALS AND METHODS

2.1. SYNTHESIS OF Au-Fe3O4 NPs
The Au-Fe 3 O4 NPs were synthesized by a one-pot synthesis technique based on
the method that has been published by Pariti et al.35 Briefly, the NPs were synthesized by
injecting 2.5 mM of Fe(CO)5, 0.25 mM of HAuCU, 2.5 mM oleic acid, and 2.5 mM of
oleylamine into 5 ml of Triton® X-100 at 85 °C. The reaction was conducted for 10 min
in a three-neck round bottom flask equipped with a magnetic stir bar and air condenser.
The temperature was increased to 300°C. The product was a black precipitate that was
isolated from the reaction mixture by magnetic filtration, followed by ultrasonication,
centrifugation, and washing to remove excess Triton® X-100 and any unreacted
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precursors. The powder collected at the bottom of the centrifuge tube was dried in air.
The preparation of Au-Fe 3 O4 NPs was confirmed by XRD analysis using a D/max-2400
diffractometer and CuK radiation (k = 0.1541 nm).

2.2. POLYMER COATING ON Au-Fe3O4 NPs
25 mg of Au-Fe3 O4 NPs were dispersed in 1 ml of reverse osmosis water. 660 |il
of 0.1 % ( j) PLL (Sigma Aldrich, MW: 150000-300000) was added into the NP
dispersion and incubated for 24 h at room temperature (~22 °C) under continuous
shaking. Unbound PLL was removed by centrifuging at 5000X g for 30 min that was
repeated twice and measured using the trypan blue assay, spectrophotometry, and a
standard curve (SI Figure 1a).36 The concentration of Au-Fe 3 O4 NPs was determined
using a standard curve of the NP absorption at 710 nm peak (SI Figure 1b). The mass
ratio of PLL and NPs were calculated. The presence of PLL coating was confirmed by
Fourier Transform Infrared (FT-IR) spectroscopy. The FT-IR spectrometer (PerkinElmer) was equipped with an Electronic Temperature Control (ETC) EverGlo IR Source
and a Deuterated Triglycine Sulfate (DTGS) detector. FT-IR analysis was carried out for
uncoated and PLL coated Au-Fe 3 O4 NPs by mixing with potassium bromide (KBr) and a
pellet method, after a baseline correction being made with dried KBr, to confirm the
compatibility. The pellet was prepared to a pressure of about 5 x 106 Pa, in an evacuated
chamber, to produce a clear transparent disc of diameter 2 cm and thickness of 0.2 cm.
The spectra were recorded at room temperature (~25 °C) from 4000 cm-1 to 400 cm-1.
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2.3. NANOPARTICLE CHARACTERIZATION
To measure the dmean of Au-Fe3 O4 and PLL-Au-Fe 3 O4 NPs, transmission
electron microscope (TEM) images were obtained using a Tecnai F20 at an accelerating
voltage of 120 kV. A drop of 10 ^l of each NP sample in water was air-dried on carboncoated copper grids (Ted Pella). Images were recorded and analyzed using ImageJ
(version 1.45S, NIH, USA) to calculate dmean for at least 20 particles. The size
distribution of Au-Fe 3 O4 and PLL-Au-Fe 3 O4 NPs was determined by dynamic light
scattering (DLS). The zeta potential was measured via laser Doppler anemometry using a
Zetasizer Nano ZS (Malvern Instruments). Samples were prepared in water, PBS, RPMI
1640 cell culture medium and PBS with 10% FBS. Measurements were performed in
triplicates and shown as the mean ± standard deviation (S.D.). The X-ray diffraction
(XRD) patterns were performed by a Philips X-Pert X-ray powder diffractometer with
CuKa (1.5418 A) radiation from 5 to 90 degrees. The UV-Vis absorption spectra of AuFe3 O4 and PLL-Au-Fe 3 O4 NPs were measured using a Bio-Tek microplate reader
(BioTek Synergy 2) between 400-900 nm. Fourier transform infrared (FT-IR)
spectroscopy of Au-Fe 3 O4 and PLL-Au-Fe 3 O4 NPs was carried out using a Perkin Elmer
spectrum GX spectrophotometer. Thermal gravimetric analysis (TGA) was performed
using a Q50 thermal gravimetric analyzer (TA instruments). The samples were heated
from 25°C to 1000°C at a heating rate of 10°C /min under N 2 flow. Results are expressed
in weight percent as a function of temperature.
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2.4. MRI RELAXOMETRY OF PLL- Au-Fe3O4 NPs
To measure the relaxation variables in M RI, Au-Fe 3 O 4 NPs coated with PLL (PLLAu-Fe 3 O 4 ) were prepared in water at 250 Mg/ml concentration. All measurements were
conducted at room temperature using a Bruker’s magnetic relaxometer mq20 (0.47 T) for
the spin-spin magnetic relaxation time (T 2 ) experiments. The specimens were dispersed
in PBS and PBS containing 10% FBS at different Au-Fe 3 O 4 and PLL-Au-Fe 3 O 4 NP
concentrations (1, 10 and 100 Mg/ml). The proton spin relaxation time, T 2 was measured
as a function of the NP concentration.

2.5. CYTOTOXICITY OF PLL- Au-Fe3O4 NPs IN BREAST CANCER CELLS
BT-474 and M D A -M B -2 3 1 breast cancer cells (ATCC) were cultured at 37°C and
5% CO 2 in Hybri-Care (ATCC) and R P M I 1640 (Life Technologies), respectively
supplemented with 10% FBS (Corning) and 1% (100 units/ml) Penicillin-Streptomycin
(Gibco). Cells in the exponential growth phase were seeded in a 96-well plate at an initial
density of 10,000 cells/ well and incubated overnight. Different concentrations of P L L Au-Fe 3 O 4 NPs (0-500 Mg/ml) were added to the cell culture media. After 2 h of
incubation, the media was removed, and the cells were washed using PBS followed by re
incubation in cell culture media for additional 72 h. The viable and dead cells were
measured using a live-dead (calcein AM ; C A M and EthD-1) assay (Invitrogen) and
calculated according to the manufacturer’s protocol. The cells without any NP treatments
were used as the control. The percentage cell death was calculated by the following
equation:
% cell death=

p N P s ~ F b l a n k

Fco ntrol

F b la n k .

x 100

(1)
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Where, Fnps is the Ethd-1 fluorescence of the cells treated with PLL-Au-Fe 3 O 4 NPs,
Fbiank is the Ethd-1 fluorescence of the cell culture medium alone, and Fcontrol is the Ethd-1
fluorescence of the cells without any NP treatments. The concentration at which cell death
was less than 10% was identified as a non-toxic dose.

2.6. INTRACELLULAR UPTAKE OF PLL- Au-Fe3O4 NPs
Cellular uptake of PLL-Au-Fe 3 O 4 NPs was observed using a Carl Zeiss Axio
observer Z1 research microscope system with Apitome.2 optical structuring device. BT474 and MDA-MB-231cells were seeded in 8-well chambers containing 10,000 cells/well
and grown until 70% confluence. PLL-Au-Fe 3 O 4 NPs of 100 ^.g/ml were added to the
wells, incubated for 2 h, and washed using PBS for 3 times. Live cells were re-incubated
with media and imaged on a Zeiss microscope using a 63x objective (water) through
phase contrast. The intracellular uptake of PLL-Au-Fe 3 O 4 NPs by BT-474 and M D A M B-231 cells were further examined by T EM at a voltage of 80 kV. Briefly, cells were
seeded in T25 flasks at a density of 1 x 106 cells/ml. After overnight incubation at 37°C
and 5% CO 2 , the cells were incubated with 100 ^g/ml PLL-Au-Fe 3 O 4 NPs. After
incubation for another 24 h, the medium was carefully removed and cells were washed
with PBS for 3 times and fixed at 4°C for 1 h using glutaraldehyde (2.5% in PBS). Then
the cells were further subjected to a sequence of treatments to obtain sections that were
subsequently mounted onto copper grids before T EM measurements.
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2.7. PHOTOTHERMAL TREATMENT OF BREAST CANCER CELLS USING
PLL- Au-Fe3O4 NPs
A series of specimens with different PLL-Au-Fe 3 O4 NP concentrations (0, 50,
100, 200, 400 and 800 Mg/ml) were put into quartz cuvettes and irradiated by an 808 nm
laser for 10 min with 1 W/cm2 power density. An in-situ thermocouple thermometer
(Cole-Parmer) was used to record the temperature change. To investigate the in v itro
photothermal ablation of breast cancer cells, BT-474 and MDA-MB-231 cells were
incubated with 100 Mg/ml of PLL-Au-Fe 3 O4 NPs in cell culture media for 2 h, washed
using PBS (3x) to remove the unbound NPs and re-incubated in the corresponding cell
culture media for 72 h. The cells were exposed to NIR light (808 nm pulse laser of 1
W/cm2with a diameter of 6 mm for 10 min) to induce photothermal damage. The
following control samples were used: cell culture medium, cells without any treatment,
and the cells treated with PLL-Au-Fe 3 O4 NPs without any exposure to lasers. After
exposure to the NIR light, cells were incubated for an additional 72 h at 37°C. Cell
viability was assessed using CAM and EthD-1 (Invitrogen). To further confirm the in
v itro photothermal ablation of breast cancer cells, cytotoxicity following irradiation was

also performed using MTT viability assay (Invitrogen). Briefly, BT-474 and MDA-MB23 1 cells were seeded in a 96-well plate at a density of 10,000 cells/well. After overnight
incubation at 37°C and 5% CO2 , cells were incubated with PLL-Au-Fe 3 O4 NPs of 0, 50,
100, 200, 400 and 800 Mg/ml for 2 h. The medium was replaced with 100 m1 of fresh
medium. A 10 m1 MTT of 5 mg/ml in PBS was added to the medium. Cells were
incubated at 37°C for 4 h for labeling cells with MTT. All medium was removed from the
well except 25 m1. A 50 m1 DMSO was added to each well for dissolving the insoluble
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formazan crystals. The absorbance at 540 nm was recorded using a Bio-Tek
microplate reader (Synergy 2). Mean and standard deviations of two independent
experiments were reported for each sample.

3. STATISTICAL ANALYSIS
Each experiment was carried out with three independent experiments of at least
triplicate measurements. The mean differences and standard deviations were evaluated.

4. RESULTS

4.1. SYNTHESIS AND CHARACTERIZATION OF PLL-Au-Fe3O4 NPs
TEM images revealed that Au-Fe 3 O4 NPs were uniform and averaged ~55 ± 8.6
nm in diameter (Figure 1a). The thickness of PLL coating on Au-Fe 3 O4 was estimated to
be approximately 9 ± 2.5 nm by analyzing the TEM images (Figure 1b and 1c). SI Table
1 shows the amount of PLL coating on Au-Fe 3 O4 . The hydrodynamic dimeter of AuFe3 O4 NPs in water as characterized using DLS showed a wide size distribution of AuFe3 O4 dispersions with more than one particle populations and a high polydispersity
index (PDI) of 0.856 ± 0.07 (SI Figure 2a). The differences in size between TEM and
DLS techniques could be explained by NP agglomeration and the presence of small
aggregates. The PLL coating decreased the PDI of Au-Fe 3 O4 NPs from 0.856 to 0.539 ±
0.03 (Table 1). The hydrodynamic diameters of NPs after PLL coating eliminated the
large and small particle aggregates in water, PBS, RPMI 1640 cell culture medium and
PBS containing 10% FBS indicating a better colloidal stability (SI Figure 2b). The
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stability of PLL-Au-Fe 3 O4 NPs was further probed using a time-resolved video (SI
Movie File 1). As you can see from this video that Au-Fe 3 O4 NPs without any coating
(left hand side tube in the video) precipitate down quickly in water while PLL-Au-Fe 3 O4
NPs (right hand side tube) were stably suspended in black emulsion.

(a)

(b)

(c)

Figure 1. TEM images showing Au-Fe 3 O4 NPs. (a) without, and (b) and (c) with PLL
coating. Scale bar = 50 nm in (a) and (b), and 20 nm in (c). The dark black circles
indicate Au and the shaded hexagons represent Fe3O4. Arrows in (c) indicate a thin layer
of PLL coating

The Au-Fe 3 O4 NPs possess a negative surface charge of -7.9 ± 0.8 mV and -12 ±
7 mV in water and PBS, respectively as determined by zeta potential (Table 1 and Figure
2a). The zeta potentials of Au-Fe 3 O4 NPs increased in cell culture medium and PBS with
10% FBS indicating pronounced differences in the particle surface chemistry caused by
different solvent compositions. The PLL coated Au-Fe 3 O4 NPs showed a strong positive
charge in water and PBS due to the positive amine groups on the polymer backbone
which confirmed the successful grating of PLL polymer on the surface of NPs (Table 1
and Figure 2b). This further confirms that the PLL coating made the NPs disperse better
in aqueous solutions and as a result no agglomeration on storage. Particles that are
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surface engineered with amine functional groups like PLL has been reported to
effective release of encapsulated molecules from endosomal compartments.37

Table 1. Characterization of Au-Fe 3 O4 before and after PLL coating

(a)

(b)

R P M I 1 6 4 0 ce l l c u l t u r e m e d i u m

PBS + 10% FBS

Figure 2. Surface zeta potential. (a) Au-Fe3O4, and (b) PLL-Au-Fe3O4 NPs
in water, PBS, RPMI 1640 cell culture medium and PBS containing 10% FBS. Three
colored (red, green and blue) lines indicate three replicates from three independent
experiments. Multiple peaks in Au-Fe3O4 (a) indicate their aggregation behavior that
disappears after PLL coating (b)
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The crystal structures of Au-Fe 3 O4 and PLL-Au-Fe 3 O4 NPs were recorded by
the X-ray diffraction (XRD), as shown in Figure 3a. The XRD pattern of Fe 3 O4 shows
characteristic peaks at (111), (220), (311), (400), (422), (511) and (400) and (111), (220),
(220), (311), (222) peaks for Au which is in agreement to the controls of Fe 3 O4-PDF #
65-3107 and Au-PDF # 05-0681, respectively. XRD pattern contains no impurity peak
indicating the high purity of Au and Fe3 O4 samples and perfect phase transformation. The
XRD pattern of PLL-Au-Fe 3 O4 NPs has similar diffraction peaks as those of A uFe3 O4 NPs with more peak to noise ratio which could be attributed to PLL polymeric
coating.
To confirm the successful synthesis of NPs, UV-Vis absorption and FT-IR spectra
were measured. A complete spectra analysis of Au-Fe 3 O4 NPs shows a broad surface
plasmon absorption with an absorption maximum at around 710 nm (Xmax) (Figure 3b;
dotted line).38 The PLL coating showed an absorption shift to lower wavelengths with an
absorption maximum at 640 nm (Figure 3b; solid line). This explains the enhanced
dispersion of PLL-Au-Fe 3 O4 NPs in the aqueous phase by redistributing agglomerated
Au-Fe3O4 NPs.
FT-IR spectra were used to study the transformation of Au-Fe 3 O4 and PLL-AuFe3 O4 NP compositions (Figure 3c). As shown in Figure 3c, the strong absorption peak at
about 590 cm-1 in the FT-IR o f Au-Fe 3 O4 originates from Fe-O stretching of the Fe3 O4
core. The bare Au- Fe3O4 spectrum contains a peak at 1630 cm-1 due to water physiosorbed
on the iron oxide surface and a broad band around 3400 cm-1 due to surface hydroxyl groups
(Fe-OH). For PLL-Au-Fe 3 O4 NPs, new and broad absorption bands were observed in the
range of 3340 and 3600 cm-1, which were attributed to amine N -H stretching and O-H
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stretching, respectively. The peaks at 1647 and 1587 cm 1 attributed to to the stretching
vibration of C=O from the PLL coating.

(a)

Figure 3.Characterization of PLL-Au-Fe 3 O4 NPs. (a) XRD patterns; (b) Absorption
spectra (solid line: PLL-Au-Fe 3 O4 NPs and dotted line: Au-Fe 3 O4 NPs); (c) FT-IR
characterization and (d) TGA curves of Au-Fe 3 O4 and PLL-Au-Fe 3 O4 NPs

To quantify the amount of PLL on the surface of PLL-Au-Fe 3 O4 NPs, TGA was
performed (Figure 3d). The PLL coating results in a weight loss of 7.4% between 100 °C
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and 650°C when compared with the uncoated particles (Au-Fe 3 O4). No change in
PLL-Au-Fe 3 O4 mass was observed above 850°C. Combinedly, these findings suggest a
successful surface functionalization of Au-Fe 3 O4 NPs by PLL polymer coating.

4.2. T2 MR RELAXIVIITY OF PLL-Au-Fe3O4 NPs AS DETERMINED BY MRI
Saturation magnetization value (Ms) and the T2 relaxation time were analyzed in
order to evaluate the magnetic properties o f Au-Fe 3 O4 with and without the PLL coating
(SI Figure 3). Generally, the spin-spin magnetic relaxation of water protons changes in
the presence of magnetic materials in the solution, such as synthesized Au-Fe 3 O4 NPs.
This leads to enhance the magnetic property of the solution. Fe 3 O4 NPs are generally
used for MR contrast agents because of their capacity to short the T2 relaxation time of
their surrounding protons. As can be clearly seen in SI Figure 3, T2 was decreased
gradually with the increase in NP concentration. The T2 relaxation time of PLL-AuFe3 O4 NPs was higher than that of Au-Fe 3 O4 NPs due to the fact that the polymer coating
displaces the water molecules from the vicinity of the Au-Fe 3 O4 nanocomposite, leading
to an increase in the MR values.

4.3. CYTOTOXICITY
STUDY
INTRACELLULAR UPTAKE

BY

PLL-Au-Fe3O4

NPs

AND

ITS

Figure 4a shows the cytotoxicity induced by various concentrations of PLL-AuFe3 O4 NPs in BT-474 and M D A -M B -231 cells is dose-dependent. PLL-Au-Fe 3 O4 NPs
did not show much cytotoxicity (< 20% cell death) at a concentration < 100 ^g/ml, and
hence the concentration was chosen for subsequent studies. To investigate the
intracellular uptake of the NPs, phase contrast images were used. It can be seen from
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Figure 4b and Figure 4c that the PLL-Au-Fe 3 O4 NPs (black spots as indicated by
arrows) entered in the cytoplasm of BT-474 and MDA-MB-231 cells. No black clusters
were found in control cells without any NPs indicating the internalization of NPs by the
cells. No morphological changes in cellular physiology have been observed when
compared to control cells demonstrating negligible cytotoxicity by PLL-Au-Fe 3 O4 NPs.
The uptake of PLL-Au-Fe 3 O4 NPs was further evaluated by TEM imaging (SI Figure 4).
Clearly, cells treated with NPs show a remarkable distribution inside endoplasmic
vesicles of the cells.

(a)

Figure 4.Cytotoxicity and cellular uptake o f PLL-Au-Fe 3 O4 NPs. (a) Cytotoxicity of
PLL-Au-Fe 3 O4 NPs in BT-474 and M D A -M B -231 cells using live-dead assay at
increasing NP concentration; Cellular uptake of PLL-Au-Fe 3 O4 NPs in (b) BT-474 and
(c) MDA-MB-231 cells. Arrows indicate the NPs inside cells. Cells without any NP
treatment (control) did not show the black NP dots inside cells. Scale bar = 10 ^m
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(b)

(c)

MDA-MB-231 cells
control; no NPs

MDA-MB-231: 100 ^g/ml
PLL-A u-Fe30 4

Figure 4.Cytotoxicity and cellular uptake of PLL-Au-Fe 3 O4 NPs.(a) Cytotoxicity of
PLL-Au-Fe 3 O4 NPs in BT-474 and M D A -M B -231 cells using live-dead assay at
increasing NP concentration; Cellular uptake of PLL-Au-Fe 3 O4 NPs in (b) BT-474 and
(c) MDA-MB-231 cells. Arrows indicate the NPs inside cells. Cells without any NP
treatment (control) did not show the black NP dots inside cells. Scale bar = 10 ^.m (cont.)

4.4. PHOTOTHERMAL EFFECTS BY PLL-Au-Fe3O4 NPs
In order to investigate, the potential of PLL-Au-Fe 3 O4 as nanothermal ablators,
suspensions of the NPs in PBS were irradiated using 808 nm light emitted by a laser. The
photothermal behavior of PLL-Au-Fe 3 O4 NPs was investigated by a temperature change
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versus the NP concentration (Figure 5). Clearly, the NPs were able to induce a
temperature enhancement in a concentration dependent manner.

Figure 5. Temperature change of a PBS solution containing PLL-Au-Fe 3 O4 NPs under
an 808 nm laser irradiation as a function of different NP concentrations

The temperature of the NP suspension reached 50°C at the PLL-Au-Fe 3 O4 NP
concentration of 800 ^g/ml. Laser irradiation of PBS negative control without NPs did
not show any temperature increase under the same conditions. The results indicate that
the synthesized PLL-Au-Fe 3 O4 NPs were able to transform NIR laser into heat under
laser irradiation. For laser treatment, BT-474 and MDA-MB-231 cells were first
incubated with PLL-Au-Fe 3 O4 NPs for 2 h followed by a wash process to remove un
internalized NPs, laser irradiation for 10 min and then for additional 72 h incubation
period. In the control groups (cells + laser irradiation in absence of NPs), no significant
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cell death was observed. The cells treated with 100 ^g/ml of PLL-Au-Fe 3 O4 NPs but
without laser illumination reached 90 ± 4.7% of cell survival rate compared to those
treated with PBS control. In contrast, the combination of PLL-Au-Fe 3 O4 NPs and laser
treated cells underwent photothermal destruction as shown by both phase contrast and
cell viability (green live cells) and dead cell (red stain) staining (Figure 6).

BT-474:

Laser; no NPs

Laser + 100 ng/ml
PLL-Au-Fe30 4

MDA-MB-231:
Laser; no NPs

Laser + 100 |ig/ml
PLL-Au-Fe30 4

Phase
contrast

Figure 6. Phase contrast images of PLL-Au-Fe 3 O4 treatment on cancer cells. Phase
contrast (row 1) and fluorescence (rows 2 and 3) images of BT-474 and MDA-MB-231
cells treated with 2 h incubation of PLL-Au-Fe 3 O4 followed by 10 min laser irradiation
and 72 h of incubation in the medium. Uninternalized NPs were washed with PBS before
the imaging. Green fluorescence represents live cells as stained with calcein AM, while
the red fluorescence represents dead cells as stained with EthD-1. Scale bars are shown
on images
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The groups for PLL-Au-Fe 3 O4 NPs + 10 min exposure to laser illumination
2
at 1 W/cm showed the inhibition in cell growth by 49 ± 12% in BT-474 cells (Figure 7;
filled circle) and 60 ± 10% in MDA-MB-231 cells (Figure 7; open circle) suggesting
significant therapeutic effects following the photothermal treatment. Cells without any
treatment, with laser treatment alone and with NP groups showed <5% inhibition in cell
growth. The cytocompatibility of PLL-Au-Fe 3 O4 NPs was further assessed by MTT cell
viability assay (SI Figure 5). The quantitative analysis further reveal that the percentage
of cell viability decreased to 63.5 ± 5.5% and 31.6 ± 3.2% in BT-474 and MDA-MB-231
cells, respectively at concentrations >10 ^g/ml of NPs following laser irradiation.

Figure 7. Inhibition of cancer cell growth by PLL-Au-Fe 3 O4 NPs treatment following
photothermal therapy. Quantitative assay of BT-474 (solid line; filled circle) and MDAMB-231 (dotted line; open circle) cell growth inhibition following photothermal therapy
in presence of PBS + laser and 100 ^g/ml of PLL-Au-Fe 3 O4 NPs. The data represent the
average o f three independent experiments
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5. DISCUSSION

A dumbbell shaped Au-Fe 3 O4 superparamagnetic NPs is synthesized that is
similar in morphology to multifaceted Janus particles.39,40 The structure (Au-decorated
Fe3 O4 ) is chosen to provide added advantages of both Au and Fe3 O4 functionalities for
the full utilization of their potential. Several Au dots on the Fe 3 O4 host ensures that there
is a maximum number of spots for molecular recognition since Au-terminal acts as
anchors for targeting agents. Perhaps the most challenging aspect of applying Au-Fe 3 O4
NPs involves the colloidal stability and shelf-life, surface functionalization, cellular
internalization, and biocompatibility. Designing a properly grafted surface is therefore of
paramount importance. Dextran,41 PEG,42 and silica coating43 have been used
extensively, however, each method has its benefits and drawbacks and requires trade-offs
and optimizations. For example, although silica coatings can provide colloidal stability, it
may also retard R2 relaxation in MRI imaging, as well dampens the superparamagnetic
moment which reduces hyperthermia efficiency. Reduction in the superparamagnetic
moment also leads to the necessity for increased dosage of the magnetic NPs. In that
regards, the Janus-like particle with larger Fe 3 O4 anchored with several Au dots serves
the multifaceted purpose of retaining high superparamagnetic moment over larger size35
as well as optimizing SPR and photothermal effect of Au. Here, we report a simple and
versatile method to adsorb PLL on bare Au-Fe 3 O4 dispersed in aqueous solutions. The
polycationic PLL backbone ensures tight coulomb attachment onto anionic surfaces of
Au endowing the NP surface with a robust coverage.
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This approach can be generalized to many anionic surfaces onto which
cationic polymers can adhere tightly, such as glass or silica. The results are comparable
with previous studies on Au nanoshells where polymers (i.e., polyethylene imine; PEI)
have been used as an intermediate separating layer during the fabrication of Au-Fe 3 O4
where the polymer layer prevents the migration of Au shell into the magnetic core by
connecting between the core and shell structure.44,45 In contrast, we show an outer layer
of PLL on the surface of Au-Fe 3 O4 that attribute to the columbic interactions between the
Au surface and aliphatic monoamines that is clearly responsible for the observed stability
of Au-Fe 3 O4 against aggregation in PBS. The TEM images showed the presence of a
layer of PLL of approximately 9 nm thickness. The PLL coating improved the interaction
of negatively charged Au-Fe 3 O4 at the cellular level by the resulting surface charge as
confirmed by the zeta potential data.
The next step of PLL-Au-Fe 3 O4 involves cell culture experiments that suggest
the overall intracellular uptake of the NPs at a non-toxic dose in breast cancer cells. The
live/dead assay indicates that PLL-Au-Fe 3 O4 NPs are not cytotoxic in breast cancer cells
at concentrations <100 ^g/ml (Figure 5). When compared to other cell viability data of
polymer-coated NPs, our results are comparable to the literature data showing 20%
reduction in cell viability using similar NP concentrations.45,46 Furthermore, the results
from the phase contrast imaging microscopy demonstrated the effective internalization of
the NPs presumably due to the combination of electrostatic interaction with the
negatively charged glycocalyx on the cell membrane47,48 and the receptor-mediated
endocytosis v ia EGCG49-53 The results are in agreement with the previous finding where
Au NPs functionalized with methoxy-PEG-thiol were internalized by MDA-MB-231

186

cells v ia endocytosis.54,55 Importantly, the observed uptake of PLL-Au-Fe 3 O4 NPs in
breast cancer cells associated with low toxicity suggest a potential theranostic use of
these Au NPs. It is worth noting that PLL-Au-Fe 3 O4 had higher levels of uptake in
MDA-MB-231 cells than BT-474 cells. The differences in cell surface protein
expressions and proteoglycans may attribute to the differential uptake of NPs inside the
cells.56-58 Importantly, the higher observed uptake of PLL-Au-Fe3O4 in MDA-MB-231
than BT-474 cells was associated with pronounced toxicity (Figure 5 and 6) suggesting a
potential theranostic use of these gold nanoparticles.
Multiple studies have demonstrated the heating effect of Au shell NPs.
Thermal ablation using PEG-coated Au nanoshells with silica cores have been reported to
induce photothermal morbidity in SK-BR-3 breast cancer cells.59 The treated cells
revealed lost in cell membrane integrity and cell death that was not observed in the
controls with laser irradiation or gold nanoshells alone.59 Photothermal destruction was
effective in reducing colon tumors in mice with a mean survival life of 90 days after the
treatment.60 We found that at 100 ^.g/ml of PLL-Au-Fe 3 O4 and 10 min laser exposure, a
AT of 15±7.6°C was achieved. The current study reveals the effectiveness o f using PLLAu-Fe 3 O4 as a potent MRI-visible photosensitizer during the laser irradiation of cancer
cells.61-63 The noticeable combination of properties of PLL-Au-Fe 3 O4 with the local
application of NIR laser irradiation offers a promising approach for the photothermal
ablation therapy of breast cancer cells following internalization inside cells.

187

6. CONCLUSIONS

A multifunctional NP was constructed using the PLL polymer coating on A uFe3 O4 with a mean diameter of ~60 nm that are less prone to aggregation and thus
suitable for a wide range of biological applications. PLL-Au-Fe 3 O4 NPs showed good
colloidal stability, NIR light absorption property, magnetic relaxivity and
cytocompatibility. Upon exposure to a NIR light, the SPR of Au increased their
temperature inside the cells. The PLL-Au-Fe 3 O4 NPs were also demonstrated the
importance of having a surface of the polymer layer that enhanced MRI contrast. As an
integrated all-in-one NP platform, the polymeric theranostic agent was shown for
intracellular uptake and hyperthermal treatments of breast cancer cells for further
translational therapeutic applications.

6.1. FUNDING
This research was funded by S B ’s start-up and ACS PRF 56629-UNI7 to S.S.

ACKNOWLEDGMENTS

For this work, we would like to acknowledge the Environmental Research Center
(ERC) and Materials Research Center (MRC) at Missouri S&T for TEM and Zetasizer
use. The authors would like to thank Dr. Hai-Lung Tsai of the Department of Mechanical
Engineering at Missouri S&T to allow us using their laser facility.

188

REFERENCES

(1)

Key, J.; Park, K. Multicomponent, Tumor-Homing Chitosan Nanoparticles for
Cancer Imaging and Therapy. International Journal of Molecular Sciences 2017,
18.

(2)

Ma, Y.; Liang, X. L.; Tong, S.; Bao, G.; Ren, Q. S.; Dai, Z. F. Gold Nanoshell
Nanomicelles for Potential Magnetic Resonance Imaging, Light-Triggered Drug
Release, and Photothermal Therapy. Advanced Functional Materials 2013, 23,
815-822.

(3)

Bammer, R.; Skare, S.; Newbould, R.; Liu, C.; Thijs, V.; Ropele, S.; Clayton, D.
B.; Krueger, G.; Moseley, M. E.; Glover, G. H. Foundations of Advanced
Magnetic Resonance Imaging. NeuroRx 2005, 2, 167-196.

(4)

Belyanina, I.; Kolovskaya, O.; Zamay, S.; Gargaun, A.; Zamay, T.; Kichkailo, A.
Targeted Magnetic Nanotheranostics of Cancer. Molecules 2017, 22.

(5)

Chen, C. W.; Syu, W. J.; Huang, T. C.; Lee, Y. C.; Hsiao, J. K.; Huang, K. Y.;
Yu, H. P.; Liao, M. Y.; Lai, P. S. Encapsulation of Au/Fe3O4 nanoparticles into a
polymer nanoarchitecture with combined near infrared-triggered chemophotothermal therapy based on intracellular secondary protein understanding.
Journal of Materials Chemistry B 2017, 5, 5774-5782.

(6)

Hu, J.; Dehsorkhi, A.; Al-Jamal, W. T.; Zhang, Y.; Chen, S. Y.; Yang, C. Y.; Tan,
D.; Zhao, Q.; Yang, C.; Wang, Y. L. Studies on the Photothermal Effect of
PEGylated Fe3O4 Nanoparticles. Nanoscience and Nanotechnology Letters 2017,
9, 556-561.

(7)

Tang, J. L.; Zhou, H. G.; Liu, J. M.; Liu, J.; Li, W. Q.; Wang, Y. Q.; Hu, F.; Huo,
Q.; Li, J. Y.; Liu, Y.; Chen, C. Y. Dual-Mode Imaging-Guided Synergistic
Chemo- and Magnetohyperthermia Therapy in a Versatile Nanoplatform To
Eliminate Cancer Stem Cells. Acs Applied Materials & Interfaces 2017, 9, 23497
23507.

(8)

Wang, Y. X. J.; Idee, J. M. A comprehensive literatures update of clinical
researches of superparamagnetic resonance iron oxide nanoparticles for magnetic
resonance imaging. Quantitative Imaging in Medicine and Surgery 2017, 7, 88
122.

189

(9)

Yang, H. Y.; Jang, M. S.; Li, Y.; Lee, J. H.; Lee, D. S. Multifunctional and
Redox-Responsive Self-Assembled Magnetic Nanovectors for Protein Delivery
and Dual-Modal Imaging. Acs Applied Materials & Interfaces 2017, 9, 19184
19192.

(10)

Yang, R. M.; Fu, C. P.; Fang, J. Z.; Xu, X. D.; Wei, X. H.; Tang, W. J.; Jiang, X.
Q.; Zhang, L. M. Hyaluronan-modified superparamagnetic iron oxide
nanoparticles for bimodal breast cancer imaging and photothermal therapy.
International Journal of Nanomedicine 2017, 12, 197-206.

(11)

Hemery, G.; Garanger, E.; Lecommandoux, S.; Wong, A. D.; Gillies, E. R.;
Pedrono, B.; Bayle, T.; Jacob, D.; Sandre, O. Thermosensitive polymer-grafted
iron oxide nanoparticles studied by in situ dynamic light backscattering under
magnetic hyperthermia. Journal of Physics D-Applied Physics 2015, 48.

(12)

Kale, S. S.; Burga, R. A.; Sweeney, E. E.; Zun, Z. H.; Sze, R. W.; Tuesca, A.;
Subramony, J. A.; Fernandes, R. Composite iron oxide-Prussian blue
nanoparticles for magnetically guided T-1-weighted magnetic resonance imaging
and photothermal therapy of tumors. International Journal of Nanomedicine 2017,
12, 6413-6424.

(13)

Narayanan, S.; Sathy, B. N.; Mony, U.; Koyakutty, M.; Nair, S. V.; Menon, D.
Biocompatible Magnetite/Gold Nanohybrid Contrast Agents via Green Chemistry
for MRI and CT Bioimaging. Acs Applied Materials & Interfaces 2012, 4, 251
260.

(14)

Salah, E. D. T. A.; Bakr, M. M.; Kamel, H. M.; Abdel, K. M.: Magnetite
nanoparticles as a single dose treatment for iron deficiency anemia. Google
Patents, 2010.

(15)

Thiesen, B.; Jordan, A. Clinical applications of magnetic nanoparticles for
hyperthermia. International Journal of Hyperthermia 2008, 24, 467-474.

(16)

Bashir, M. R.; Bhatti, L.; Marin, D.; Nelson, R. C. Emerging applications for
ferumoxytol as a contrast agent in MRI. Journal of Magnetic Resonance Imaging
2015, 41, 884-898.

(17)

Kharlamov, A. N.; Gabinsky, J. L. Plasmonic Photothermic and Stem Cell
Therapy of Atherosclerotic Plaque As a Novel Nanotool for Angioplasty and
Artery Remodeling. Rejuvenation Research 2012, 15, 222-230.

(18)

Pisanic, T. R.; Blackwell, J. D.; Shubayev, V. I.; Finones, R. R.; Jin, S.
Nanotoxicity of iron oxide nanoparticle internalization in growing neurons.
Biomaterials 2007, 28, 2572-2581.

190

(19)

Hanini, A.; Schmitt, A.; Kacem, K.; Chau, F.; Ammar, S.; Gavard, J.
Evaluation of iron oxide nanoparticle biocompatibility. International Journal of
Nanomedicine 2011, 6, 787-794.

(20)

Zhang, X.-D.; Wu, D.; Shen, X.; Liu, P.-X.; Fan, F.-Y.; Fan, S.-J. In vivo renal
clearance, biodistribution, toxicity of gold nanoclusters. Biomaterials 2012, 33,
4628-4638.

(21)

Siddiqi, N. J.; Abdelhalim, M. A. K.; El-Ansary, A. K.; Alhomida, A. S.; Ong, W.
Y. Identification of potential biomarkers of gold nanoparticle toxicity in rat
brains. Journal of Neuroinflammation 2012, 9, 123-123.

(22)

Joris, F.; Valdeperez, D.; Pelaz, B.; Soenen, S. J.; Manshian, B. B.; Parak, W. J.;
De Smedt, S. C.; Raemdonck, K. The impact o f species and cell type on the
nanosafety profile o f iron oxide nanoparticles in neural cells. Journal o f
Nanobiotechnology 2016, 14.

(23)

Lewinski, N.; Colvin, V.; Drezek, R. Cytotoxicity of nanoparticles. Small 2008, 4,
26-49.

(24)

Escamilla-Rivera, V.; Uribe-Ramirez, M.; Gonzalez-Pozos, S.; Lozano, O.;
Lucas, S.; De Vizcaya-Ruiz, A. Protein corona acts as a protective shield against
Fe3O4-PEG inflammation and ROS-induced toxicity in human macrophages.
Toxicology Letters 2016, 240, 172-184.

(25)

Soenen, S. J.; Rivera-Gil, P.; Montenegro, J.-M.; Parak, W. J.; De Smedt, S. C.;
Braeckmans, K. Cellular toxicity of inorganic nanoparticles: Common aspects and
guidelines for improved nanotoxicity evaluation. Nano Today 2011, 6, 446-465.

(26)

Smith, B. M.; Pike, D. J.; Kelly, M. O.; Nason, J. A. Quantification of
Heteroaggregation between Citrate-Stabilized Gold Nanoparticles and Hematite
Colloids. Environmental Science & Technology 2015, 49, 12789-12797.

(27)

Shiraishi, K.; Kawano, K.; Maitani, Y.; Yokoyama, M. Polyion complex micelle
MRI contrast agents from poly(ethylene glycol)-b-poly(l-lysine) block
copolymers having Gd-DOTA; preparations and their control of T1-relaxivities
and blood circulation characteristics. Journal of Controlled Release 2010, 148,
160-167.

(28)

Al-Jamal, K. T.; Al-Jamal, W. T.; Akerman, S.; Podesta, J. E.; Yilmazer, A.;
Turton, J. A.; Bianco, A.; Vargesson, N.; Kanthou, C.; Florence, A. T.; Tozer, G.
M.; Kostarelos, K. Systemic antiangiogenic activity of cationic poly-L-lysine
dendrimer delays tumor growth. Proceedings of the National Academy of
Sciences of the United States of America 2010, 107, 3966-3971.

191

(29)

Tunyaboon, L.; Hannah, H. K.; Kelly, D.; Caitlin, B.; Dipak, B.; Daniel, F.;
Yue-Wern, H.; Sutapa, B. Bioresponsive polymer coated drug nanorods for breast
cancer treatment. Nanotechnology 2017, 28, 045601.

(30)

Alconcel, S. N. S.; Baas, A. S.; Maynard, H. D. FDA-approved poly(ethylene
glycol)-protein conjugate drugs. Polymer Chemistry 2011, 2, 1442-1448.

(31)

Vexler, V. S.; Clement, O.; Schmitt-Willich, H.; Brasch, R. C. Effect of varying
the molecular weight of the MR contrast agent Gd-DTPA-polylysine on blood
pharmacokinetics and enhancement patterns. Journal of Magnetic Resonance
Imaging 1994, 4, 381-388.

(32)

Bogdanov, A.; Wright, S. C.; Marecos, E. M.; Bogdanova, A.; Martin, C.;
Petherick, P.; Weissleder, R. A long-circulating co-polymer in ''passive targeting''
to solid tumors. Journal of Drug Targeting 1997, 4, 321-&.

(33)

Gref, R.; Luck, M.; Quellec, P.; Marchand, M.; Dellacherie, E.; Harnisch, S.;
Blunk, T.; Muller, R. H. ‘Stealth’ corona-core nanoparticles surface modified by
polyethylene glycol (PEG): influences of the corona (PEG chain length and
surface density) and of the core composition on phagocytic uptake and plasma
protein adsorption. Colloids and Surfaces B: Biointerfaces 2000, 18, 301-313.

(34)

Amstad, E.; Zurcher, S.; Mashaghi, A.; Wong, J. Y.; Textor, M.; Reimhult, E.
Surface Functionalization of Single Superparamagnetic Iron Oxide Nanoparticles
for Targeted Magnetic Resonance Imaging. Small 2009, 5, 1334-1342.

(35)

Pariti, A.; Desai, P.; Maddirala, S. K. Y.; Ercal, N.; Katti, K. V.; Liang, X.; Nath,
M. Superparamagnetic Au-Fe3O4 nanoparticles: one-pot synthesis,
biofunctionalization and toxicity evaluation. Materials Research Express 2014, 1.

(36)

Grotzky, A.; Manaka, Y.; Fornera, S.; Willeke, M.; Walde, P. Quantification of
[small alpha]-polylysine: a comparison of four UV/Vis spectrophotometric
methods. Analytical Methods 2010, 2, 1448-1455.

(37)

Luo, R.; Mutukumaraswamy, S.; Venkatraman, S. S.; Neu, B. Engineering of
erythrocyte-based drug carriers: control of protein release and bioactivity. Journal
of Materials Science: Materials in Medicine 2012, 23, 63-71.

(38)

Lou, L.; Yu, K.; Zhang, Z.; Huang, R.; Wang, Y.; Zhu, Z. Facile methods for
synthesis of core-shell structured and heterostructured Fe3O4@Au
nanocomposites. Applied Surface Science 2012, 258, 8521-8526.

(39)

Lattuada, M.; Hatton, T. A. Synthesis, properties and applications of Janus
nanoparticles. Nano Today 2011, 6, 286-308.

192

(40)

Perro, A.; Reculusa, S.; Ravaine, S.; Bourgeat-Lami, E.; Duguet, E. Design
and synthesis of Janus micro- and nanoparticles. Journal of Materials Chemistry
2005, 15, 3745-3760.

(41)

Li, W.; Tutton, S.; Vu, A. T.; Pierchala, L.; Li, B. S. Y.; Lewis, J. M.; Prasad, P.
V.; Edelman, R. R. First-pass contrast-enhanced magnetic resonance angiography
in humans using ferumoxytol, a novel ultrasmall superparamagnetic iron oxide
(USPIO)-based blood pool agent. Journal of Magnetic Resonance Imaging 2005,
21, 46-52.

(42)

Shen, J. W.; Li, K. Y.; Cheng, L.; Liu, Z.; Lee, S. T.; Liu, J. Specific Detection
and Simultaneously Localized Photothermal Treatment of Cancer Cells Using
Layer-by-Layer Assembled Multifunctional Nanoparticles. Acs Applied Materials
& Interfaces 2014, 6, 6443-6452.

(43)

Pinho, S. L. C.; Pereira, G. A.; Voisin, P.; Kassem, J.; Bouchaud, V.; Etienne, L.;
Peters, J. A.; Carlos, L.; Mornet, S.; Geraldes, C. F. G. C.; Rocha, J.; Delville, M H. Fine Tuning of the Relaxometry of y-Fe2O3@SiO2 Nanoparticles by
Tweaking the Silica Coating Thickness. ACS Nano 2010, 4, 5339-5349.

(44)

Goon, I. Y.; Lai, L. M. H.; Lim, M.; Munroe, P.; Gooding, J. J.; Amal, R.
Fabrication and Dispersion of Gold-Shell-Protected Magnetite Nanoparticles:
Systematic Control Using Polyethyleneimine. Chemistry of Materials 2009, 21,
673-681.

(45)

Hoskins, C.; Min, Y.; Gueorguieva, M.; McDougall, C.; Volovick, A.; Prentice,
P.; Wang, Z.; Melzer, A.; Cuschieri, A.; Wang, L. Hybrid gold-iron oxide
nanoparticles as a multifunctional platform for biomedical application. Journal of
Nanobiotechnology 2012, 10, 27.

(46)

Hoskins, C.; Cuschieri, A.; Wang, L. The cytotoxicity of polycationic iron oxide
nanoparticles: Common endpoint assays and alternative approaches for improved
understanding of cellular response mechanism. Journal of Nanobiotechnology
2012, 10, 15.

(47)

Schweiger, C.; Hartmann, R.; Zhang, F.; Parak, W. J.; Kissel, T. H.; Rivera_Gil,
P. Quantification of the internalization patterns of superparamagnetic iron oxide
nanoparticles with opposite charge. Journal of Nanobiotechnology 2012, 10, 28.

(48)

Ojea-Jimenez, I.; Gartia-Fernandez, L.; Lorenzo, J.; Puntes, V. F. Facile
preparation of cationic gold nanoparticle-bioconjugates for cell penetration and
nuclear targeting. ACS Nano 2012, 6, 7692-7702.

193
(49)

Ahmad, N.; Feyes, D. K.; Agarwal, R.; Mukhtar, H.; Nieminen, A.-L. Green
Tea Constituent Epigallocatechin-3-Gallate and Induction of Apoptosis and Cell
Cycle Arrest in Human Carcinoma Cells. JNCI: Journal of the National Cancer
Institute 1997, 89, 1881-1886.

(50)

Liang, Y.-C.; Lin-shiau, S.-Y.; Chen, C.-F.; Lin, J.-K. Suppression of
extracellular signals and cell proliferation through EGF receptor binding by (-)epigallocatechin gallate in human A431 epidermoid carcinoma cells. Journal of
Cellular Biochemistry 1997, 67, 55-65.

(51)

Pianetti, S.; Guo, S.; Kavanagh, K. T.; Sonenshein, G. E. Green Tea Polyphenol
Epigallocatechin-3 Gallate Inhibits Her-2/Neu Signaling, Proliferation, and
Transformed Phenotype of Breast Cancer Cells. Cancer Research 2002, 62, 652
655.

(52)

Tachibana, H.; Koga, K.; Fujimura, Y.; Yamada, K. A receptor for green tea
polyphenol EGCG. Nature Structural &Amp; Molecular Biology 2004, 11, 380.

(53)

Shukla, R.; Chanda, N.; Zambre, A.; Upendran, A.; Katti, K.; Kulkarni, R. R.;
Nune, S. K.; Casteel, S. W.; Smith, C. J.; Vimal, J.; Boote, E.; Robertson, J. D.;
Kan, P.; Engelbrecht, H.; Watkinson, L. D.; Carmack, T. L.; Lever, J. R.; Cutler,
C. S.; Caldwell, C.; Kannan, R.; Katti, K. V. Laminin receptor specific
therapeutic gold nanoparticles (198AuNP-EGCg) show efficacy in treating
prostate cancer. Proceedings of the National Academy of Sciences 2012, 109,
12426-12431.

(54)

Shukla, R.; Bansal, V.; Chaudhary, M.; Basu, A.; Bhonde, R. R.; Sastry, M.
Biocompatibility of Gold Nanoparticles and Their Endocytotic Fate Inside the
Cellular Compartment: A Microscopic Overview. Langmuir 2005, 21, 10644
10654.

(55)

Shenoy, D.; Fu, W.; Li, J.; Crasto, C.; Jones, G.; DiMarzio, C.; Sridhar, S.; Amiji,
M. Surface functionalization of gold nanoparticles using hetero-bifunctional
poly(ethylene glycol) spacer for intracellular tracking and delivery. International
Journal of Nanomedicine 2006, 1, 51-57.

(56)

Holliday, D. L.; Speirs, V. Choosing the right cell line for breast cancer research.
Breast Cancer Research 2011, 13, 215.

(57)

Sheridan, C.; Kishimoto, H.; Fuchs, R. K.; Mehrotra, S.; Bhat-Nakshatri, P.;
Turner, C. H.; Goulet, R.; Badve, S.; Nakshatri, H. CD44+/CD24-breast cancer
cells exhibit enhanced invasive properties: an early step necessary for metastasis.
Breast Cancer Research 2006, 8, R59.

194

(58)

Lacroix, M.; Leclercq, G. Relevance of Breast Cancer Cell Lines as Models
for Breast Tumours: An Update. Breast Cancer Research and Treatment 2004, 83,
249-289.

(59)

Hirsch, L. R.; Stafford, R. J.; Bankson, J. A.; Sershen, S. R.; Rivera, B.; Price, R.
E.; Hazle, J. D.; Halas, N. J.; West, J. L. Nanoshell-mediated near-infrared
thermal therapy o f tumors under magnetic resonance guidance. Proceedings of the
National Academy of Sciences 2003, 100, 13549-13554.

(60)

Hirsch, L. R.; Gobin, A. M.; Lowery, A. R.; Tam, F.; Drezek, R. A.; Halas, N. J.;
West, J. L. Metal Nanoshells. Annals of Biomedical Engineering 2006, 34, 15-22.

(61)

Sciortino, F.; Casterou, G.; Eliat, P. A.; Troadec, M. B.; Gaillard, C.; Chevance,
S.; Kahn, M. L.; Gauffre, F. Simple Engineering of Polymer-Nanoparticle Hybrid
Nanocapsules. Chemnanomat 2016, 2, 796-799.

(62)

Ma, Y.; Huang, W.; Liu, C.; Li, Y.; Xia, Y.; Yang, X.; Sun, W.; Bai, H.; Li, Q.;
Peng, Z. Immunization against TGF-beta1 reduces collagen deposition but
increases sustained inflammation in a murine asthma model. Human vaccines &
immunotherapeutics 2016, 12, 1876-1885.

(63)

Hoskins, C.; Min, Y.; Gueorguieva, M.; McDougall, C.; Volovick, A.; Prentice,
P.; Wang, Z. G.; Melzer, A.; Cuschieri, A.; Wang, L. J. Hybrid gold-iron oxide
nanoparticles as a multifunctional platform for biomedical application. Journal of
Nanobiotechnology 2012, 10.

195

V. ISOLATION AND PURIFICATION OF GLYCOGLYCEROLIPIDS TO
INDUCE APOPTOSIS IN BREAST CANCER CELLS

ABSTRACT

Monogalactosyldiacylglycerol (MGDG) is the most abundant type of
glycoglycerolipid found in the plant cell membrane and mostly in the chloroplast
thylakoid membrane. The amphiphilic nature of MGDG is attractive in pharmaceutical
fields for interaction with other biological molecules and hence exerting therapeutic anti
cancer, anti-viral, and anti-inflammatory activities. In this study, we investigated the
therapeutic efficacy of cyanobacteria derived MGDG to inhibit breast cancer cell growth.
MGDG was extracted from a cyanobacteria S y n e c h o c y s tis sp. PCC 6803 followed by a
subsequent fractionation by column chromatographic technique. The purity and
molecular structure of MGDG were analyzed by nuclear magnetic resonance (NMR)
spectroscopy analysis. The presence o f MGDG in the extracted fraction was further
confirmed and quantified by high-performance liquid chromatography (HPLC). The anti
proliferation activity of the extracted MGDG molecule was tested against BT-474 and
MDA-MB-231 breast cancer cell lines. The in vitro study showed that MGDG extracted
from S y n e c h o c y s tis sp. PCC 6803 induced apoptosis in (70 ± 8) % of BT-474 (p<0.001)
and (58 ± 5) % o f MDA-MB-231 cells (p <0.001) using ~60 and 200 ng/ml of
concentrations, respectively. The half-maximal inhibitory concentration, IC50 of MGDG
extracted from S y n e c h o c y s tis sp. PCC 6803 were (27.2 ± 7.6) and (150 ± 70) ng/ml in
BT-474 and MDA-MB-231 cell lines, respectively. Quantification of caspase-3/7 activity
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showed 2.3 and 2.1-fold (p<0.01) higher protein expressions in the MGDG treated
BT-474 and MDA-MB-231 cells, respectively than untreated controls conferring to the
caspase-dependent apoptosis. The MGDG did not show any significant cytotoxic side
effects in human dermal fibroblasts cells. A commercially available MGDG control did
not induce any apoptotic cell death in cancer cells substantiating the potential of the
MGDG extracted from S y n e c h o c y s tis sp. PCC 6803 for the treatment of breast cancer
cells through the apoptosis-mediated pathway.

1. INTRODUCTION

Glycoglycerolipids (GGLs) are natural products abundantly found in the cell
membrane of marine algae,1,2 cyanobacteria,3,4 and higher plants,5-9 with one or two
carbohydrate units, glycerol, and diversified acyl lipid groups.9,10 GGLs are conserved in
both gram-negative and gram-positive bacteria, i.e., B a c illu s p u m ilu s ,11 L a c to b a c illu s
p la n ta r u m ,12M ic r o b a c te r iu m sp.,13 M ic r o c o c c u s lu te u s ,14 and P h o r m id iu m te n u e 15 with

highly conserved structures. The amphiphilic nature of GGLs is attractive in
pharmaceutical fields for interaction with other biological molecules and hence exerting
therapeutic anti-cancer,16-18 anti-viral,19,20 and anti-inflammatory activities.21,22 GGLs
potently inhibit angiogenesis,23 cancer cells,16 and solid tumor18,24,25 growth by
selectively inhibiting the replicative DNA polymerase activity both in v itro and in
vivo.17,18,25 Monogalactosyl diacylglycerol (MGDG), a GGL isolated from spinach,
combined with gemcitabine anti-cancer drug revealed synergistic effects of inhibitive
proliferation on human pancreatic cancer cell lines BxPC-3, MiaPaCa2, and PANC-1
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through the inhibition of DNA replicative pols alpha and gamma activities, compared
with MGDG or gemcitabine alone.26 The fractions of GGLs e.g., MGDG, digalactosyl
diacylglycerol (DGDG), and sulfoquinovosyl diacylglycerol (SQDG) in spinach potently
affect in v itro colon cancer cells, angiogenesis, and solid tumor growth v ia their
inhibitory activities of DNA polymerase.18,23-25 Naturally occurring
sulfoquinovosylglycerolipids show promising anti-proliferative activity toward human
cancer cells not only by targeting DNA polymerases,27 but also inhibiting the mitotic
centromere-associated kinesin (MCAK).17 Another interesting feature of these
compounds is their involvement in cell recognition and signaling which make them
promising agents in drug delivery systems.28 Several GGLs have been related to the
activation of natural killer T cells, which is a central event in a variety of immune
responses including the development of autoimmunity, tolerance, and maintenance in
defense responses to tumors and infectious agents.29 A series of sulfonic acid-containing
GGLs isolated from cultured cyanobacteria (blue-green algae) have been discovered as a
new class of compounds to inhibit the cytopathic effects of the human immunodeficiency
virus (HIV-1).20 The high potential of GGL therapy strategy has attracted great interest in
recent years and thus is explored to evaluate its therapeutic efficiency for the treatment of
breast cancer cells.
We investigated the anti-proliferative efficacy of marine cyanobacterium
S y n e c h o c y s tis sp. derived MGDG molecule on human epidermal growth factor receptor-2

(HER2)-positive BT-474, MDA-MB-231 triple-negative breast cancer cells, and human
dermal fibroblasts. MGDG molecule is more abundantly and predominantly present in
cyanobacterial cell chloroplast membrane than in plant sources. MGDG constitutes
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nearly 60% of the chloroplast lipid in S y n e c h o c y s tis sp. cyanobacterial cells.
S y n e c h o c y s tis sp. PCC 6803 was chosen because monogalactosyldiacylglycerol (MGDG)

from this strain contains 18:3 fatty acid residues making it a more lipophilic molecule
than other polar MGDG molecules with 16:0 carbon fatty acid residues.30 This
characteristic of glycoglycerolipids from S y n e c h o c y s tis sp. PCC 6803 would catalyze the
intracellular uptake and high biological activation to induce apoptosis in breast cancer
cells. Polyunsaturated fatty acids containing 18:3 y- linolenic acid (GLA) showed higher
apoptosis in various cancer cells (cervical, gastric, and prostate cancers) than normal cells
both in v itro and in v iv o by generating reactive oxygen species, suppressing angiogenesis
v ia Akt cell signaling pathway and inducing apoptosis.31-34 . The plant-derived MGDG

molecule abundantly contains 18:3 a- linolenic acid (n-3 ALA) on average at the sn-1
fatty acid chain. The plant extract MGDG or n-3 ALA, a member o f ro-3 fatty acids, and
its active metabolites have known anti-cancer activity. However, the treatment efficacy is
limited by the higher dosage requirement for inducing apoptosis and cell death posing
off-target toxicity to the healthier cells. In contrast, the marine cyanobacteria
S y n e c h o c y s tis sp. derived MGDG molecule predominantly contains 18:3 n-6 GLA at the

sn-1 fatty acid chain. The n-6 GLA molecule, a member of the ro-6 fatty acids selectively
inhibits breast tumor cells without affecting the healthy cells35,36. Moreover, the n-6 GLA
molecule has been shown to sensitize breast cancer cells to antimitotic and endocrine
therapeutic drugs in vitro . Hence, the cyanobacteria derived MGDG molecule is of great
interest in the current study. We separated MGDG with high purity from the total lipid
extract of S y n e c h o c y s tis sp. PCC 6803 cyanobacterial cells. In this study, we
comparatively investigated the anti-proliferative and apoptosis induction efficacy o f the
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cyanobacterial extract M G D G with high n-6 G L A content and plant extract n-3 A LA rich pure M G D G in BT-474 and M D A -M B -2 3 1 breast cancer cells.

2. MATERIALS AND METHODS

2.1. GROWTH KINETICS OF S y n e c h o c y s tis sp. PCC 6803
S

y n

e c h

o

c y s t i s

sp. PCC 6803 was a kind donation from Dr. Himadri Pakrasi’s

laboratory at Washington University in St. Louis.9,37"40 The

S

y n

e c h

o

c y s t i s

sp. was

cultured in batch cultures of 10 ml solid and 250 ml liquid B G 1 1 media at 30°C and 300
rpm in a rotary shaker under 30 pmol/m2/s (~2200 Lux) fluorescent lamps 41.
Fluorescence microscopic images of PCC 6803 and the corresponding spectra analysis
were captured using a scanning laser inverted confocal microscope (Ti-Eclipse; Nikon).
For the growth curve analysis, the species was inoculated in a 5 ml liquid B G 1 1 media.
150 pl aliquots of liquid samples were transferred to a 96 well plate (Corning) at different
times to measure the growth kinetics of PCC 6803 after adjusting the initial absorbance at
680 nm,

A

680,0= 0.05 at 24 h. B G 1 1 media alone without any inoculum was used as a

negative control. The maximum absorbance at the wavelength of 680 nm was measured
using a microplate reader (BioTek). The specific growth rate,

a

was computed using

Equation (3).
^ • ^

680

dt

Where
t = t,

= aN

A

6 8 Q

(1)
is the absorbance of cells at time, t. By integrating Equation (1) from t = 0 to
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. ^680t

,

.

I n - ------ = a ( t - t0)

(2)

^6800
In
a =

^6S0t
^6800

(3)

(t - t0)
The doubling time,

t d

is calculated using Equation (4):

0.693
td

(4)

a

2.2. TOTAL LIPID EXTRACTION FROM S y n e c h o c y s tis Sp. PCC 6803
The total lipid was extracted from the

S

y n

e c h

o

c y s t i s

sp. using the Bligh and Dyer

Method 42. Cell pellets from 250 ml of culture were collected at ^ 68o,t= 3.0 after 120 h,
centrifuged at 15,000 g for 15 min and suspended in deionized water for two times to
remove residual medium. One ml of cell suspension was mixed with 3.75 ml of
chloroform: methanol (1:2, v/v) solution for 15 min using a vortex mixer. After thorough
mixing, 1.25 ml of chloroform was added and vortexed for 1 min. Two distinctive layers
were obtained after adding 1.25 ml of water to the mixture. The chloroform layer (lower
phase) contained all the lipids, and the aqueous methanol layer (upper phase) contained
the non-lipid fractions. The upper phase was discarded carefully, and the lower phase was
collected. Chloroform was then evaporated completely under vacuum in a fume hood to
obtain the total lipid. Total lipid was reconstituted in 1 ml of chloroform and stored in 20oC.
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2.3. SEPARATION OF MGDG USING COLUMN CHROMATOGRAPHY
Total lipid was fractionated using the normal phase column chromatography
technique. A handmade column was used for the separation process (SI Figure 1 (a)).
Silica gel (particle size 10-40 micron) particles were used as a stationary phase.
Chloroform and acetone were used as mobile phases. A gradient elution method was
applied for the fractionation (SI Table 1). Samples (A-K) were collected for each
combination of the eluent and labeled for further detection, structural analysis, and
quantification (SI Figure 1 (b)).

2.4. IDENTIFICATION OF MGDG USING NMR ANALYSIS
The presence o f the MGDG molecule in the eluted fractions was investigated
using 1H NMR analysis. Each of the eluted fractions was analyzed to investigate the
presence of MGDG molecule. The plant extract standard MGDG molecule was used as a
reference. MGDG (> 99% purity, MW: 752.369) was purchased from Avanti Polar
Lipids Inc. Chloroform-d (CDCh) was chosen both as the reference and the solvent for
NMR analysis. The NMR peaks have been interpreted from the lipid handbook NMR
database 43 and the previous studies on structural analysis o f plant-derived GGLs 44,45.

2.5. QUANTITATIVE ANALYSIS OF MGDG USING HPLC-UV
The extracted MGDG molecule was both detected and quantified using a HPLCUV system. The following instruments and solvents were used for chromatographic
analysis. Column: LiChrospher 100 Diol (particle size: 5 |im, column size: 250 *4 mm)
(Millipore Sigma), guard column: LiChroCart 4-4, mobile phase: chloroform (solvent A),
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methanol-water (95:5) (solvent B), detector: UV, injection volume: 20-25 |iL, flow
rate: 1 ml/min. The MGDG molecule was detected by the UV detector at 240 nm. The
gradient elution method used in HPLC is shown in SI Table 2 and SI Table 3 46. A
calibration curve was developed correlating the peak areas against the increasing
concentrations of plant extract standard MGDG. The peak areas corresponding to the
known concentrations of standard MGDG are shown in SI Table 4.

2.6. IN

V IT R O

THERAPEUTIC EFFICACY

BT-474, MDA-MB-231, and human dermal fibroblast cells (ATCC) were
cultured in Hybri-care ATCC 46-X medium, RPMI 1640, and fibroblast growth factor
supplemented basal medium (ATCC), respectively, supplemented with 10% fetal bovine
serum (FBS) and 1% penicillin-streptomycin at 37oC and 5% CO2 . Approximately,
10,000 cells per well were plated in 96-well plates and treated with 0-200 ng/ml doses of
standard MGDG and extracted MGDG from S y n e c h o c y s tis sp. by column
chromatography technique. To examine the cytotoxicity effects on human dermal
fibroblasts, the cells were treated with 100 ng/ml of MGDG extracted from S y n e c h o c y s tis
sp. and MGDG standard. After 72 h of incubation, cell viability was assessed using MTT
(3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide, MW 414) assay. MTT
reagent was added to each well to convert into an insoluble formazan from water-soluble
MTT. After 4 h, sodium dodecyl sulfate (SDS) solution prepared in 0.01 N HCl was
added to each well to solubilize the formazan. The percentage of live cells proportional to
the absorbance value of solubilized formazan solution was quantified by measuring the
absorbance at 570 nm (BioTek Synergy 2). The absorbance value was adjusted by
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subtracting the mean absorbance level of wells containing medium only. Cell viability
was calculated as a means of six wells containing BT-474, MDA-MB-231, and dermal
fibroblast cells. The cells treated with PBS were used as live control that was placed in
every alternative column in the well plate adjacent to corresponding dosage or treatments
to remove the variability in the number of seeded cells in adjacent wells. The live
controls were replicated at least six times for each dosage. For dead control, we treated
the cells with saponin in at least six replicates. The % cell viability was calculated as
follows Equation (5):
,,
. . . . .
-^ 5 7 0 o f sample
-^ 5 7 0 o f medium
......
% c e l l v i a b i l i t y = --------- ------- --------- --------------------- x 100
•™5 7 0 o f live cells
^ 5 7 0 o f medium

(5)

2.7. APOPTOSIS ASSAY
The BT-474 and MDA-MB-231 cells were investigated for the caspase-dependent
apoptosis mechanism by staining for the cleaved or active form of caspase-3/7 marker
fluorescence dye. The cells at a density of 10,000 cells/ml were seeded in 96 well plates
in replicates of at least n=3. The cells were treated with MGDG extracted from
S y n e c h o c y s tis sp. PCC 6803 and MGDG standard and were incubated for 48 and 72 h.

The cells treated with PBS were used as live control with at least three replicates. After
incubation, cells were stained with green fluorescent active caspase-3/7 marker
(Invitrogen). The cells were imaged in the phase contrast field along with green
fluorescent signals using a Zeiss Apotome 2.0 microscope equipped with a 10X
objective, 470/40 excitation filter, and 525/50 nm emission filter. To quantify the
caspase-3/7 protein expression, 50,000 each of BT-474 and MDA-MB-231 cells were
treated with 100 ng/ml of MGDG. After 48 and 72 h of incubation, cells were washed
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twice using 100 pl of PBS and stained with 5 pM of caspase-3/7 green fluorescence
apoptosis marker in 100 pl of the respective medium. The cells were incubated for 30-45
minutes at 37oC. The fluorescence data was detected for 20,000 events/sample and
acquired using a flow cytometer (BD Accuri C6 plus). The bandpass filters used in the
flow cytometry were 530/30 and 585/40, respectively. The laser excitation wavelength
was 488 nm.

2.8. STATISTICAL ANALYSIS
Each experiment was carried out in independent repetitions to have at least
triplicates valid measurements. The results were reported as mean ± standard deviation
and analyzed using the Student’s t-tests with two-tailed hypotheses and using the JMP
statistical software (version 15, SAS Institute). For toxicity analysis, P<0.001 was
considered as statistically significant and was denoted by ***. For quantification of
apoptosis assay in flow cytometry, p<0.01 was considered statistically significant and
was denoted by ***.

3. RESULTS

3.1.

S y n e c h o c y s tis sp. GROWTH CURVE KINETICS AND MOLECULAR
STRUCTURE OF MGDG

Figure 1 demonstrates the confocal fluorescence images and fluorescence
emission spectra analysis of S y n e c h o c y s tis sp. PCC 6803, indicating that the
microorganism grew properly with the highest absorbance spectrum at 680 nm 47,48.
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Figure 1. (a) Time-lapse video microscopic images of S y n e c h o c y s tis sp. PCC 6803, and
(b) its fluorescence emission spectra analysis. Red color indicates the abundance of
photosynthetic pigments

The growth kinetics of S y n e c h o c y s tis sp. PCC 6803 was studied to obtain the
maximum total lipid yield. The growth curve shows that the lag phase extended for
almost 30 h (Figure 2a). It took the species for six days to reach the stationary phase. The
specific growth rate, a was calculated as 0.04 h"1. The doubling time ( t d) was calculated
as 18.3 h. We extracted the MGDG molecule from the cells at the beginning of the
stationary phase for maximum yield. Structurally, the MGDG molecule is constructed on
a glycerol backbone (Figure 2b). The galactose residue is bound to the sn-3 position of
the glycerol backbone v ia a P-anomeric linkage. This head group remains conserved
across the average molecular structures found in plant and cyanobacterial sources. The
molecule has two long fatty acid chains in the sn-1 and sn-2 position of the backbone.
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The long fatty acid chains show variability in length, double bond position, and
degree of unsaturation across and within the sources

7 ,9

Typically, 18:1 or 18:3 /16:3 or

16:0 (sn-1/sn-2) average fatty acid composition is common in plant extract MGDG 45,49.
In contrast, the fatty acid composition can vary from long-chain composition of 18/16
(sn-1/sn-2) to a very long chain composition of 34 configurations in S y n e c h o c y s tis sp.
extract MGDG 7,5°. Mostly, the S y n e c h o c y s tis sp. PCC 6803 contains the 18:3 GLA
polyunsaturated fatty acid chain at the sn-1 position and 16:0 palmitic acid saturated fatty
acid chain at the sn-2 position 7,S1,52.

Figure 2. The growth kinetics of S y n e c h o c y s tis sp. and structure of MGDG. (a) Growth
curve o f S y n e c h o c y s tis sp. PCC 6803 wild type strain. The growth was measured in
terms of absorbance value obtained at 680 nm. (b) Structure of MGDG extracted from
S y n e c h o c y s tis sp. PCC 6803 containing n-6 18:3 y-linolenic acid (n-6 GLA) and 16:0
palmitic acid at sn-1 and sn-2 fatty acid chains, respectively (upper panel); the most
abundant structure of plant extracted MGDG standard containing n-3 18:3 a-linolenic
acid (n-3 ALA) and 16:3 palmitolinolenic acid at sn-1 and sn-2 fatty acid chains,
respectively (lower panel)
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3.2. NMR ANALYSIS CONFIRMS THE SEPARATION OF MGDG FROM
TOTAL LIPID EXTRACT
MGDG molecule was separated from the total lipid extract of S y n e c h o c y s tis sp.
PCC 6803 using column chromatography. The fractions with each eluent were collected
separately and analyzed individually by NMR analysis. The MGDG molecule was
separated with an eluent combination of 40% chloroform and 60% acetone. The fractions
(H, I, J) were collected with the same eluent combination. The NMR analysis confirms
the presence of MGDG molecule in fraction I (Figure 3).

Figure 3. Confirmation o f the presence of MGDG extracted from S y n e c h o c y s tis sp. PCC
6803 in fraction I. *H NMR analysis of S y n e c h o c y s tis sp. extracted fractions H, I, and J
with 40% chloroform and 60% acetone eluent combination. The NMR spectra of the
MGDG standard are shown in the lowest panel. The NMR analysis confirms the presence
of MGDG molecule in fraction I
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The set of NMR peaks of fraction I were completely identical to the standard
MGDG molecule suggesting the separation of MGDG molecule with high purity. The
structure of MGDG in fraction I was analyzed from the peaks obtained in the NMR
analysis (Figure 4).

Figure 4. Structural identification of MGDG extracted from S y n e c h o c y s tis sp. PCC 6803.
1H NMR analysis of MGDG extracted from the S y n e c h o c y s tis sp. shows that the fraction
molecule (upper panel) contains all the major structural H components 5 2.8 (diallylic
methylene), 5 3.6 and 3.8 (Glycosidic H moiety), 5 4.18 (sn-1 H), 5 5.15 (sn-2 H), 5 5.25
cis A9 moieties present in the standard MGDG molecule (lower panel). The
cyanobacterial NMR spectra are identical to the NMR spectra of the MGDG standard
confirming the purity of the extracted MGDG molecule
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The chemical shift values at 5 4.18, 5.15 represent the sn-1 and sn-2 H atom,
respectively. The peaks at 5 4.29, 4.55, 4.70, and 4.85 confirm four H atoms of the OH
group in the carbohydrate sugar present in MGDG. Glycosidic bond in MGDG is
represented by the chemical shift 5 3.6 and 3.8. A very broad and sharp peak at chemical
shift 5 5.25 might represent the unsaturated cis A9 fatty acid attached to the sn-1 or sn-2
position 43. The presence of the unsaturated fatty acids can be confirmed by the diallylic
methylene functional group at chemical shift 5 2.8. The results are consistent with the
NMR data of MGDG reported earlier by Marcolongo et. al. and Maeda et. al. 44,45.

3.3. DETECTION AND QUANTIFICATION OF MGDG USING HPLC-UV
SYSTEM
The S y n e c h o c y s tis sp. extracted MGDG molecule was detected and quantified
using the HPLC coupled with a UV detector. The correlation of area under the peak with
known concentrations of standard MGDG was observed in HPLC analysis (Figure 5).
The R2 value of the fitted curve was 0.99. After the separation of MGDG from total lipid
extract in chromatographic fraction I, the fraction was run through the HPLC column for
quantification. The peak obtained at 6.24 min confirmed the presence of the MGDG
molecule (Figure 6). The amount of detected MGDG in fraction I was quantified using
the concentration correlation plot obtained in Figure 5.
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Figure 5. Calibration curve for quantification of MGDG extracted from S y n e c h o c y s tis sp.
PCC 6803. A standard calibration curve was prepared using known concentrations of
plant extract MGDG molecule and the corresponding peak areas in terms o f milliabsorbance unit x seconds (mAu.s) in HPLC-UV analysis. The equation obtained for the
unknown concentration of the MGDG molecule for any known peak area is y= 0.061x
with the R2 value of 0.99

Figure 6. HPLC-UV analysis of MGDG extracted from S y n e c h o c y s tis sp. PCC 6803.
(upper panel) and MGDG standard (lower panel). The MGDG peak was obtained at ~6
minutes for the MGDG molecule from both of the sources. The peaks obtained at ~2 and
~7-8 minutes represent the pigments and glucosides peaks eluted with the methanol/
water solvents
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3.4. IN

V IT R O

ANTI-PROLIFERATION EFFICACY

To determine the anti-proliferation efficacy in vitro, the dose-response
cytotoxicity of MGDG extracted S y n e c h o c y s tis sp. and MGDG standard was evaluated.
The anti-proliferation activity o f extracted MGDG was compared against the MGDG
standard in HER2-positive BT-474 (Figure 7a) and MDA-MB-231 triple-negative breast
cancer cells (Figure 7b). In BT-474 cells, MGDG extracted from S y n e c h o c y s tis sp.
inhibited up to 70% cell proliferation over the concentration range of 0-200 ng/ml
(•, Figure 7a). The maximum inhibition in BT-474 cells was (70 ± 8) % at 60 ng/ml (p <
0.001). At higher concentrations (>60 ng/ml), a decrease in % cell death was observed in
BT-474 cells indicating cell-dependent drug resistance to MGDG extracted from
S y n e c h o c y s tis sp.53,54 In MDA-MB-231 cell line, for the concentration range of 0-200

ng/ml, MGDG extracted from S y n e c h o c y s tis sp. showed significant cell growth inhibition
from 0-60% in a dose-dependent manner (•, Figure 7b). The extracted MGDG inhibited
(58 ± 5) % of MDA-MB-231 breast cancer cells at the concentration of 200 ng/ml (p <
0.001). The half-maximal inhibitory concentration, IC50 values of MGDG extracted from
S y n e c h o c y s tis sp. are (27.2 ± 7.6) and (150 ± 70) ng/ml in BT-474 and MDA-MB-231

cells, respectively. In contrast, in both BT-474 and MDA-MB-231 cell lines, standard
MGDG did not show any statistically significant anti-proliferation activity (<10% cell
death) compared to untreated positive control within the concentration range of 0-200
ng/ml (o, Figures 7a and 7b).
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(a)

Figure 7. In v itro anti-cell proliferation analysis. MGDG extracted from
Synechocystis sp. PCC 6803 (solid line) and MGDG standard (dotted line) in (a) BT-474
and (b) MDA-MB-231 cell lines. Mean percentage values are presented from six
replicates (n=6) for each drug dosage. The MGDG from the Synechocystis sp. inhibits up
to 70% (p<0.001) and 60% (P<0.001) of BT-474 and MDA-MB-231 cancer cells,
respectively where MGDG standard does not show any toxicity within the concentration
range of 0-200 ng/ml. *** indicates the p-value < 0.001 showing a statistical significant
difference between % cell death in MGDG extracted from the Synechocystis sp. and
MGDG standard. (c) MGDG extracted from the Synechocystis sp. does not show any
cytotoxic side effects in human dermal fibroblasts normal cell line control
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Figure 7. I n v itro anti-cell proliferation analysis. MGDG extracted from S y n e c h o c y s tis sp.
PCC 6803(solid line) and MGDG standard (dotted line) in (a) BT-474 and (b) MDA-MB231 cell lines. Mean percentage values are presented from six replicates (n=6) for each
drug dosage. The MGDG from the S y n e c h o c y s tis sp. inhibits up to 70% (p<0.001) and
60% (P<0.001) of BT-474 and MDA-MB-231 cancer cells, respectively where MGDG
standard does not show any toxicity within the concentration range of 0-200 ng/ml. ***
indicates the p-value < 0.001 showing a statistical significant difference between % cell
death in MGDG extracted from the S y n e c h o c y s tis sp. and MGDG standard. (c) MGDG
extracted from the S y n e c h o c y s tis sp. does not show any cytotoxic side effects in human
dermal fibroblasts normal cell line control (cont.)
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Although MGDG from S y n e c h o c y s tis sp. induced the % cell death of breast
cancer cells in a concentration-dependent manner, the cytotoxicity of fibroblast cells
(normal cell control) was less (<15%) than breast cancer cells after exposure to 100 ng/ml
of MGDG for 72 h (Figure 7c), indicating that breast cancer cells were more sensitive to
the MGDG derived from S y n e c h o c y s tis sp. than normal cells. Taken together, the results
revealed that MGDG extracted from S y n e c h o c y s tis sp. induced selective apoptotic cell
death in BT-474 and MDA-MB-231 breast cancer cells with different potency after 72 h
of incubation, while causing less toxicity in normal fibroblasts.

3.5.

S y n e c h o c y s tis

sp. EXTRACTED MGDG INDUCES CASPASE-DEPENDENT

APOPTOSIS
To investigate the late phase apoptosis, BT-474 and MDA-MB-231 cells were
treated with 100 ng/ml of MGDG extracted from S y n e c h o c y s tis sp. and MGDG standard
and stained with green fluorescently labeled caspase-3/7, a well-known apoptotic marker.
The assay utilizes a nucleic acid binding dye conjugated with a four amino acid peptide,
DEVD (Asp-Glu-Val-Asp motifs) that is recognized by caspase-3/7 and cleaved,
enabling the dye to bind with DNA and fluoresce at ~530 nm 55-57 The conjugated dye is
non-fluorescent until the DEVD peptide is cleaved by active caspase-3/7. After 48 h and
72 h of treatment, cells treated with MGDG extracted from S y n e c h o c y s tis sp. showed
green fluorescently stained DNA indicating the activation of caspase-3/7 in BT-474
(Figure 8a) and MDA-MB-231 cells (Figure 8b). The combined phase and fluorescent
signal images show the overlap of caspase-3/7 positive cells and the unhealthy shrinking
cells suggesting the initiation of apoptosis. The induction of apoptosis was assessed by
Western blot technique (SI Figure 3). The Western blot analysis showed that the full-
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length caspase-3 (MW: 32 KDa) expression was reduced in BT-474 and MDA-MB231 cells treated with MGDG from S y n e c h o c y s tis sp., while the protein expression did
not change in cells treated with MGDG standard relative to untreated cell controls. The
reduced expression of full-length caspase-3 suggests the cleavage of the protein into an
active form of low molecular weight (17 kDa) active cleaved caspase-3. The cleaved
caspase-3/7 expression was quantified using flow cytometry. The fold enhancement of
caspase-3/7 was quantified using flow cytometry analysis (Figures 8c and 8d). We
observed a statistically significant increase of 1.7±0.04 fold (p<0.01) in caspase-3/7
concentrations after 48 h and a statistically significant 2.34±0.44 fold (p<0.01) increase
after 72 h in BT-474 cells treated with MGDG extracted from S y n e c h o c y s tis sp.
compared to untreated cell controls (filled column, Figure 8c). After 72 h, the number of
apoptotic cells in the extracted MGDG treated cells significantly increased 2.1±0.03 fold
(p<0.01) in MDA-MB-231 cells (filled column, Figure 8d). MGDG standard did not
show any significant changes in cleaved caspase-3/7 expressions compared to untreated
control cells. The obtained scatter plots and histogram data from flow cytometry are
shown for each treatment in SI Figure 5. These results are in good agreement with
fluorescent microscopic images indicating the cells being shrunk and round shaped with a
complete halt in growth of cancer cells. In contrast, after 48 and 72 h of treatment, there
was no sign of apoptosis in the standard MGDG treated compared to untreated cell
controls (open column, Figures 8c, and 8d). The untreated cells and the cells treated with
standard MGDG were compact multilayered colonized and elongated in shape in the case
of BT-474 and MDA-MB-231 cell lines, respectively, and were observed healthy
suggesting continuous growth capability.
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Figure 8. In v itro apoptosis induction. MGDG extracted from the Synechocystis sp. and
MGDG standard after 48 and 72 h treatments in (a) BT-474, and (b) MDA-MB-231 cells.
The green fluorescence of apoptotic caspase-3/7 proteins increases in both BT-474 and
MDA-MB-231 cells treated with MGDG extracted from the Synechocystis sp. The
combined phase contrast and the fluorescence images show that the cyanobacterial
extracted MGDG enhances the intensity and density of green fluorescence cells
indicative of caspase-dependent apoptosis in both cell lines. In contrast, cells treated with
MGDG standard molecule did not show any sign of apoptosis in either cell line even after
72 h of treatment. The scale bars represent 100 p,m. Quantification of the active caspase3/7 expression in (c) BT-474, and (d) MDA-MB-231 cells treated with MGDG extracted
from the Synechocystis sp. and MGDG standard after 48 h and 72 h of treatments. In
BT-474 cells, the active caspase-3/7 expression was increased by 1.7 (p<0.01) and 2.3
(p<0.01) fold after 48 h and 72 h treatments, respectively compared to untreated control.
The increase in caspase-3/7 expression was 2.1 (p<0.01) fold after 72 h treatment in
MDA-MB-231 cells compared to the untreated control. Mean ± standard deviation from
two independent experiments in at least three replicates (n=6) are presented. ***
indicates the p-value < 0.01, showing a statistically significant difference compared to
untreated control cells

4. DISCUSSION

MGDG contains fatty acyl groups derived from two fatty acid molecules at sn-1
and sn-2 position and a polar head at sn-3 position in a 3-carbon glycerol scaffold (Figure
2b). Fatty acid molecules such as n-6 GLA may exert anti-proliferative effect by
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regulating genes and proteins involved in cell cycle and apoptosis, altering the
cellular composition of fatty acids, and by producing downstream anti-proliferative
metabolites such as 1-series prostaglandins and free radical molecules from
cyclooxygenase (COX) catalyzed lipid peroxidation. The potent anti-proliferative activity
of the MGDG is mostly attributed to the fatty acyl components of the MGDG molecular
structure.58,59 The structure of the MGDG molecule and the fatty acid content of MGDG
derived from S y n e c h o c y s tis sp. PCC 6803 is well studied. The molecule is rich in 18:3 n6 GLA fatty acids. The fast atom bombardment tandem mass spectrometry (FAB-MS)
analysis of glycolipids derived from S y n e c h o c y s tis sp. PCC 6803 showed 18:3 n-6 GLA,
18:2, and 18:1 combination of fatty acid chains with a relative abundance of 100, 47 and
41, respectively at the sn-1 position7. Yuzawa et. al. showed the relative abundance of n6 GLA, 18:2, and 18:1 fatty acid content in wild type S y n e c h o c y s tis sp. derived MGDG
as 30%, 10%, and 5% respectively52. However, the larger fatty acid chains at the sn-1
position have also been reported recently. The time of flight mass spectrometry (TOFMS) analysis of the same cyanobacterial strain showed the predominance o f 34:2 or
34:3 fatty acid chain at the sn-1 position 50. Wada et. al. showed that the most abundant
n-6 GLA moiety in S y n e c h o c y s tis sp. derived MGDG is subject to desaturation when the
growth temperature was shifted from 38oC to 22oC 51. In contrast to the variable sn-1
fatty acid content, the sn-2 position was shown to be conserved mostly with 16: 0
(palmitic acid) fatty acid chain in S y n e c h o c y s tis sp. derived MGDG and was not affected
with the shifts in temperature 7,51>52.
The MGDG lipid molecule was separated in a normal phase column using
chloroform and acetone gradient eluent combinations. The column length to diameter
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ratio was ~10. Multiple samples were collected with each eluent combination for
better purification. We confirmed the presence o f MGDG molecule in fraction I using !H
NMR analysis (Figure 3). Though fraction H, I, and J were eluted with the same mobile
phase combination of 40% chloroform and 60% acetone, only fraction I contained the
MGDG molecule. The peaks obtained for a fraction I identical with >99% pure standard
MGDG molecule suggests the high purity of MGDG molecule in that fraction. The
diallylic methylene moiety obtained at 5 2.8 in the NMR analysis shown in Figure 4
confirmed the polyunsaturation in the long fatty acid chain at the sn-1 position. The
extracted MGDG molecule in fraction I was quantified using the HPLC-UV system. We
prepared a calibration curve (Figure 5) with known >99% pure standard MGDG molecule
to quantify the MGDG in each extracted fraction. The peak obtained at retention time
6.24 min shown in Figure 6, upper panel corresponds to the MGDG molecule in the
fraction 46. The large peak obtained at retention time 2.36 min is the lipid pigments eluted
initially by the chloroform. The peak at 7.23 min might be due to the presence of steryl
glucosides present as a contaminant in the fraction46. Glucosides do not have any known
effects on the HER2-positive and triple-negative breast cancer cells. The peaks for
pigments and glucosides were also observed in the standard >99% pure standard MGDG
chromatogram (Figure 6, lower panel). So, the contaminant should not have any effect in
this study during the drug formulation used for cytotoxicity analysis. However, the GGL
molecules are detected with high quality and precision using the evaporative light
scattering detectors (ELSD) providing with sharp and clear peaks in the
chrom atogram 46,60,61
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We investigated the in v itro anti-proliferation efficacy of cyanobacteria
derived MGDG molecule in comparison with MGDG molecule from plant source on the
HER2-positive and triple-negative breast cancer cell lines. We observed significant
differences in the % of cancer cell death using MGDG extracted from S y n e c h o c y s tis sp.
v e r su s a commercially available MGDG standard. MGDG extracted from
S y n e c h o c y s tis sp. induced apoptosis in (70 ± 8) % of BT-474 and (58 ± 5) % of MDA-

MB-231 cells at 60 and 200 ng/ml, respectively, while <15% cell death was observed in
fibroblasts at 100 ng/ml. While the precise mechanism by which each molecule works
about their cell-killing effect is unknown, it is possible that the presence of
polyunsaturated y-linolenic acid in the sn-1 position and palmitic acid in the sn-2 position
of MGDG from S y n e c h o c y s tis sp. resulted in the mitochondrial depolarization,
cytochrome c release, DNA fragmentation and generation of free radicals causing
specific cell death response in breast cancer cells compared to normal cells.62-66 ylinolenic acid has been shown to exhibit anti-proliferative activities specifically in a
variety of cancer cell lines both in vitro and in vivo. y-linolenic acid inhibited the cell
growth of four human neuroblastoma cell lines (GOTO, SK-N-DZ, NKP, and NCG) in
v itr o ,67 three human glioma cell lines (MOG, U87, U373) and a rodent glioma cell line

(C6) in v itro and a rat C6 glioma model in v i v o 68 Glioma regression and apoptosis had
been reported using both C18 and C20 fatty acids of the n-6 and n-3 series y-linolenic
acid along with the preservation of normal neural tissue and vasculature in adjacent
brain.68 y-linolenic acid at a concentration of 150

inhibited Walker 256 cancer cell

growth both in v itro and in v iv o causing decrease in mitochondrial membrane potential,
and increase in cytochrome c release, caspase activation, and DNA fragmentation.63 The
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mitochondrial apoptosis pathway was likely induced by an increase in reactive
oxygen species (ROS), lipid peroxide production, ATP generation and the deposition of
large amounts of triacylglycerol in the form of lipid droplets.63,65 A diet containing 5.5%
y-linolenic acid caused 45% decrease in Walker 256 tumor growth in v iv o by reducing
mitochondrial metabolic activity.62 More interestingly, in v itr o , in vivo and clinical study
data showed that y-linolenic acid has selective anti-proliferative actions in cancer cells
with little or no side effects on normal cell growth. Polyunsaturated fatty acids including
y-linolenic acid incubated with human breast, lung, and prostate cancer cells suppressed
the cancer cell growth exhibiting no adverse effects on normal human fibroblasts or
normal animal cell lines.69 Intraarterial injection of a lithium salt derivative of y-linolenic
acid demonstrated its ability to selectively suppress angiogenesis.64 These reports,
together with our data increases lead to the conclusion that MGDG from
S y n e c h o c y s tis sp. is a promising cancer therapeutic agent with high selectivity of cancer

cell growth inhibition leading to apoptosis and a decrease in cancer development. Also,
saturated fatty acid, palmitic acid at the sn-2 position of MGDG from S y n e c h o c y s tis sp.
plays a significant role in the elevation of calcium flux, endoplasmic reticulum stress,
caspase-3, and caspase-9 activity, and thus inducing apoptosis which is in good
agreement with previous reports.70-72 Treatment of mouse 3T3-L1 and rat primary
preadipocytes with palmitic acid induced multiple cell signaling pathways, endoplasmic
reticulum stress responses, and cell cycle arrest leading to apoptosis.70 Palmitic acid
induced oxidative stress and DNA damage in rodent-derived insulin-secreting cell line
RINm5F and primary human fibroblasts.72 Spinach MGDG molecule in combination
with gemcitabine in v itro 59and radiation in v iv o 73 showed enhanced suppression of
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MIAPaCa-2, PANC-1, and BxPC-3 pancreatic cancer cell lines compared to MGDG
treatment alone. With the in v itro spinach MGDG treatment alone the IC50 values for the
mentioned pancreatic cell lines ranged from 18-25 ^M 73,74 MGDG molecule extracted
from the spinach has been shown to inhibit human replicative and repair DNA
polymerase enzymes with the IC50 values ranging from 10-200 ^M.59 These results
illustrate the specificity of the MGDG extracted from S y n e c h o c y s tis sp. PCC 6803 to
breast cancer cells by caspase-dependent apoptotic pathway.

5. CONCLUSION

Fatty acids are of great interest as natural anti-proliferative factors because of
their selective inhibition of cancer cells. The structure and efficacy of fatty acid
molecules are variable within and across the sources. We investigated the cancer cell
inhibition efficacy of plant and cyanobacterial derived MGDG molecule. The marine
cyanobacteria Synechocystis sp. derived MGDG molecule predominantly rich in n-6
GLA was separated from the total lipid extract in this study. The molecule was separated
in a handmade low-cost normal phase silica column with the gradient elution method
using chloroform and acetone as the mobile phase. We confirmed the presence of MGDG
molecule in the fraction eluted with 40% chloroform and 60% acetone eluent
combination. The NMR analysis confirmed the high purity of the separated MGDG
molecule from the cyanobacterial total lipid extract. The separated MGDG molecule was
quantified by the HPLC-UV system. The anti-proliferative activity of the cyanobacterial
MGDG was tested against the MDA-MB-231 breast cancer cell line. The in vitro
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cytotoxicity study showed that MGDG extracted from Synechocystis sp. PCC 6803
potently inhibited (70 ± 8)% and (58 ± 5)% of BT-474 and MDA-MB-231 cells,
respectively using 60 and 200 ng/ml of the MGDG. The IC50s of MGDG extracted from
Synechocystis sp. are (27.2 ± 7.6) and (150 ± 70) ng/ml in BT-474 and MDA-MB-231
cells, respectively. In contrast, plant extract n-3 ALA-rich MGDG did not have any
cytotoxic effect in the concentration range of 0-200 ng/ml. It did not show any cytotoxic
effects in human dermal fibroblasts normal cell controls. Our results support these
findings showing that the cyanobacteria derived MGDG induces caspase-dependent
apoptosis pathway to inhibit the HER2-positive BT-474 and triple-negative MDA-MB231 breast cancer cell growth. Further studies involving additional mechansisms of
actions, intracellular uptake, and robust screening of additional cancer cell lines will
confirm the potential novel therapeutic efficacy o f cyanobacteria derived MGDG
molecule for a low dosage selective treatment of cancer cells.
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SECTION

2. CONCLUSION

The synthesis and therapeutic efficacy of PTXNR-TTZ ADNs in v itro were
presented which arrested the HER2-positive breast cancer cells in G2/M phase of the cell
cycle and induced caspase mediated apoptosis. The synthesized ~95 nm in diameter and
500 nm in length PTXNR particles showed significantly high stability in aqueous phase
compared to the PTX, suggesting removal of the compromising need for organic carrier
solvent for intravenous delivery. The in v itro toxicity analysis showed that the engineered
drug PTXNR-TTZ was more efficacious than the individual drug treatments with PTX or
TTZ alone, inhibiting >80% of HER2-positive cell line growth suggesting a synergistic
effect on the cancer cells. The I C 50 of PTXNR-TTZ on HER2-positive BT-474 breast
cancer cell line was 106 nM, facilitating lower dose and reduced side effects than the
individual treatment with PTX and TTZ alone. The Western blot analysis showed that
PTXNR-TTZ significantly downregulated the anti-apoptotic protein XIAP and induced
caspase dependent apoptosis pathway in HER2-positive breast cancer cell line.
Altogether, the investigation might facilitate rational remodeling of conventional
combination therapy in cancer through ADN that integrates high therapeutic index and
active targeting capability.
The present work showed that PTXNR-TTZ induced apoptosis in HER2-positive
breast cancer cell lines following the G2/M cell cycle arrest. The cell cycle is critical for
normal tissue functioning and also an important regulator of ungoverned cancer cell
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progression. Hence, a comprehensive knowledge of cell cycle regulation and its
regulators is a prior need for better understanding of cancer. The review article presented
in the dissertation has discussed some of the critical intracellular cell cycle regulating
signaling pathways such as MAPK/Ras/Raf/ERK, PI3K/Akt. Jak-STAT. The intrinsic
and extrinsic apoptosis pathways were also discussed. The article showed the molecular
interplay between the cell proliferation and cell death pathways.
Transcriptional regulation and genetic alterations induced by PTXNR-TTZ was
investigated in breast cancer cell lines. The objective of the study was to investigate the
potential role of cell cycle arresting mechanism on the therapeutic efficacy of the
PTXNR-TTZ treatment in breast cancer cells. PTXNR-TTZ significantly overexpressed
PRKG1 and NR4A3 genes in HER2-positive cell line. The gene regulatory network
showed that PTXNR-TTZ might potentially induce intrinsic apoptosis pathway through
positive regulation of PRKG1- NR4A3 gene expression. PTXNR-TTZ treatment
upregulated the CDC20 gene expression which plays an oncogenic role in cancer
progression. The study concluded that hyperactivity of CDC20 and subsequent activation
of its substrates e.g., APC/C might cause therapeutic inefficacy of PTXNR-TTZ
treatment in HER2-positive breast cancer cells. Hence, we proposed CDC20 as a
potential therapeutic target to enhance the treatment response of PTXNR-TTZ. PTXNRTTZ also significantly upregulated a set of tumor promoting inflammatory genes in a
non-specific triple negative MDA-MB-231 cell line. Taken together, the study
investigated cell cycle dependent gene regulatory pathways induced by PTXNR-TTZ that
can be addressed for possible therapeutic response or treatment resistance in breast cancer
cells.
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Additionally, in this work, multifunctional efficacy of a polymer coated
superparamagnetic nanoparticle therapeutic system was investigated in cancer treatment.
The work showed the significant enhancement of the metal nanoparticle stability by using
a biocompatible polymer coating and utilization as a potential nanomedicine platform.
The application of the therapeutic platform integrated both diagnostics and therapeutics
capability in a single system.
Finally, in v itro anti-proliferation efficacy of a natural glycoglycerolipid molecule
MGDG, was investigated for breast cancer treatment. The MGDG molecule rich in ro-6
y-linolenic fatty acid content was extracted from a cyanobacterial species S y n e c h o c y s tis
sp. A simple low cost technique was shown in the study to efficiently extract the MGDG
molecule with high purity. The molecule had better therapeutic efficacy than the
commercial plant extract molecule and did not show any significant toxicity in normal
human cell line. Altogether, the study presented a cost effective extraction method and
anti-proliferation efficacy of a natural source potential anti-cancer molecule.
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3. FUTURE WORKS

3.1. INVESTIGATION OF THERAPEUTIC EFFICACY OF PTXNR-TTZ IN IN
V IV O SETTINGS

We have shown the formulation of a combination therapeutic system PTXNR-TTZ
for targeted HER2-positive breast cancer cell growth inhibition. We thoroughly
investigated the therapeutic efficacy of PTXNR-TTZ in

in v itro

settings. The

in vitro

results showed synergistic cell growth inhibition in HER2-positive breast cancer cell line
by PTXNR-TTZ treatment. In future, we propose to investigate the therapeutic efficacy of
PTXNR-TTZ in an in vivo HER2-positive breast cancer model.
•

In v iv o tumor cell growth inhibition: A cell derived xenografts (CDX) model

with the HER2-positive breast cancer phenotype will be chosen for the in vivo study. For
example, an established BT-474 cancer cell line transplanted (subcutaneously) nude mice
model representing the luminal B/HER2-positive subtype of breast cancer is available and
can be used for investigating the

in v iv o

tumor growth inhibition upon intraperitoneal

injection (i.p.) of PTXNR-TTZ drug. The controls for the investigation will include 1) no
treatment, 2) PTXNR treatment, 3) TTZ treatment and 4) combination treatment of
PTXNR+TTZ. The tumor growth can be monitored in every 3 days and normalized to the
initial tumor volume at the starting point of the treatment.
•

In vivo biodistribution study: The PTXNR-TTZ particles will be functionalized

with a metal binding chelator molecule p-SCN-Bn-DOTA (SBnD) by utilizing the solvent
accessible the e-lysine amino group of TTZ. The immunoconjugate (TTZ-SBnD) will then
be radiolabeled with 64Cu isotope to produce a radioactive PTXNR-TTZ-SBnD-64Cu
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complex. For biodistribution analysis, the PTXNR-TTZ-SBnD-64Cu complex will be
intravenously administered in a subcutaneously engrafted BT-474 tumor bearing mice
model. The mice will be sacrificed at 2, 6, 12, 24, 48 and 72 h following administration of
the radioactive complex. The organs will be separated and weighed followed by the
measurement of the radioactivity. The time dependent measurements for each organ will
be expressed as a percentage of injected dose per gram (%ID/gram).

3.2. INVESTIGATION OF GENE REGULATION ACTIVITY OF PTXNR-TTZ IN
IN V IT R O AND I N V IV O PLATFORM
We found that PTXNR-TTZ significantly induced the high mRNA expression of
NR4A3 and PRKG1 genes in HER2-positive breast cancer cells by analyzing the
transcriptional data obtained from RNAseq analysis. In subsequent gene regulatory
network analysis, we showed that the overregulation of NR4A3-PRKG1 axis can
potentially mediate the intrinsic apoptosis pathway. We have also showed the activation
of downstream Rho-GTPase signaling pathway in HER2-positive breast cancer cells by
PTXNR-TTZ treatment. Notably, we found that PTXNR-TTZ significantly upregulates
the CDC20 gene expression which exerts an oncogenic activity in tumor progression by
activating APC/CCDC20 complex. We predicted that the targeted inhibition of CDC20 will
enhance the therapeutic efficacy of PTXNR-TTZ. In future, we propose to verify our
predictions from RNA sequencing data analysis experimentally in both in v itro and in
v iv o settings. The gene expression of NR4A3 and PRKG1 and induction of possible

apoptosis pathway in HER2-positive breast cancer will be investigated in HER2-positive
cell lines in v itro and in mouse xenograft model in vivo. Similarly, in v itro and in vivo
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therapeutic efficacy of PTXNR-TTZ will be evaluated upon targeted inhibition of
CDC20 gene expression. We have outlined our plans in the following points.
•

Investigation of PTXNR-TTZ induced NR4A3 mediated apoptosis: The HER2positive cell lines BT-474 and SK-BR-3 will be treated with PTXNR-TTZ in vitro . The
controls will include 1) no treatment 2) PTXNR treatment 3) TTZ treatment 4)
PTXNR+TTZ treatment. The gene expression of NR4A3 and PRKG1 will be investigated
using reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) analysis.
For RT-qPCR analysis, the cells will be lysed followed by the synthesis of cDNA from the
cell lysates. The synthesized cDNA will then be incorporated with the primers of NR4A3
and PRKG1 genes along with the DNA polymerase enzymes for subsequent RT-PCR
amplification reactions. Appropriate commercial kits and manufacturer’s protocols will be
used for cDNA synthesis and RT-qPCR reactions. For in v itro apoptosis response study,
the total protein will be extracted from the HER2-positive breast cancer cell lines. The
PTXNR-TTZ treated HER2-negative cell line extracted total protein will be used as a
control sample. The protein expression of NR4A3, PRKG1 and other downstream proteins
associated with intrinsic apoptosis pathway will be investigated using the Western blot
analysis. For in vivo analysis, the PTXNR-TTZ drug along with the other appropriate
controls will be injected in a transplanted xenograft mice model with established HER2positive breast tumor. For selective gene expression analysis, a patient derived xenografts
(PDX) immune-deficient mice model with established HER2-positive breast cancer is
more preferable than CDX model due to high similarity and maintenance in the genomic
signature of the tumor tissue representing the original primary tumor in patient. The tumor
volume will be monitored and tumor tissue sample will be collected upon significant
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volume remission with PTXNR-TTZ treatment. The total protein will be extracted from
the tumor tissue for subsequent protein expression analysis using Western blot technique.
•

Efficacy of PTXNR-TTZ upon targeted inhibition of CDC20 gene
expression: The PTXNR-TTZ induced gene expression of CDC20 in HER2-positive
breast cancer cell lines will be verified by RT-qPCR analysis. To investigate the possible
role of CDC20 gene overexpression on cell growth CDC20 will be inhibited by a CDC20
antagonist drug. The CDC20 gene may be knocked down using an appropriate silencing
RNA (siRNA) molecule as well. The cell viability assays will be conducted following the
PTXNR-TTZ treatment with the cells 1) before, and 2) after the targeted inhibition of
CDC20 gene expression. The control treatments will include 1) no treatment, and 2)
PTXNR+TTZ treatment. The investigation can also be conducted in an immune-deficient
nude mice PDX model with established HER2-positive breast cancer phenotype. The
mice will be treated with i.p. injection of CDC20 inhibitor for CDC20 gene inhibition.
The mice treated with i.p. injection of PTXNR-TTZ along with other mentioned
appropriate controls before and after the CDC20 inhibition will be monitored every three
days and normalized to tumor volume at treatment start point.
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Homogenizer

Paclitaxel molecule

Paclitaxel Nanorods
500nm X lOOnm

Figure 1. Synthesis process of PTXNRs. PTXNRs were synthesized using the
nanoprecipitation method. The figure shows the stability o f the paclitaxel molecule and
PTXNR in aqueous media before and after the synthesis process

C D I. PB S . pH 7.4

T ra slu z u m a b

2 O H u i i c l e o n l i i l i c s it e

Paclitaxel Nanorod (P1XNR)

Paclitaxel-imidazole carbamate (PIXNR-CDI)

Paclitaxel-1 rastuzumab (PIX N R -1 1Z)

Figure 2. Schematic diagram of reactions involved for PTXNR functionalization and
TTZ conjugation on the surface of PTXNRs
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Figure 3. Calibration curve of PTX for quantification of the amount of PTXNRs in
PTXNR-TTZ particles after conjugation with TTZ. The calibration curve was obtained
using PTXNRs in PBS at 230 nm absorbance values

Figure 4. Calibration curve of Trastuzumab (TTZ) monoclonal antibody for
quantification of unconjugated TTZ after conjugation with Paclitaxel nanorods
(PTXNRs). The calibration curve was obtained using a BCA protein quantification assay
at 562 nm absorbance values
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Figure 5. Calibration curve of B S A protein for quantification of protein in cell lysates for
Western blot experiments. The calibration curve was obtained using a B C A protein
quantification assay at 562 nm absorbance values

Table 1. Stability analysis of PT XN R and PTXNR-TTZ as a measure of zeta potential
___________________________value, ^ (mV)___________________________

Zeta potential, £ (mV)
Sample

DI water

PBS

PTXNR

-32.6± 4.82

-13.4± 2.81

PTXNR-TTZ

' -17.1±3.83

' -9.5± 0.02

'
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PTXNR-TTZ in DI Water

PTXNR-TTZ in PBS

Figure 6. Colloidal suspensions o f PTXNR-TTZ in DI water and PBS at 0.6, 1, and 2
mg/ml concentrations

Table 2. Analysis o f TTZ conjugation on the surface of PTXNRs
Initial
PTX
am ount
(m g)

% NR
form ation

Initial
PT X N R CDI
am ount
(mg)

Initial
TTZ
am ount
(mg)

% T TZ
conjugation
efficiency

A m ount
of
PTXNR
in 1 mg o f
PT X N R T TZ (mg)

A m ount
o f T TZ in
1 mg o f
PT X N R T T Z (mg)

PTXNR:
TTZ
(w /w )

30

64.98±2.37

1.0

0.10

95.24±1.40

0.8±0.02

0.2±0.02

4.0±0.53
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(a) Untreated

(b)

PTXNR

(c )

TTZ

(d)

P T X N R -T T Z

Figure 7. Flow cytometry data for cell cycle analysis of (a) untreated,
(b) PTXNR, (c) TTZ, and (d) PTXNR-TTZ treated BT-474 cells after 24 h. The side
scatter (SSC-A) v e r s u s forward scatter (FSC-A) gating is used to identify BT-474 cells as
gated by E1. The forward scatter height (FSC-H) versus forward scatter area (FSC-A)
density plots exclude doublet cells for accurate counting as shown by E2 gating. The
plots showing FITC-A and PE-A represent live cells and their stained DNA, respectively,
and gated for DNA analysis using Count versus PE-A plots. The Count versus PE-A plots
were analyzed using the flow cytometry software to calculate the percentage arrests in
G0/G1 (first sharp peak), S (flattened areas), and G2/M (second sharp peak) phases
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(a)

Untreated

(b )

PTXNR

(c )

TTZ

(d)

|

AO2 PTX N R
Gate: (G0/G1 in (E2 in (E1 in all))) and

§

AO 3 TTZ
Gate: (G0JG1 in (E2 in (E1 in all))) and

9

P T X N R -T T Z

Figure 8. Flow cytometry data for cell cycle analysis of (a) untreated,
(b) PTXNR, (c) TTZ, and (d) PTXNR-TTZ treated BT-474 cells after 48 h. The
histogram of relative DNA content in Count v e r s u s PE-A plots shows a shift in peaks
from G0/G1 to G2/M cells in PTXNR and PTXNR-TTZ treated cells compared to
untreated and TTZ treated cells
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(a) Untreated

(b ) P T X N R

(c )

TTZ

(d )

P T X N R -T T Z

Figure 9. Flow cytometry data for cell cycle analysis of (a) untreated,
(b) PTXNR, (c) TTZ, and (d) PTXNR-TTZ treated BT-474 cells after 72h. By the end oi
the incubation periods, >80% of cells were arrested in G2/M phases after PTXNR and
PTXNR-TTZ treatments, while untreated and TTZ treated cells showed most cells in
G0/G1
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Absorbance

Figure 1. (a): PLL trypan blue standard curve; and (b) Au-Fe 3 O4 concentration
measurement standard line
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Figure 2. Hydrodynamic diameters of (a) Au-Fe 3 O4 NPs and (b) PLL coated Au-Fe 3 O4
NPs in water as measured by dynamic light scattering (DLS). Three color codes indicate
three independent DLS measurements
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Figure 3. Magnetic relaxation (MR) characterization of (A and C) Au-Fe 3 O4 and (B and
D) PLL-Au-Fe 3 O4 NPs. A) Spin-spin MR (T2 ms) of bare Au-Fe 3 O4 NPs was found to
be 190 ms, whereas, it was B) 280 ms for PLL-Au-Fe 3 O4 NPs at a given concentration
of 10 p,g/mL. This change in T2 MR value is the indicative of effective PLL coatings.
Concentration dependent (1-100 p,g/mL) T2 values were obtained in PBS (pH 7.2)
and in 10% FBS for C) Au-Fe 3 O4 and D) PLL-Au-Fe 3 O4 NPs. These results indicated
that with increase in concentration, the MR properties of these NPs increase and were
found to be stable in physiological pH and in sera
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(a)

(b)

Figure 4. The PLL-Au-Fe 3 O4 NPs uptake by (a) BT-474 and (b) MDA-MB-231 cells
after 24 h incubation. Red circles indicate the endosomal vesicles that clearly retain the
NPs as appeared in dark black spots
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•

BT-474
MDA-MB-231

Figure 5. MTT cell viability assay o f BT-474 (filled circle, solid line) and MDA-MB-231
(open circle, dotted line) cell viability after treatment with PLL-Au-Fe 3 O4 NPs under a
650 nm laser irradiation for 10 min

Table 1. The percentage encapsulation efficiency of PLL on Au-Fe 3 O4 NPs

mg Au-Fe3O4

mg of PLL in PLL-Au-Fe3O4

% PLL encapsulation efficiency

25

0.47 ±0.03

73 ± 3
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Figure 1. Fractionation o f total lipid using column chromatography technique.
(a) Fractionation of total lipid in a handmade column. Silica gel (10-40 gm) was used as a
stationary phase. Chloroform and acetone were used as the mobile phase.
(b) The fractionated samples were collected separately by observing the color difference
o f individual lipid class. Eluent 1: fraction A, eluent 2: fraction B, eluent 3: fraction C, D,
E, F, G, eluent 4: fraction H, I, J, eluent 5: fraction K
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Table 1. Chromatographic fractionation method of total lipid, A-Chloroform; BAcetone

Eluent

A (%)

B (%)

Volume
(ml)
10

1

100

0

2

90

10

10

3

75

25

10

4

40

60

10

5

0

100

10

Table 2. HPLC column preparation and conditions for detection and quantification of
MGDG
Column

LiChrospher 100 Diol 25-4, 5 |im (Normal Phase
Column)

Detector

UV (240 nm)

Mobile phase

Solution A: Chloroform, Solution B: Methanol/water
(95:5 v/v)

Flow rate

1 ml/min

Injection volume

25 |il

Column
temperature

RT
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Table 3. HPLC elution method for detection and quantification of MGDG
Time (min)

A (%)

B (%)

0

99

1

15

75

25

20

10

90

25

10

90

30

99

1

Table 4. Corresponding peak areas o f increasing concentration of standard MGDG
Concentration

Peak Area

fag/ml)

(mAU.s)

0

0

5

24.57

8

47.26

10

66.28

50

596.63

100

1610.78

150

2505.67

256

Figure 2. Calibration curve of BSA protein for quantification of protein in cell lysates for
Western blot experiments. The calibration curve was obtained using a BCA protein
quantification assay at 562 nm absorbance values
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1. WESTERN BLOT ANALYSIS

Western blot analysis was performed to verify the active caspase-3 expression of
the standard and

S

y n

e c h

o

c y s t i s

sp. extracted M G D G treated BT-474 and M D A -M B -2 3 1

cells. Approximately, 106 cells were seeded in 25 cm2 cell culture flasks and treated with
100 ng/ml standard M G D G and

S

y n

e c h

o

c y s t i s

sp. extracted MGDG. After 72 h of

incubation, the cells were trypsinized for total protein extraction using the
radioimmunoprecipitation assay (RIPA) lysis buffer. The total protein was quantified
using the B C A calibration curve (SI Figure 2). For SDS-PAGE, the samples were
prepared in 2X Laemmli loading buffer. The samples were denatured at 86oC for 2-3 min
and loaded on the 16% Novex Tris-Glycine gels (Invitrogen). The gel was run in trisglycine-SDS running buffer at constant 200 V for 30-40 min. The separated protein bands
on the gel were transferred to the nitrocellulose membrane using the Power Blotter
(Invitrogen). The membrane blot was rinsed briefly with tris buffered saline including 1%
tween-20 (TBST) for 2-3 min and was blocked with 3% bovine serum albumin (BSA)
protein (Fisher Scientific) at room temperature for 5 h. After blocking, the membrane was
incubated overnight in the primary antibody caspase-3 (ThermoFisher, Cat. 43-7800) and
actin (ThermoFisher Cat. MA5-11869) at 4oC with the dilution factor of 1:500 and
1:3000, respectively. The membrane was washed 3-5 times with TBST buffer for 5 min
each followed by the incubation with anti-mouse horseradish peroxidase (HRP)
conjugated secondary antibody (ThermoFisher Cat. A27025). The membrane blot was
incubated in secondary the antibody for 1 h with the dilution factor of 1:10,000 followed
by washing with TBST buffer. Finally, the blot was incubated in electro-
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chemiluminescent reagent (Super Signal West Dura, ThermoFisher, and Cat. 34075)
for 5 min and was imaged using a Bio-Rad gel imaging system.

Caspase-3 (32 KDa)
Actin (42 KDa)

BT-474

MDA-MB-231

No
MGDG MGDG
Treatment (Plant) (Syn. Sp.)
1
0.8
0.55

No
MGDG MGDG
Treatment (Plant) (Syn. sp.)

Cleaved into
active caspase-3

Cleaved into
active caspase-3

Figure 3. The Western blot assay confirming the reduced full-length caspase-3 protein
expressions in BT-474 (left panel) and MDA-MB-231 (right panel) cell lines treated with
MGDG extracted from S y n e c h o c y s tis sp. compared to untreated and MGDG standard
treated samples. Caspase-3 (32 kDa) is cleaved into lower molecular weight (17kDa)
active caspase-3/7 that is shown by fluorescence microscopic images and flow cytometry
quantification in Figure 8 of the main texts
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Figure 4. Dead control cells induced by saponin was used in MTT assay
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Figure 5. Quantification of apoptosis assay. For quantification of apoptosis induction the
BT-474 and MDA-MB-231 cells were treated with standard plant extract MGDG and
S y n e c h o c y s tis sp. extracted MGDG with 100 ng/ml dose. The cleaved caspase-3/7
fluorescence intensity data were collected using flow cytometry. The scatter plots were
generated for each treatment showing cleaved caspase-3/7 fluorescence data in x-axis and
forward scattering (FSC) values in y-axis. A combined histogram was also generated for
each treatment showing cleaved caspase-3//7 fluorescence intensity distribution in cell
population. The green, blue and red lines represent the histogram data for untreated,
MGDG standard treated and S y n e c h o c y s tis sp. extracted MGDG treated samples. The
scatter plots and combined histograms were generated for treatments in BT-474 cell line
after (a) 48 h and (b) 72 h and in MDA-MB-231 cell line after (c) 48 h and (d) 72 h. In
BT-474 cell line, the mean cleaved caspase-3/7 fluorescence intensity was shifted by
1.7±0.04 (p<0.01) and 2.34±0.44 (p<0.01) fold in S y n e c h o c y s tis sp. extracted MGDG
treated cells compared to untreated control cells after 48 h and 72 h of treatment,
respectively. In MDA-MB-231 cell line, the shift in mean fluorescence intensity was
0.95±0.01 and 2.1±0.03 fold (p<0.01) in S y n e c h o c y s tis sp. treated cells after 48 h and 72
h, respectively compared to untreated control cells

261

BIBLIOGRAPHY

(1)

Siegel, R. L.; Miller, K. D.; Jemal, A. Cancer statistics, 2019. CA: a cancer
journal for clinicians 2019, 69, 7-34.

(2)

Shi, J.; Kantoff, P. W.; Wooster, R.; Farokhzad, O. C. Cancer nanomedicine:
progress, challenges and opportunities. Nature Reviews Cancer 2017, 17, 20.

(3)

Specification, P. A.: Terminology for nanomaterials. British Standards Institute
London, 2007.

(4)

Kim, B. Y.; Rutka, J. T.; Chan, W. C. Nanomedicine. New England Journal of
Medicine 2010, 363, 2434-2443.

(5)

Kim, B. Y. S.; Rutka, J. T.; Chan, W. C. W. Nanomedicine. New England Journal
of Medicine 2010, 363, 2434-2443.

(6)

Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C.; Margalit, R.; Langer, R.
Nanocarriers as an emerging platform for cancer therapy. Nature nanotechnology
2007, 2, 751-760.

(7)

Xia, Y.; Xiong, Y.; Lim, B.; Skrabalak, S. E. Shape-controlled synthesis of metal
nanocrystals: simple chemistry meets complex physics? Angewandte Chemie
International Edition 2009, 48, 60-103.

(8)

Doll, T. A.; Raman, S.; Dey, R.; Burkhard, P. Nanoscale assemblies and their
biomedical applications. Journal of The Royal Society Interface 2013, 10,
20120740.

(9)

Wang, A. Z.; Tepper, J. E. Nanotechnology in radiation oncology. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology
2014, 32, 2879-2885.

(10)

Fisher, B. Biological Research in the Evolution of Cancer Surgery: A Personal
Perspective. Cancer Research 2008, 68, 10007-10020.

(11)

Fisher, B. Cancer surgery: A commentary. Cancer Treat Rep 1984, 68, 31-41.

(12)

Baskar, R.; Dai, J.; Wenlong, N.; Yeo, R.; Yeoh, K.-W. Biological response of
cancer cells to radiation treatment. Frontiers in molecular biosciences 2014, 1, 24.

262
(13)

Kannan, R.; Zambre, A.; Chanda, N.; Kulkarni, R.; Shukla, R.; Katti, K.;
Upendran, A.; Cutler, C.; Boote, E.; Katti, K. V. Functionalized radioactive gold
nanoparticles in tumor therapy. Wiley Interdisciplinary Reviews: Nanomedicine
and Nanobiotechnology 2012, 4, 42-51.

(14)

Van den Heuvel, F.; Locquet, J.-P.; Nuyts, S. Beam energy considerations for
gold nano-particle enhanced radiation treatment. Physics in Medicine & Biology
2010, 55, 4509.

(15)

Wunderlich, G.: Radioactive Microspheres. In Clinical Nuclear Medicine;
Springer, 2020; pp 951-959.

(16)

Abshire, D.; Lang, M. K. In Tilte2018; Elsevier.

(17)

Baskar, R.; Lee, K. A.; Yeo, R.; Yeoh, K.-W. Cancer and radiation therapy:
current advances and future directions. Int J Med Sci 2012, 9, 193-199.

(18)

Jackson, S. P.; Bartek, J. The DNA-damage response in human biology and
disease. Nature 2009, 461, 1071-1078.

(19)

Chen, H. H.; Kuo, M. T. Improving radiotherapy in cancer treatment: promises
and challenges. Oncotarget 2017, 8, 62742.

(20)

Wang, W.; Zhang, F.; Hu, K.; Hou, X. Image-guided, intensity-modulated
radiation therapy in definitive radiotherapy for 1433 patients with cervical cancer.
Gynecologic Oncology 2018, 151, 444-448.

(21)

Gupta, T.; Narayan, C. A. Image-guided radiation therapy: Physician's
perspectives. Journal of medical physics/Association of Medical Physicists of
India 2012, 37, 174.

(22)

Ma, L.; Wang, L.; Tseng, C. L.; Sahgal, A. Emerging technologies in stereotactic
body radiotherapy. Chinese clinical oncology 2017, 6, S12.

(23)

Czernin, J.; Allen-Auerbach, M.; Schelbert, H. R. Improvements in cancer staging
with PET/CT: literature-based evidence as o f September 2006. Journal of Nuclear
Medicine 2007, 48, 78S.

(24)

Bar-Shalom, R.; Yefremov, N.; Guralnik, L.; Gaitini, D.; Frenkel, A.; Kuten, A.;
Altman, H.; Keidar, Z.; Israel, O. Clinical performance of PET/CT in evaluation
of cancer: additional value for diagnostic imaging and patient management.
Journal of nuclear medicine 2003, 44, 1200-1209.

263

(25)

Chandarana, H.; Wang, H.; Tijssen, R. H. N.; Das, I. J. Emerging role of MRI
in radiation therapy. Journal of magnetic resonance imaging : JMRI 2018, 48,
1468-1478.

(26)

Das, I. J.; McGee, K. P.; Tyagi, N.; Wang, H. Role and future of MRI in radiation
oncology. The British journal of radiology 2019, 92, 20180505.

(27)

Abshire, D.; Lang, M. K. The Evolution of Radiation Therapy in Treating Cancer.
Seminars in oncology nursing 2018, 34, 151-157.

(28)

Chidambaram, M.; Manavalan, R.; Kathiresan, K. Nanotherapeutics to overcome
conventional cancer chemotherapy limitations. Journal of pharmacy &
pharmaceutical sciences 2011, 14, 67-77.

(29)

Bianchini, G.; Balko, J. M.; Mayer, I. A.; Sanders, M. E.; Gianni, L. Triple
negative breast cancer: challenges and opportunities of a heterogeneous disease.
Nature reviews Clinical oncology 2016, 13, 674.

(30)

Kondo, N.; Takahashi, A.; Ono, K.; Ohnishi, T. DNA damage induced by
alkylating agents and repair pathways. Journal of nucleic acids 2010, 2010.

(31)

Malhotra, V.; Perry, M. C. Classical chemotherapy: mechanisms, toxicities and
the therapeutc window. Cancer biology & therapy 2003, 2, 1-3.

(32)

Fu, D.; Calvo, J. A.; Samson, L. D. Balancing repair and tolerance of DNA
damage caused by alkylating agents. Nature Reviews Cancer 2012, 12, 104-120.

(33)

Longley, D. B.; Harkin, D. P.; Johnston, P. G. 5-fluorouracil: mechanisms of
action and clinical strategies. Nature reviews cancer 2003, 3, 330-338.

(34)

Burger, R. M.; Peisach, J.; Horwitz, S. B. Mechanism of bleomycin action: in
vitro studies. Life sciences 1981, 28, 715-727.

(35)

Dorr, R. T. In Tilte1992.

(36)

Zunino, F.; Capranico, G. DNA topoisomerase II as the primary target of anti
tumor anthracyclines. Anti-cancer drug design 1990, 5, 307.

(37)

Chow, K.-C.; Macdonald, T. L.; Ross, W. E. DNA binding by
epipodophyllotoxins and N-acyl anthracyclines: implications for mechanism of
topoisomerase II inhibition. Molecular Pharmacology 1988, 34, 467-473.

(38)

Jordan, M. A.; Thrower, D.; Wilson, L. Mechanism of inhibition of cell
proliferation by Vinca alkaloids. Cancer research 1991, 51, 2212-2222.

264

(39)

Yang, C.-P. H.; Horwitz, S. B. Taxol®: the first microtubule stabilizing agent.
International journal of molecular sciences 2017, 18, 1733.

(40)

Weaver, B. A. How Taxol/paclitaxel kills cancer cells. Molecular biology o f the
cell 2014, 25, 2677-2681.

(41)

Rahier, N. J.; Thomas, C. J.; Hecht, S. M. Camptothecin and its analogs.
Anticancer agents from natural products 2005, 5, 22.

(42)

Crow, R. T.; Crothers, D. M. Structural modifications of camptothecin and effects
on topoisomerase I inhibition. Journal of medicinal chemistry 1992, 35, 4160
4164.

(43)

Couzin-Frankel, J.: Cancer immunotherapy. American Association for the
Advancement of Science, 2013.

(44)

Postow, M. A.; Callahan, M. K.; Wolchok, J. D. Immune checkpoint blockade in
cancer therapy. Journal of clinical oncology 2015, 33, 1974.

(45)

Ribas, A.; Wolchok, J. D. Cancer immunotherapy using checkpoint blockade.
Science 2018, 359, 1350-1355.

(46)

Seidel, J. A.; Otsuka, A.; Kabashima, K. Anti-PD-1 and anti-CTLA-4 therapies in
cancer: mechanisms of action, efficacy, and limitations. Frontiers in oncology
2018, 8, 86.

(47)

Wei, S. C.; Duffy, C. R.; Allison, J. P. Fundamental mechanisms of immune
checkpoint blockade therapy. Cancer discovery 2018, 8, 1069-1086.

(48)

Stoiber, S.; Cadilha, B. L.; Benmebarek, M.-R.; Lesch, S.; Endres, S.; Kobold, S.
Limitations in the design of chimeric antigen receptors for cancer therapy. Cells
2019, 8, 472.

(49)

Hudis, C. A. Trastuzumab— mechanism of action and use in clinical practice.
New England Journal of Medicine 2007, 357, 39-51.

(50)

Shashidharamurthy, R.; Bozeman, E. N.; Patel, J.; Kaur, R.; Meganathan, J.;
Selvaraj, P. Immunotherapeutic strategies for cancer treatment: a novel protein
transfer approach for cancer vaccine development. Medicinal research reviews
2012, 32, 1197-1219.

(51)

Peer, D. Harnessing RNAi nanomedicine for precision therapy. Molecular and
cellular therapies 2014, 2, 5.

265

(52)

de Lazaro, I.; Mooney, D. J. A nanoparticle’s pathway into tumours. Nature
Materials 2020, 19, 486-487.

(53)

Rosenblum, D.; Joshi, N.; Tao, W.; Karp, J. M.; Peer, D. Progress and challenges
towards targeted delivery of cancer therapeutics. Nature communications 2018, 9,
1-12.

(54)

Barenholz, Y. C. Doxil®—the first FDA-approved nano-drug: lessons learned.
Journal of controlled release 2012, 160, 117-134.

(55)

Gradishar, W. J.; Tjulandin, S.; Davidson, N.; Shaw, H.; Desai, N.; Bhar, P.;
Hawkins, M.; O'Shaughnessy, J. Phase III trial o f nanoparticle albumin-bound
paclitaxel compared with polyethylated castor oil-based paclitaxel in women with
breast cancer. Journal of clinical oncology 2005, 23, 7794-7803.

(56)

Miele, E.; Spinelli, G. P.; Miele, E.; Tomao, F.; Tomao, S. Albumin-bound
formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer.
International journal of nanomedicine 2009, 4, 99.

(57)

Silverman, J. A.; Deitcher, S. R. Marqibo®(vincristine sulfate liposome injection)
improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer
chemotherapy and pharmacology 2013, 71, 555-564.

(58)

Rosenthal, E.; Poizot-Martin, I.; Saint-Marc, T.; Spano, J.-P.; Cacoub, P.; Group,
D. S. Phase IV study of liposomal daunorubicin (DaunoXome) in AIDS-related
Kaposi sarcoma. American journal of clinical oncology 2002, 25, 57-59.

(59)

Zhang, H. Onivyde for the therapy of multiple solid tumors. Onco Targets Ther
2016, 9, 3001.

(60)

Lamb, Y. N.; Scott, L. J. Liposomal irinotecan: a review in metastatic pancreatic
adenocarcinoma. Drugs 2017, 77, 785-792.

(61)

Lancet, J. E.; Uy, G. L.; Cortes, J. E.; Newell, L. F.; Lin, T. L.; Ritchie, E. K.;
Stuart, R. K.; Strickland, S. A.; Hogge, D.; Solomon, S. R.: Final results of a
phase III randomized trial of CPX-351 versus 7+ 3 in older patients with newly
diagnosed high risk (secondary) AML. American Society of Clinical Oncology,
2016.

(62)

Swenson, C.; Perkins, W.; Roberts, P.; Janoff, A. Liposome technology and the
development of Myocet™(liposomal doxorubicin citrate). The Breast 2001, 10, 1
7.

266

(63)

Leonard, R.; Williams, S.; Tulpule, A.; Levine, A.; Oliveros, S. Improving the
therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin
(Myocet™). The Breast 2009, 18, 218-224.

(64)

Meyers, P. A. Muramyl tripeptide (mifamurtide) for the treatment of
osteosarcoma. Expert review of anticancer therapy 2009, 9, 1035-1049.

(65)

Frampton, J. E. Mifamurtide. Pediatric Drugs 2010, 12, 141-153.

(66)

Kim, T.-Y.; Kim, D.-W.; Chung, J.-Y.; Shin, S. G.; Kim, S.-C.; Heo, D. S.; Kim,
N. K.; Bang, Y.-J. Phase I and pharmacokinetic study of Genexol-PM, a
cremophor-free, polymeric micelle-formulated paclitaxel, in patients with
advanced malignancies. Clinical cancer research 2004, 10, 3708-3716.

(67)

Maeda, H. SMANCS and polymer-conjugated macromolecular drugs: advantages
in cancer chemotherapy. Advanced drug delivery reviews 2001, 46, 169-185.

(68)

Maeda, H. Macromolecular therapeutics in cancer treatment: the EPR effect and
beyond. Journal of Controlled Release 2012, 164, 138-144.

(69)

Chauhan, V. P.; Jain, R. K. Strategies for advancing cancer nanomedicine. Nature
materials 2013, 12, 958-962.

(70)

Byrne, J. D.; Betancourt, T.; Brannon-Peppas, L. Active targeting schemes for
nanoparticle systems in cancer therapeutics. Advanced drug delivery reviews
2008, 60, 1615-1626.

(71)

Bertrand, N.; Wu, J.; Xu, X.; Kamaly, N.; Farokhzad, O. C. Cancer
nanotechnology: the impact o f passive and active targeting in the era of modern
cancer biology. Advanced drug delivery reviews 2014, 66, 2-25.

(72)

Shi, J.; Xiao, Z.; Kamaly, N.; Farokhzad, O. C. Self-assembled targeted
nanoparticles: evolution of technologies and bench to bedside translation.
Accounts of chemical research 2011, 44, 1123-1134.

(73)

Maruyama, K. PEG-immunoliposome. Bioscience reports 2002, 22, 251-266.

(74)

Karmali, P. P.; Kotamraju, V. R.; Kastantin, M.; Black, M.; Missirlis, D.; Tirrell,
M.; Ruoslahti, E. Targeting of albumin-embedded paclitaxel nanoparticles to
tumors. Nanomedicine: Nanotechnology, Biology and Medicine 2009, 5, 73-82.

(75)

Davis, M. E.; Zuckerman, J. E.; Choi, C. H. J.; Seligson, D.; Tolcher, A.; Alabi,
C. A.; Yen, Y.; Heidel, J. D.; Ribas, A. Evidence of RNAi in humans from
systemically administered siRNA via targeted nanoparticles. Nature 2010, 464,
1067-1070.

267

(76)

Pederzoli, F.; Tosi, G.; Vandelli, M. A.; Belletti, D.; Forni, F.; Ruozi, B.
Protein corona and nanoparticles: how can we investigate on? Wiley
Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 2017, 9, e1467.

(77)

Xiao, W.; Gao, H. The impact of protein corona on the behavior and targeting
capability of nanoparticle-based delivery system. International Journal of
Pharmaceutics 2018, 552, 328-339.

(78)

Caracciolo, G.; Farokhzad, O. C.; Mahmoudi, M. Biological identity of
nanoparticles in vivo: clinical implications of the protein corona. Trends in
biotechnology 2017, 35, 257-264.

(79)

Hadjidemetriou, M.; Kostarelos, K. Evolution of the nanoparticle corona. Nature
nanotechnology 2017, 12, 288-290.

(80)

Cheng, X.; Tian, X.; Wu, A.; Li, J.; Tian, J.; Chong, Y.; Chai, Z.; Zhao, Y.; Chen,
C.; Ge, C. Protein corona influences cellular uptake of gold nanoparticles by
phagocytic and nonphagocytic cells in a size-dependent manner. ACS applied
materials & interfaces 2015, 7, 20568-20575.

(81)

Schmidt, M. M.; Wittrup, K. D. A modeling analysis of the effects of molecular
size and binding affinity on tumor targeting. Molecular cancer therapeutics 2009,
8, 2861-2871.

(82)

Sahay, G.; Alakhova, D. Y.; Kabanov, A. V. Endocytosis of nanomedicines.
Journal of controlled release 2010, 145, 182-195.

(83)

Vermeulen, L. M.; De Smedt, S. C.; Remaut, K.; Braeckmans, K. The proton
sponge hypothesis: Fable or fact? European Journal of Pharmaceutics and
Biopharmaceutics 2018, 129, 184-190.

(84)

Sahay, G.; Querbes, W.; Alabi, C.; Eltoukhy, A.; Sarkar, S.; Zurenko, C.;
Karagiannis, E.; Love, K.; Chen, D.; Zoncu, R. Efficiency of siRNA delivery by
lipid nanoparticles is limited by endocytic recycling. Nature biotechnology 2013,
31, 653-658.

(85)

Stuchbery, R.; J Kurganovs, N.; J McCoy, P.; C Nelson, C.; M Hayes, V.; M
Corcoran, N.; M Hovens, C. Target acquired: progress and promise of targeted
therapeutics in the treatment of prostate cancer. Current cancer drug targets 2015,
15, 394-405.

(86)

Pearce, A. K.; O’Reilly, R. K. Insights into active targeting o f nanoparticles in
drug delivery: advances in clinical studies and design considerations for cancer
nanomedicine. Bioconjugate chemistry 2019, 30, 2300-2311.

268

(87)

Hamaguchi, T.; Matsumura, Y.; Nakanishi, Y.; Muro, K.; Yamada, Y.;
Shimada, Y.; Shirao, K.; Niki, H.; Hosokawa, S.; Tagawa, T. Antitumor effect of
MCC-465, pegylated liposomal doxorubicin tagged with newly developed
monoclonal antibody GAH, in colorectal cancer xenografts. Cancer science 2004,
95, 608-613.

(88)

Camp, E.; Wang, C.; Little, E.; Watson, P.; Pirollo, K.; Rait, A.; Cole, D.; Chang,
E.; Watson, D. Transferrin receptor targeting nanomedicine delivering wild-type
p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer gene
therapy 2013, 20, 222-228.

(89)

Senzer, N.; Nemunaitis, J.; Nemunaitis, D.; Bedell, C.; Edelman, G.; Barve, M.;
Nunan, R.; Pirollo, K. F.; Rait, A.; Chang, E. H. Phase I study of a systemically
delivered p53 nanoparticle in advanced solid tumors. Molecular Therapy 2013,
21, 1096-1103.

(90)

Adams, G. P.; Weiner, L. M. Monoclonal antibody therapy of cancer. Nature
biotechnology 2005, 23, 1147-1157.

(91)

Romond, E. H.; Perez, E. A.; Bryant, J.; Suman, V. J.; Geyer Jr, C. E.; Davidson,
N. E.; Tan-Chiu, E.; Martino, S.; Paik, S.; Kaufman, P. A. Trastuzumab plus
adjuvant chemotherapy for operable HER2-positive breast cancer. New England
Journal of Medicine 2005, 353, 1673-1684.

(92)

Lane, D. Designer combination therapy for cancer. Nature Biotechnology 2006,
24, 163-164.

(93)

Braso-Maristany, F.; Griguolo, G.; Pascual, T.; Pare, L.; Nuciforo, P.; LlombartCussac, A.; Bermejo, B.; Oliveira, M.; Morales, S.; Martinez, N.; Vidal, M.;
Adamo, B.; Martinez, O.; Pernas, S.; Lopez, R.; Munoz, M.; Chic, N.; Galvan, P.;
Garau, I.; Manso, L.; Alarcon, J.; Martinez, E.; Gregorio, S.; Gomis, R. R.;
Villagrasa, P.; Cortes, J.; Ciruelos, E.; Prat, A. Phenotypic changes of HER2positive breast cancer during and after dual HER2 blockade. Nature
communications 2020, 11, 385.

(94)

Marty, M.; Cognetti, F.; Maraninchi, D.; Snyder, R.; Mauriac, L.; Tubiana-Hulin,
M.; Chan, S.; Grimes, D.; Anton, A.; Lluch, A. Randomized phase II trial o f the
efficacy and safety of trastuzumab combined with docetaxel in patients with
human epidermal growth factor receptor 2-positive metastatic breast cancer
administered as first-line treatment: the M77001 study group. Journal of clinical
oncology 2005, 23, 4265-4274.

269

(95)

Von Minckwitz, G.; Procter, M.; De Azambuja, E.; Zardavas, D.; Benyunes,
M.; Viale, G.; Suter, T.; Arahmani, A.; Rouchet, N.; Clark, E. Adjuvant
pertuzumab and trastuzumab in early HER2-positive breast cancer. New England
Journal of Medicine 2017, 377, 122-131.

(96)

Goldhirsch, A.; Gelber, R. D.; Piccart-Gebhart, M. J.; De Azambuja, E.; Procter,
M.; Suter, T. M.; Jackisch, C.; Cameron, D.; Weber, H. A.; Heinzmann, D. 2
years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer
(HERA): an open-label, randomised controlled trial. The Lancet 2013, 382, 1021
1028.

(97)

Piccart-Gebhart, M. J.; Procter, M.; Leyland-Jones, B.; Goldhirsch, A.; Untch,
M.; Smith, I.; Gianni, L.; Baselga, J.; Bell, R.; Jackisch, C. Trastuzumab after
adjuvant chemotherapy in HER2-positive breast cancer. New England Journal of
Medicine 2005, 353, 1659-1672.

(98)

Slamon, D.; Eiermann, W.; Robert, N.; Pienkowski, T.; Martin, M.; Press, M.;
Mackey, J.; Glaspy, J.; Chan, A.; Pawlicki, M. Adjuvant trastuzumab in HER2positive breast cancer. New England Journal of Medicine 2011, 365, 1273-1283.

(99)

Perez, E.; Romond, E.; Suman, V. Trastuzumab plus adjuvant chemotherapy for
HER2-positive breast cancer: Final planned joint analysis o f overall survival (OS)
from NSABP B-31 and NCCTG N9831. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2014, 32, 3744-3752.

(100) Baselga, J.; Norton, L.; Albanell, J.; Kim, Y. M.; Mendelsohn, J. Recombinant
humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of
paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer
xenografts. Cancer Res 1998, 58, 2825-2831.
(101) Topham, C. H.; Taylor, S. S. Mitosis and apoptosis: how is the balance set?
Current opinion in cell biology 2013, 25, 780-785.
(102) Vegran, F.; Boidot, R.; Coudert, B.; Fumoleau, P.; Arnould, L.; Garnier, J.;
Causeret, S.; Fraise, J.; Dembele, D.; Lizard-Nacol, S. Gene expression profile
and response to trastuzumab-docetaxel-based treatment in breast carcinoma. Br J
Cancer 2009, 101, 1357-1364.
(103) Tolaney, S. M.; Barry, W. T.; Dang, C. T.; Yardley, D. A.; Moy, B.; Marcom, P.
K.; Albain, K. S.; Rugo, H. S.; Ellis, M.; Shapira, I.; Wolff, A. C.; Carey, L. A.;
Overmoyer, B. A.; Partridge, A. H.; Guo, H.; Hudis, C. A.; Krop, I. E.; Burstein,
H. J.; Winer, E. P. Adjuvant Paclitaxel and Trastuzumab for Node-Negative,
HER2-Positive Breast Cancer. New England Journal of Medicine 2015, 372, 134
141.

270

(104) Tolaney, S. M.; Guo, H.; Pernas, S.; Barry, W. T.; Dillon, D. A.; Ritterhouse,
L.; Schneider, B. P.; Shen, F.; Fuhrman, K.; Baltay, M.; Dang, C. T.; Yardley, D.
A.; Moy, B.; Marcom, P. K.; Albain, K. S.; Rugo, H. S.; Ellis, M. J.; Shapira, I.;
Wolff, A. C.; Carey, L. A.; Overmoyer, B.; Partridge, A. H.; Hudis, C. A.; Krop,
I. E.; Burstein, H. J.; Winer, E. P. Seven-Year Follow-Up Analysis of Adjuvant
Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth
Factor Receptor 2-Positive Breast Cancer. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2019, 37, 1868-1875.
(105) Chalouni, C.; Doll, S. Fate of Antibody-Drug Conjugates in Cancer Cells. J Exp
Clin Cancer Res 2018, 37, 20-20.
(106) Chalouni, C.; Doll, S. Fate of antibody-drug conjugates in cancer cells. Journal of
Experimental & Clinical Cancer Research 2018, 37, 20.
(107) Kalim, M.; Chen, J.; Wang, S.; Lin, C.; Ullah, S.; Liang, K.; Ding, Q.; Chen, S.;
Zhan, J. Intracellular trafficking o f new anticancer therapeutics: antibody-drug
conjugates. Drug design, development and therapy 2017, 11, 2265.
(108) Kovtun, Y. V.; Audette, C. A.; Ye, Y.; Xie, H.; Ruberti, M. F.; Phinney, S. J.;
Leece, B. A.; Chittenden, T.; Blattler, W. A.; Goldmacher, V. S. Antibody-drug
conjugates designed to eradicate tumors with homogeneous and heterogeneous
expression of the target antigen. Cancer research 2006, 66, 3214-3221.
(109) Parslow, A. C.; Parakh, S.; Lee, F.-T.; Gan, H. K.; Scott, A. M. Antibody-drug
conjugates for cancer therapy. Biomedicines 2016, 4, 14.
(110) Schrama, D.; Reisfeld, R. A.; Becker, J. C. Antibody targeted drugs as cancer
therapeutics. Nature reviews Drug discovery 2006, 5, 147-159.
(111) Sievers, E. L.; Senter, P. D. Antibody-drug conjugates in cancer therapy. Annual
review of medicine 2013, 64.
(112) Wagner-Rousset, E.; Janin-Bussat, M.-C.; Colas, O.; Excoffier, M.; Ayoub, D.;
Haeuw, J.-F.; Rilatt, I.; Perez, M.; Corvai'a, N.; Beck, A. In Tilte2014; Taylor &
Francis.
(113) Beck, A.; Goetsch, L.; Dumontet, C.; Corvai'a, N. Strategies and challenges for
the next generation of antibody-drug conjugates. Nature reviews Drug discovery
2017, 16, 315-337.
(114) Casi, G.; Neri, D. Antibody-Drug Conjugates and Small Molecule-Drug
Conjugates: Opportunities and Challenges for the Development of Selective
Anticancer Cytotoxic Agents: Miniperspective. Journal of medicinal chemistry
2015, 58, 8751-8761.

271

(115) Gordon, M. R.; Canakci, M.; Li, L.; Zhuang, J.; Osborne, B.; Thayumanavan,
S. Field guide to challenges and opportunities in antibody-drug conjugates for
chemists. Bioconjugate chemistry 2015, 26, 2198-2215.
(116) Kamath, A. V.; Iyer, S. Challenges and advances in the assessment of the
disposition of antibody-drug conjugates. Biopharmaceutics & drug disposition
2016, 37, 66-74.
(117) Nejadmoghaddam, M.-R.; Minai-Tehrani, A.; Ghahremanzadeh, R.; Mahmoudi,
M.; Dinarvand, R.; Zarnani, A.-H. Antibody-drug conjugates: possibilities and
challenges. Avicenna J Med Biotechnol 2019, 11, 3.
(118) Sau, S.; Alsaab, H. O.; Kashaw, S. K.; Tatiparti, K.; Iyer, A. K. Advances in
antibody-drug conjugates: a new era of targeted cancer therapy. Drug discovery
today 2017, 22, 1547-1556.
(119) Beck, A.; Goetsch, L.; Dumontet, C.; Corvaia, N. Strategies and challenges for
the next generation of antibody-drug conjugates. Nat Rev Drug Discov 2017, 16,
315-337.
(120) Benderra, Z.; Faussat, A. M.; Sayada, L.; Perrot, J.-Y.; Tang, R.; Chaoui, D.;
Morjani, H.; Marzac, C.; Marie, J.-P.; Legrand, O. MRP3, BCRP, and Pglycoprotein activities are prognostic factors in adult acute myeloid leukemia.
Clinical cancer research 2005, 11, 7764-7772.
(121) Naito, K.; Takeshita, A.; Shigeno, K.; Nakamura, S.; Fujisawa, S.; Shinjo, K.;
Yoshida, H.; Ohnishi, K.; Mori, M.; Terakawa, S. Calicheamicin-conjugated
humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676)
shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on Pglycoprotein-expressing sublines. Leukemia 2000, 14, 1436-1443.
(122) Tang, R.; Cohen, S.; Perrot, J.-Y.; Faussat, A.-M.; Zuany-Amorim, C.;
Marjanovic, Z.; Morjani, H.; Fava, F.; Corre, E.; Legrand, O. P-gp activity is a
critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia
cell lines, but not a major mechanism of chemoresistance in cells from acute
myeloid leukaemia patients. BMC cancer 2009, 9, 1-10.
(123) Strop, P.; Liu, S.-H.; Dorywalska, M.; Delaria, K.; Dushin, R. G.; Tran, T.-T.; Ho,
W.-H.; Farias, S.; Casas, M. G.; Abdiche, Y. Location matters: site of conjugation
modulates stability and pharmacokinetics o f antibody drug conjugates. Chemistry
& biology 2013, 20, 161-167.

272

(124) Junutula, J. R.; Raab, H.; Clark, S.; Bhakta, S.; Leipold, D. D.; Weir, S.;
Chen, Y.; Simpson, M.; Tsai, S. P.; Dennis, M. S. Site-specific conjugation of a
cytotoxic drug to an antibody improves the therapeutic index. Nature
biotechnology 2008, 26, 925.
(125) Hamblett, K. J.; Senter, P. D.; Chace, D. F.; Sun, M. M.; Lenox, J.; Cerveny, C.
G.; Kissler, K. M.; Bernhardt, S. X.; Kopcha, A. K.; Zabinski, R. F. Effects of
drug loading on the antitumor activity of a monoclonal antibody drug conjugate.
Clinical cancer research 2004, 10, 7063-7070.
(126) Strop, P.; Delaria, K.; Foletti, D.; Witt, J. M.; Hasa-Moreno, A.; Poulsen, K.;
Casas, M. G.; Dorywalska, M.; Farias, S.; Pios, A. Site-specific conjugation
improves therapeutic index of antibody drug conjugates with high drug loading.
Nature biotechnology 2015, 33, 694-696.
(127) Jaracz, S.; Chen, J.; Kuznetsova, L. V.; Ojima, I. Recent advances in tumor
targeting anticancer drug conjugates. Bioorganic & medicinal chemistry 2005, 13,
5043-5054.
(128) Chari, R. V.; Miller, M. L.; Widdison, W. C. Antibody-drug conjugates: an
emerging concept in cancer therapy. Angewandte Chemie International Edition
2014, 53, 3796-3827.
(129) Abdollahpour-Alitappeh, M.; Lotfinia, M.; Gharibi, T.; Mardaneh, J.;
Farhadihosseinabadi, B.; Larki, P.; Faghfourian, B.; Sepehr, K. S.; AbbaszadehGoudarzi, K.; Abbaszadeh-Goudarzi, G. Antibody-drug conjugates (ADCs) for
cancer therapy: Strategies, challenges, and successes. Journal of Cellular
Physiology 2019, 234, 5628-5642.
(130) Singh, A. P.; Sharma, S.; Shah, D. K. Quantitative characterization of in vitro
bystander effect of antibody-drug conjugates. Journal of pharmacokinetics and
pharmacodynamics 2016, 43, 567-582.
(131) Masuda, S.; Miyagawa, S.; Sougawa, N.; Sawa, Y. CD30-targeting
immunoconjugates and bystander effects. Nature reviews Clinical oncology 2015,
12, 245.
(132) Scott, L. J. Brentuximab vedotin: a review in CD30-positive Hodgkin lymphoma.
Drugs 2017, 77, 435-445.
(133) Schonberger, S.; van Beekum, C.; Gotz, B.; Nettersheim, D.; Schorle, H.;
Schneider, D. T.; Casati, A.; Craveiro, R. B.; Calaminus, G.; Dilloo, D.
Brentuximab vedotin exerts profound antiproliferative and pro-apoptotic efficacy
in CD30-positive as well as cocultured CD30-negative germ cell tumour cell
lines. Journal of Cellular and Molecular Medicine 2018, 22, 568-575.

273

(134) Katz, J.; Janik, J. E.; Younes, A. Brentuximab vedotin (SGN-35). Clinical
Cancer Research 2011, 17, 6428-6436.
(135) van der Lee, M. M.; Groothuis, P. G.; Ubink, R.; van der Vleuten, M. A.; van
Achterberg, T. A.; Loosveld, E. M.; Damming, D.; Jacobs, D. C.; Rouwette, M.;
Egging, D. F. The preclinical profile of the duocarmycin-based HER2-targeting
ADC SYD985 predicts for clinical benefit in low HER2-expressing breast
cancers. Molecular cancer therapeutics 2015, 14, 692-703.
(136) Hong, E. E.; Erickson, H.; Lutz, R. J.; Whiteman, K. R.; Jones, G.; Kovtun, Y.;
Blanc, V.; Lambert, J. M. Design of coltuximab ravtansine, a CD19-targeting
antibody-drug conjugate (ADC) for the treatment of B-cell malignancies:
structure-activity relationships and preclinical evaluation. Molecular
pharmaceutics 2015, 12, 1703-1716.
(137) Golfier, S.; Kopitz, C.; Kahnert, A.; Heisler, I.; Schatz, C. A.; Stelte-Ludwig, B.;
Mayer-Bartschmid, A.; Unterschemmann, K.; Bruder, S.; Linden, L. Anetumab
ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors
with heterogeneous target expression favored by bystander effect. Molecular
cancer therapeutics 2014, 13, 1537-1548.
(138) Thomas, A.; Teicher, B. A.; Hassan, R. Antibody-drug conjugates for cancer
therapy. The Lancet Oncology 2016, 17, e254-e262.
(139) Alley, S. C.; Okeley, N. M.; Senter, P. D. Antibody-drug conjugates: targeted
drug delivery for cancer. Current opinion in chemical biology 2010, 14, 529-537.

274

VITA

Muhammad Raisul Abedin grew up in a remote town in Chandpur, Bangladesh.
He pursued his Bachelor’s degree in Chemical Engineering from Bangladesh University
of Engineering and Technology (BUET), Dhaka, Bangladesh (2017). He worked on the
development of a low cost and mammalian cell friendly antibacterial paper towel and
filter at the International Centre for Diarrheal Disease Research, Bangladesh (ICDDR, B).
In January 2018, he joined “Biomaterials and Tissue Engineering Lab” at the Department
of Chemical and Biochemical Engineering in Missouri S&T as a graduate Ph.D. student.
His primary research goal was engineering a synergistic drug delivery system that
combines targeted nanoscale drug nanoparticles and combination therapeutic approach
for breast cancer treatment. Since January 2018, he authored in seven scientific articles
that include publications in J o u r n a l o f N a n o b io te c h n o lo g y (2 0 1 8 ), A C S A p p l ie d B io
M a te r ia ls (2 019) and S c ie n tific R e p o r ts (2020). He published in the prestigious high

impact journals including N a tu r e and A C S . He also presented five conference talks and
three research posters in the AIChE Annual Meetings (2018, 2019) and the OBI
Symposium (2019) at Missouri S&T. He was the semifinalist at 3MT thesis presentation
competition organized by Missouri S&T. His research on personalized medicine was
highlighted by the University of Missouri System addressing the precision medicine
initiative project (2018). His research expertise lied in designing nanoparticle based
targeted therapeutic platforms for cancer treatment and mechanistic analysis of cancer
therapeutic response at cellular, molecular and genetic levels. In December 2020, he
received his Ph.D. in Chemical Engineering from Missouri S&T.

